Document:

avdx_41.htm

EXHIBIT 4.1
 
CONVERTIBLE PROMISSORY NOTE 
 
	Effective Date: January 5, 2016
	U.S. $112,500.00

 
FOR VALUE RECEIVED, Avant Diagnostics, Inc., a Nevada corporation ("Borrower"), promises to pay to St. George Investments LLC, a Utah limited liability company, or its successors or assigns ("Lender"), $112,500.00 and any interest, fees, charges, and late fees on the date that is nine (9) months after the Purchase Price Date (the "Maturity Date") in accordance with the terms set forth herein and to pay interest on the Outstanding Balance at the rate of ten percent (10%) per annum from the Purchase Price Date until the same is paid in full. This Convertible Promissory Note (this "Note") is issued and made effective as of January 5, 2016 (the "Effective Date"). This Note is issued pursuant to that certain Securities Purchase Agreement dated January 5, 2016, as the same may be amended from time to time, by and between Borrower and Lender (the "Purchase Agreement"). All interest calculations hereunder shall be computed on the basis of a 360-day year comprised of twelve (12) thirty (30) day months, shall compound daily and shall be payable in accordance with the terms of this Note. Certain capitalized terms used herein are defined in Attachment 1 attached hereto and incorporated herein by this reference.
 
This Note carries an OID of $10,000.00. In addition, Borrower agrees to pay $2,500.00 to Lender to cover Lender's legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of this Note (the "Transaction Expense Amount"), all of which amount is included in the initial principal balance of this Note. The purchase price for this Note shall be $100,000.00 (the "Purchase Price"), computed as follows: $112,500.00 original principal balance, less the OID, less the Transaction Expense Amount. The Purchase Price shall be payable by Lender by wire transfer of immediately available funds.
 
1.                  Payment; Prepayment. Provided there is an Outstanding Balance, on each Installment Date (as defined below), Borrower shall pay to Lender an amount equal to the Installment Amount (as defined below) due on such Installment Date in accordance with Section 8. All payments owing hereunder shall be in lawful money of the United States of America or Conversion Shares (as defined below), as provided for herein, and delivered to Lender at the address furnished to Borrower for that purpose. All payments shall be applied first to (a) costs of collection, if any, then to (b) fees and charges, if any, then to (c) accrued and unpaid interest, and thereafter, to (d) principal. Notwithstanding the foregoing, so long as Borrower has not received a Lender Conversion Notice (as defined below) or an Installment Notice (as defined below) from Lender where the applicable Conversion Shares have not yet been delivered and so long as no Event of Default has occurred since the Effective Date (whether declared by Lender or undeclared), then Borrower shall have the right, exercisable on not less than five (5) Trading Days prior written notice to Lender to prepay the Outstanding Balance of this Note, in full, in accordance with this Section 1. Any notice of prepayment hereunder (an "Optional Prepayment Notice") shall be delivered to Lender at its registered address and shall state: (i) that Borrower is exercising its right to prepay this Note, and (ii) the date of prepayment, which shall be not less than five (5) Trading Days from the date of the Optional Prepayment Notice. On the date fixed for prepayment (the "Optional Prepayment Date"), Borrower shall make payment of the Optional Prepayment Amount (as defined below) to or upon the order of Lender as may be specified by Lender in writing to Borrower. If Borrower exercises its right to prepay this Note, Borrower shall make payment to Lender of an amount in cash equal to 120% multiplied by the then Outstanding Balance of this Note (the "Optional Prepayment Amount"). In the event Borrower delivers the Optional Prepayment Amount to Lender prior to the Optional Prepayment Date or without delivering an Optional Prepayment Notice to Lender as set forth herein without Lender's prior written consent, the Optional Prepayment Amount shall not be deemed to have been paid to Lender until the Optional Prepayment Date. Moreover, in such event, Lender, in its sole and absolute discretion, may either (i) reject the Optional Prepayment Amount in whole or in part, and return such rejected portion of the Optional Prepayment Amount to Lender, or (ii) retain the Optional Prepayment Amount and apply such Optional Prepayment Amount to the Outstanding Balance. In addition, if Borrower delivers an Optional Prepayment Notice and fails to pay the Optional Prepayment Amount due to Lender within two (2) Trading Days following the Optional Prepayment Date, Borrower shall forever forfeit its right to prepay this Note.
 
	 
	1

	

	 

 
2.                  Security. This Note is unsecured.
 
3.                  Lender Optional Conversion.
 
3.1.          Lender Conversion Price. Subject to adjustment as set forth in this Note, the conversion price for each Lender Conversion (as defined below) shall be $0.35 (the "Lender Conversion Price"). However, in the event the Market Capitalization falls below $10,000,000.00 at any time, then in such event (a) the Lender Conversion Price for all Lender Conversions occurring after the first date of such occurrence shall equal the lower of the Lender Conversion Price and the Market Price as of any applicable date of Conversion, and (b) the true-up provisions of Section 11 below shall apply to all Lender Conversions that occur after the first date the Market Capitalization falls below $10,000,000.00, provided that all references to the "Installment Notice" in Section 11 shall be replaced with references to a "Lender Conversion Notice" for purposes of this Section 3.1, all references to "Installment Conversion Shares" in Section 11 shall be replaced with references to "Lender Conversion Shares" for purposes of this Section 3.1, and all references to the "Installment Conversion Price" in Section 11 shall be replaced with references to the "Lender Conversion Price" for purposes of this Section 3.1.
 
3.2.          Lender Conversions. Lender has the right at any time after the Purchase Price Date until the Outstanding Balance has been paid in full, including without limitation (a) until any Optional Prepayment Date (even if Lender has received an Optional Prepayment Notice) or at any time thereafter with respect to any amount that is not prepaid, and (b) during or after any Fundamental Default Measuring Period, at its election, to convert (each instance of conversion is referred to herein as a "Lender Conversion") all or any part of the Outstanding Balance into shares ("Lender Conversion Shares") of fully paid and non-assessable common stock, $0.00001 par value per share ("Common Stock"), of Borrower as per the following conversion formula: the number of Lender Conversion Shares equals the amount being converted (the "Conversion Amount") divided by the Lender Conversion Price. Conversion notices in the form attached hereto as Exhibit A (each, a "Lender Conversion Notice") may be effectively delivered to Borrower by any method of Lender's choice (including but not limited to facsimile, email, mail, overnight courier, or personal delivery), and all Lender Conversions shall be cashless and not require further payment from Lender. Borrower shall deliver the Lender Conversion Shares from any Lender Conversion to Lender in accordance with Section 9 below. 
 
3.3.          Application to Installments. Notwithstanding anything to the contrary herein, including without limitation Section 8 hereof, Lender may, in its sole discretion, apply all or any portion of any Lender Conversion toward any Installment Conversion (as defined below), even if such Installment Conversion is pending, as determined in Lender's sole discretion, by delivering written notice of such election (which notice may be included as part of the applicable Lender Conversion Notice) to Borrower at any date on or prior to the applicable Installment Date. In such event, Borrower may not elect to allocate such portion of the Installment Amount being paid pursuant to this Section 3.3 in the manner prescribed in Section 8.3; rather, Borrower must reduce the applicable Installment Amount by the Conversion Amount described in this Section 3.3. 
 
	 
	2

	

	 

  
4.                  Defaults and Remedies.
 
4.1.          Defaults. The following are events of default under this Note (each, an "Event of Default"): (a) Borrower shall fail to pay any principal, interest, fees, charges, or any other amount when due and payable hereunder; (b) Borrower shall fail to deliver any Lender Conversion Shares in accordance with the terms hereof; (c) Borrower shall fail to deliver any Installment Conversion Shares (as defined below) or True-Up Shares (as defined below) in accordance with the terms hereof; (d) a receiver, trustee or other similar official shall be appointed over Borrower or a material part of its assets and such appointment shall remain uncontested for twenty (20) days or shall not be dismissed or discharged within sixty (60) days; (e) Borrower shall become insolvent or generally fails to pay, or admits in writing its inability to pay, its debts as they become due, subject to applicable grace periods, if any; (f) Borrower shall make a general assignment for the benefit of creditors; (g) Borrower shall file a petition for relief under any bankruptcy, insolvency or similar law (domestic or foreign); (h) an involuntary proceeding shall be commenced or filed against Borrower; (i) Borrower shall default or otherwise fail to observe or perform any covenant, obligation, condition or agreement of Borrower contained herein or in any other Transaction Document (as defined in the Purchase Agreement), other than those specifically set forth in this Section 4.1 and Section 4 of the Purchase Agreement; (j) any representation, warranty or other statement made or furnished by or on behalf of Borrower to Lender herein, in any Transaction Document, or otherwise in connection with the issuance of this Note shall be false, incorrect, incomplete or misleading in any material respect when made or furnished; (k) the occurrence of a Fundamental Transaction without Lender's prior written consent; (l) Borrower shall fail to maintain the Share Reserve as required under the Purchase Agreement; (m) Borrower effectuates a reverse split of its Common Stock without twenty (20) Trading Days prior written notice to Lender; (n) any money judgment, writ or similar process shall be entered or filed against Borrower or any subsidiary of Borrower or any of its property or other assets for more than $100,000.00, and shall remain unvacated, unbonded or unstayed for a period of twenty (20) calendar days unless otherwise consented to by Lender; (o) Borrower shall fail to be DWAC Eligible; or (p) Borrower shall fail to observe or perform any covenant set forth in Section 4 of the Purchase Agreement.
 
4.2.          Remedies. At any time and from time to time after Lender becoming aware of the occurrence of any Event of Default, Lender may accelerate this Note by written notice to Borrower, with the Outstanding Balance becoming immediately due and payable in cash at the Mandatory Default Amount. Notwithstanding the foregoing, at any time following the occurrence of any Event of Default, Lender may, at its option, elect to increase the Outstanding Balance by applying the Default Effect (subject to the limitation set forth below) via written notice to Borrower without accelerating the Outstanding Balance, in which event the Outstanding Balance shall be increased as of the date of the occurrence of the applicable Event of Default pursuant to the Default Effect, but the Outstanding Balance shall not be immediately due and payable unless so declared by Lender (for the avoidance of doubt, if Lender elects to apply the Default Effect pursuant to this sentence, it shall reserve the right to declare the Outstanding Balance immediately due and payable at any time and no such election by Lender shall be deemed to be a waiver of its right to declare the Outstanding Balance immediately due and payable as set forth herein unless otherwise agreed to by Lender in writing). Notwithstanding the foregoing, upon the occurrence of any Event of Default described in clauses (d), (e), (f), (g) or (h) of Section 4.1, the Outstanding Balance as of the date of acceleration shall become immediately and automatically due and payable in cash at the Mandatory Default Amount, without any written notice required by Lender. At any time following the occurrence of any Event of Default, upon written notice given by Lender to Borrower, interest shall accrue on the Outstanding Balance beginning on the date the applicable Event of Default occurred at an interest rate equal to the lesser of 22% per annum or the maximum rate permitted under applicable law ("Default Interest"); provided, however, that no Default Interest shall accrue during the Fundamental Default Measuring Period. For the avoidance of doubt, Lender may continue making Lender Conversions at any time following an Event of Default until such time as the Outstanding Balance is paid in full. Additionally, following the occurrence of any Event of Default, Borrower may, at its option, pay any Lender Conversion in cash instead of Lender Conversion Shares by paying to Lender on or before the applicable Delivery Date (as defined below) a cash amount equal to the number of Lender Conversion Shares set forth in the applicable Lender Conversion Notice multiplied by the highest intra-day trading price of the Common Stock that occurs during the period beginning on the date the applicable Event of Default occurred and ending on the date of the applicable Lender Conversion Notice. In connection with acceleration described herein, Lender need not provide, and Borrower hereby waives, any presentment, demand, protest or other notice of any kind, and Lender may immediately and without expiration of any grace period enforce any and all of its rights and remedies hereunder and all other remedies available to it under applicable law. Such acceleration may be rescinded and annulled by Lender at any time prior to payment hereunder and Lender shall have all rights as a holder of the Note until such time, if any, as Lender receives full payment pursuant to this Section 4.2. No such rescission or annulment shall affect any subsequent Event of Default or impair any right consequent thereon. Nothing herein shall limit Lender's right to pursue any other remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to Borrower's failure to timely deliver Conversion Shares upon Conversion of the Notes as required pursuant to the terms hereof.
 
	 
	3

	

	 

 
4.3.          Fundamental Default Remedies. Notwithstanding anything to the contrary herein, in addition to all other remedies set forth herein, the Fundamental Liquidated Damages Amount shall be added to the Outstanding Balance upon Lender's delivery to Borrower of a notice (which notice Lender may deliver to Borrower at any time following the occurrence of a Fundamental Default) setting forth its election to declare a Fundamental Default and the Fundamental Liquidated Damages Amount that will be added to the Outstanding Balance.
 
4.4.          Certain Additional Rights. Notwithstanding anything to the contrary herein, in the event Borrower fails to make any payment or otherwise to deliver any Conversion Shares as and when required under this Note, then (a) the Lender Conversion Price for all Lender Conversions occurring after the date of such failure to pay shall equal the lower of the Lender Conversion Price and the Market Price as of any applicable date of Conversion, and (b) the true-up provisions of Section 11 below shall apply to all Lender Conversions that occur after the date of such failure to pay, provided that all references to the "Installment Notice" in Section 11 shall be replaced with references to a "Lender Conversion Notice" for purposes of this Section 4.4, all references to "Installment Conversion Shares" in Section 11 shall be replaced with references to "Lender Conversion Shares" for purposes of this Section 4.4, and all references to the "Installment Conversion Price" in Section 11 shall be replaced with references to the "Lender Conversion Price" for purposes of this Section 4.4. For the avoidance of doubt, Lender's exercise of the rights granted to it pursuant to this Section 4.4 shall not relieve Borrower of its obligation to continue paying the Installment Amount on all future Installment Dates.
 
4.5.          Cross Default. A breach or default by Borrower of any covenant or other term or condition contained in any Other Agreements shall, at the option of Lender, be considered an Event of Default under this Note, in which event Lender shall be entitled (but in no event required) to apply all rights and remedies of Lender under the terms of this Note.
 
5.                  Unconditional Obligation; No Offset. Borrower acknowledges that this Note is an unconditional, valid, binding and enforceable obligation of Borrower not subject to offset, deduction or counterclaim of any kind. Borrower hereby waives any rights of offset it now has or may have hereafter against Lender, its successors and assigns, and agrees to make the payments or Conversions called for herein in accordance with the terms of this Note.
 
6.                  Waiver. No waiver of any provision of this Note shall be effective unless it is in the form of a writing signed by the party granting the waiver. No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent to any other prohibited action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit a party to provide a waiver or consent in the future except to the extent specifically set forth in writing.
 
	 
	4

	

	 

 
7.                  Rights Upon Issuance of Securities. 
 
7.1.          Subsequent Equity Sales. Except with respect to Excluded Securities, if Borrower or any subsidiary thereof, as applicable, at any time this Note is outstanding, shall sell, issue or grant any Common Stock, option to purchase Common Stock, right to reprice, preferred shares convertible into Common Stock, or debt, warrants, options or other instruments or securities to Lender or any third party which are convertible into or exercisable for shares of Common Stock (collectively, the "Equity Securities"), including without limitation any Deemed Issuance, at an effective price per share less than the then effective Lender Conversion Price (such issuance is referred to herein as a "Dilutive Issuance"), then, the Lender Conversion Price shall be automatically reduced and only reduced to equal such lower effective price per share. If the holder of any Equity Securities so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options, or rights per share which are issued in connection with such Dilutive Issuance, be entitled to receive shares of Common Stock at an effective price per share that is less than the Lender Conversion Price, such issuance shall be deemed to have occurred for less than the Lender Conversion Price on the date of such Dilutive Issuance, and the then effective Lender Conversion Price shall be reduced and only reduced to equal such lower effective price per share. Such adjustments described above to the Lender Conversion Price shall be permanent (subject to additional adjustments under this section), and shall be made whenever such Equity Securities are issued. Borrower shall notify Lender, in writing, no later than the Trading Day following the issuance of any Equity Securities subject to this Section 7.1, indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price, or other pricing terms (such notice, the "DilutiveIssuance Notice"). For purposes of clarification, whether or not Borrower provides a Dilutive Issuance Notice pursuant to this Section 7.1, upon the occurrence of any Dilutive Issuance, on the date of such Dilutive Issuance the Lender Conversion Price shall be lowered to equal the applicable effective price per share regardless of whether Borrower or Lender accurately refers to such lower effective price per share in any Installment Notice or Lender Conversion Notice.
 
7.2.          Adjustment of Lender Conversion Price and Conversion Floor Price upon Subdivision or Combination of Common Stock. Without limiting any provision hereof, if Borrower at any time on or after the Effective Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Lender Conversion Price and the Conversion Floor Price in effect immediately prior to such subdivision will be proportionately reduced. Without limiting any provision hereof, if Borrower at any time on or after the Effective Date combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Lender Conversion Price and the Conversion Floor Price in effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to this Section 7.2 shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an adjustment under this Section 7.2 occurs during the period that a Lender Conversion Price is calculated hereunder, then the calculation of such Lender Conversion Price shall be adjusted appropriately to reflect such event.
 
7.3.          Other Events. In the event that Borrower (or any subsidiary) shall take any action to which the provisions hereof are not strictly applicable, or, if applicable, would not operate to protect Lender from dilution or if any event occurs of the type contemplated by the provisions of this Section 7 but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features), then Borrower's board of directors shall in good faith determine and implement an appropriate adjustment in the Lender Conversion Price and the Conversion Floor Price so as to protect the rights of Lender, provided that no such adjustment pursuant to this Section 7.3 will increase the Lender Conversion Price or the Conversion Floor Price as otherwise determined pursuant to this Section 7, provided further that if Lender does not accept such adjustments as appropriately protecting its interests hereunder against such dilution, then Borrower's board of directors and Lender shall agree, in good faith, upon an independent investment bank of nationally recognized standing to make such appropriate adjustments, whose determination shall be final and binding and whose fees and expenses shall be borne by Borrower.
 
	 
	5

	

	 

 
8.                  Borrower Installments.
 
8.1.          Installment Conversion Price. Subject to the adjustments set forth herein, the conversion price for each Installment Conversion shall be the lesser of (a) the Lender Conversion Price, and (b) the Market Price, subject to the Conversion Floor Price (the "Installment Conversion Price"). 
 
8.2.          Installment Conversions. Beginning on the date that is six (6) months after the Purchase Price Date and on the same day of each month thereafter until the Maturity Date (each, an "Installment Date"), if paying in cash, Borrower shall pay to Lender the applicable Installment Amount due on such date subject to the provisions of this Section 8, and if paying in Installment Conversion Shares (as defined below), Borrower shall deliver such Installment Conversion Shares on or before the Delivery Date. Payments of each Installment Amount may be made (a) in cash, or (b) by converting such Installment Amount into shares of Common Stock ("Installment Conversion Shares", and together with the Lender Conversion Shares, the "Conversion Shares") in accordance with this Section 8 (each an "Installment Conversion") per the following formula: the number of Installment Conversion Shares equals the portion of the applicable Installment Amount being converted divided by the Installment Conversion Price, or (c) by any combination of the foregoing, so long as the cash is delivered to Lender on the applicable Installment Date and the Installment Conversion Shares are delivered to Lender on or before the applicable Delivery Date. Notwithstanding the foregoing, Borrower will not be entitled to elect an Installment Conversion with respect to any portion of any applicable Installment Amount and shall be required to pay the entire amount of such Installment Amount in cash if on the applicable Installment Date there is an Equity Conditions Failure, and such failure is not waived in writing by Lender. Moreover, in the event Borrower desires to pay all or any portion of any Installment Amount in cash, it must notify Lender in writing of such election and the portion of the applicable Installment Amount it elects to pay in cash not more than twenty-five (25) or less than ten (10) Trading Days prior to the applicable Installment Date. If Borrower fails to so notify Lender, it shall not be permitted to elect to pay any portion of such Installment Amount in cash unless otherwise agreed to by Lender in writing or proposed by Lender in an Installment Notice delivered by Lender to Borrower. Notwithstanding that failure to repay this Note in full by the Maturity Date is an Event of Default, the Installment Dates shall continue after the Maturity Date pursuant to this Section 8 until the Outstanding Balance is repaid in full, provided that Lender shall, in Lender's sole discretion, determine the Installment Amount for each Installment Date after the Maturity Date.
 
8.3.          Allocation of Installment Amounts. Subject to Section 8.2 regarding an Equity Conditions Failure, for each Installment Date, Borrower may elect to allocate the amount of the applicable Installment Amount between cash and via an Installment Conversion, by email or fax delivery of a notice to Lender substantially in the form attached hereto as Exhibit B (each, an "Installment Notice"), provided, that to be effective, each applicable Installment Notice must be received by Lender not more than twenty-five (25) or less than ten (10) Trading Days prior to the applicable Installment Date. If Lender has not received an Installment Notice within such time period, then Lender may prepare the Installment Notice and deliver the same to Borrower by fax or email. Following its receipt of such Installment Notice, Borrower may either ratify Lender's proposed allocation in the applicable Installment Notice or elect to change the allocation by written notice to Lender by email or fax on or before 12:00 p.m. New York time on the applicable Installment Date, so long as the sum of the cash payments and the amount of Installment Conversions equal the applicable Installment Amount, provided that Lender must approve any increase to the portion of the Installment Amount payable in cash. If Borrower fails to notify Lender of its election to change the allocation prior to the deadline set forth in the previous sentence (and seek approval to increase the amount payable in cash), it shall be deemed to have ratified and accepted the allocation set forth in the applicable Installment Notice prepared by Lender. If neither Borrower nor Lender prepare and deliver to the other party an Installment Notice as outlined above, then Borrower shall be deemed to have elected that the entire Installment Amount be converted via an Installment Conversion. Borrower acknowledges and agrees that regardless of which party prepares the applicable Installment Notice, the amounts and calculations set forth thereon are subject to correction or adjustment because of error, mistake, or any adjustment resulting from an Event of Default or other adjustment permitted under the Transaction Documents (an "Adjustment"). Furthermore, no error or mistake in the preparation of such notices, or failure to apply any Adjustment that could have been applied prior to the preparation of an Installment Notice may be deemed a waiver of Lender's right to enforce the terms of any Note, even if such error, mistake, or failure to include an Adjustment arises from Lender's own calculation. Borrower shall deliver the Installment Conversion Shares from any Installment Conversion to Lender in accordance with Section 9 below on or before each applicable Delivery Date.
 
	 
	6

	

	 

 
9.                  Method of Conversion Share Delivery. On or before the close of business on the fifth (5th) Trading Day following the Installment Date or the fifth (5th) Trading Day following the date of delivery of a Lender Conversion Notice, as applicable (the "Delivery Date"), Borrower shall, provided it is DWAC Eligible at such time, deliver or cause its transfer agent to deliver the applicable Conversion Shares electronically via DWAC to the account designated by Lender in the applicable Lender Conversion Notice or Installment Notice.If Borrower is not DWAC Eligible, it shall deliver to Lender or its broker (as designated in the Lender Conversion Notice or Installment Notice, as applicable), via reputable overnight courier, a certificate representing the number of shares of Common Stock equal to the number of Conversion Shares to which Lender shall be entitled, registered in the name of Lender or its designee. For the avoidance of doubt, Borrower has not met its obligation to deliver Conversion Shares by the Delivery Date unless Lender or its broker, as applicable, has actually received the certificate representing the applicable Conversion Shares no later than the close of business on the relevant Delivery Date pursuant to the terms set forth above. Moreover, and notwithstanding anything to the contrary herein or in any other Transaction Document, in the event Borrower or its transfer agent refuses to deliver any Conversion Shares to Lender on grounds that such issuance is in violation of Rule 144 under the Securities Act of 1933, as amended ("Rule 144"), Borrower shall deliver or cause its transfer agent to deliver the applicable Conversion Shares to Lender with a restricted securities legend, but otherwise in accordance with the provisions of this Section 9. In conjunction therewith, Borrower will also deliver to Lender a written opinion from its counsel or its transfer agent's counsel opining as to why the issuance of the applicable Conversion Shares violates Rule 144.
 
10.                Conversion Delays. If Borrower fails to deliver Conversion Shares or True-Up Shares in accordance with the timeframes stated in Sections 9 or 11, as applicable, Lender, at any time prior to selling all of those Conversion Shares or True-Up Shares, as applicable, may rescind in whole or in part that particular Conversion attributable to the unsold Conversion Shares or True-Up Shares, with a corresponding increase to the Outstanding Balance (any returned amount will tack back to the Purchase Price Date for purposes of determining the holding period under Rule 144). In addition, for each Lender Conversion, in the event that Lender Conversion Shares are not delivered by the sixth Trading Day (inclusive of the day of the Lender Conversion), a late fee equal to the greater of (a) $500.00 and (b) 2% of the applicable Lender Conversion Share Value rounded to the nearest multiple of $100.00 (but in any event the cumulative amount of such late fees for each Lender Conversion shall not exceed 200% of the applicable Lender Conversion Share Value) will be assessed for each day after the fifth Trading Day (inclusive of the day of the Lender Conversion) until Lender Conversion Share delivery is made; and such late fee will be added to the Outstanding Balance (such fees, the "Conversion Delay Late Fees"). For illustration purposes only, if Lender delivers a Lender Conversion Notice to Borrower pursuant to which Borrower is required to deliver 100,000 Lender Conversion Shares to Lender and on the Delivery Date such Lender Conversion Shares have a Lender Conversion Share Value of $20,000.00 (assuming a Closing Trade Price on the Delivery Date of $0.20 per share of Common Stock), then in such event a Conversion Delay Late Fee in the amount of $500.00 per day (the greater of $500.00 per day and $20,000.00 multiplied by 2%, which is $400.00) would be added to the Outstanding Balance of the Note until such Lender Conversion Shares are delivered to Lender. For purposes of this example, if the Lender Conversion Shares are delivered to Lender twenty (20) days after the applicable Delivery Date, the total Conversion Delay Late Fees that would be added to the Outstanding Balance would be $10,000.00 (20 days multiplied by $500.00 per day). If the Lender Conversion Shares are delivered to Lender one hundred (100) days after the applicable Delivery Date, the total Conversion Delay Late Fees that would be added to the Outstanding Balance would be $40,000.00 (100 days multiplied by $500.00 per day, but capped at 200% of the Lender Conversion Share Value).
 
	 
	7

	

	 

  
11.                True-Up. On the date that is twenty (20) Trading Days (a "True-Up Date") from each date that the Installment Conversion Shares delivered by Borrower to Lender become Free Trading, there shall be a true-up where Borrower shall deliver to Lender additional Installment Conversion Shares ("True-Up Shares") if the Installment Conversion Price as of the True-Up Date is less than the Installment Conversion Price used in the applicable Installment Notice. In such event, Borrower shall deliver to Lender within five (5) Trading Days of the True-Up Date (the "True-Up Share Delivery Date") a number of True-Up Shares equal to the difference between the number of Installment Conversion Shares that would have been delivered to Lender on the True-Up Date based on the Installment Conversion Price as of the True-Up Date and the number of Installment Conversion Shares originally delivered to Lender pursuant to the applicable Installment Notice. For the avoidance of doubt, if the Installment Conversion Price as of the True-Up Date is higher than the Installment Conversion Price set forth in the applicable Installment Notice, then Borrower shall have no obligation to deliver True-Up Shares to Lender, nor shall Lender have any obligation to return any excess Installment Conversion Shares to Borrower under any circumstance. For the convenience of Borrower only, Lender may, in its sole discretion, deliver to Borrower a notice (pursuant to a form of notice substantially in the form attached hereto as Exhibit C) informing Borrower of the number of True-Up Shares it is obligated to deliver to Lender as of any given True-Up Date, provided that if Lender does not deliver any such notice, Borrower shall not be relieved of its obligation to deliver True-Up Shares pursuant to this Section 11. Notwithstanding the foregoing, if Borrower fails to deliver any required True-Up Shares on or before any applicable True-Up Share Delivery Date, then in such event the Outstanding Balance of this Note will automatically increase by a sum equal to the number of True-Up Shares deliverable as of the applicable True-Up Date multiplied by the Market Price for the Common Stock as of the applicable True-Up Date (under Lender's and Borrower's expectations that any such increase will tack back to the Purchase Price Date for purposes of determining the holding period under Rule 144).
 
12.                Ownership Limitation. Notwithstanding anything to the contrary contained in this Note or the other Transaction Documents, if at any time Lender shall or would be issued shares of Common Stock under any of the Transaction Documents, but such issuance would cause Lender (together with its affiliates) to beneficially own a number of shares exceeding 4.99% of the number of shares of Common Stock outstanding on such date (including for such purpose the shares of Common Stock issuable upon such issuance) (the "Maximum Percentage"), then Borrower must not issue to Lender shares of Common Stock which would exceed the Maximum Percentage. For purposes of this section, beneficial ownership of Common Stock will be determined pursuant to Section 13(d) of the 1934 Act. The shares of Common Stock issuable to Lender that would cause the Maximum Percentage to be exceeded are referred to herein as the "OwnershipLimitationShares". Borrower will reserve the Ownership Limitation Shares for the exclusive benefit of Lender. From time to time, Lender may notify Borrower in writing of the number of the Ownership Limitation Shares that may be issued to Lender without causing Lender to exceed the Maximum Percentage. Upon receipt of such notice, Borrower shall be unconditionally obligated to immediately issue such designated shares to Lender, with a corresponding reduction in the number of the Ownership Limitation Shares. Notwithstanding the forgoing, the term "4.99%" above shall be replaced with "9.99%" at such time as the Market Capitalization is less than $10,000,000.00. Notwithstanding any other provision contained herein, if the term "4.99%" is replaced with "9.99%" pursuant to the preceding sentence, such increase to "9.99%" shall remain at 9.99% until increased, decreased or waived by Lender as set forth below. By written notice to Borrower, Lender may increase, decrease or waive the Maximum Percentage as to itself but any such waiver will not be effective until the 61st day after delivery thereof. The foregoing 61-day notice requirement is enforceable, unconditional and non-waivable and shall apply to all affiliates and assigns of Lender.
 
	 
	8

	

	 

  
13.                Payment of Collection Costs. If this Note is placed in the hands of an attorney for collection or enforcement prior to commencing arbitration or legal proceedings, or is collected or enforced through any arbitration or legal proceeding, or Lender otherwise takes action to collect amounts due under this Note or to enforce the provisions of this Note, then Borrower shall pay the costs incurred by Lender for such collection, enforcement or action including, without limitation, attorneys' fees and disbursements. Borrower also agrees to pay for any costs, fees or charges of its transfer agent that are charged to Lender pursuant to any Conversion or issuance of shares pursuant to this Note.
 
14.                Opinion of Counsel. In the event that an opinion of counsel is needed for any matter related to this Note, Lender has the right to have any such opinion provided by its counsel. Lender also has the right to have any such opinion provided by Borrower's counsel.
 
15.                Governing Law; Venue. This Note shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Utah. The provisions set forth in the Purchase Agreement to determine the proper venue for any disputes are incorporated herein by this reference.
 
16.                Resolution of Disputes. 
 
16.1.        Arbitration of Disputes. By its acceptance of this Note, each party agrees to be bound by the Arbitration Provisions (as defined in the Purchase Agreement) set forth as an exhibit to the Purchase Agreement.
 
16.2.        Calculation Disputes. Notwithstanding the Arbitration Provisions, in the case of a dispute as to any Calculation (as defined in the Purchase Agreement), such dispute will be resolved in the manner set forth in the Purchase Agreement.
 
17.                Cancellation. After repayment or conversion of the entire Outstanding Balance (including without limitation delivery of True-Up Shares pursuant to the payment of the final Installment Amount, if applicable), this Note shall be deemed paid in full, shall automatically be deemed canceled, and shall not be reissued.
 
18.                Amendments. The prior written consent of both parties hereto shall be required for any change or amendment to this Note.
 
19.                Assignments. Borrower may not assign this Note without the prior written consent of Lender. This Note and any shares of Common Stock issued upon conversion of this Note may be offered, sold, assigned or transferred by Lender without the consent of Borrower.
 
20.                Time is of the Essence. Time is expressly made of the essence with respect to each and every provision of this Note and the documents and instruments entered into in connection herewith.
 
21.                Notices. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with the subsection of the Purchase Agreement titled "Notices."
 
	 
	9

	

	 

  
22.                Liquidated Damages. Lender and Borrower agree that in the event Borrower fails to comply with any of the terms or provisions of this Note, Lender's damages would be uncertain and difficult (if not impossible) to accurately estimate because of the parties' inability to predict future interest rates, future share prices, future trading volumes and other relevant factors. Accordingly, Lender and Borrower agree that any fees, balance adjustments, Default Interest or other charges assessed under this Note are not penalties but instead are intended by the parties to be, and shall be deemed, liquidated damages (under Lender's and Borrower's expectations that any such liquidated damages will tack back to the Purchase Price Date for purposes of determining the holding period under Rule 144).
 
23.                Waiver of Jury Trial. EACH OF LENDER AND BORROWER IRREVOCABLY WAIVES ANY AND ALL RIGHTS SUCH PARTY MAY HAVE TO DEMAND THAT ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY RELATED TO THIS NOTE OR THE RELATIONSHIPS OF THE PARTIES HERETO BE TRIED BY JURY. THIS WAIVER EXTENDS TO ANY AND ALL RIGHTS TO DEMAND A TRIAL BY JURY ARISING UNDER COMMON LAW OR ANY APPLICABLE STATUTE, LAW, RULE OR REGULATION. FURTHER, EACH PARTY HERETO ACKNOWLEDGES THAT SUCH PARTY IS KNOWINGLY AND VOLUNTARILY WAIVING SUCH PARTY'S RIGHT TO DEMAND TRIAL BY JURY.
 
24.                Voluntary Agreement. Borrower has carefully read this Note and has asked any questions needed for Borrower to understand the terms, consequences and binding effect of this Note and fully understand them. Borrower has had the opportunity to seek the advice of an attorney of Borrower's choosing, or has waived the right to do so, and is executing this Note voluntarily and without any duress or undue influence by Lender or anyone else.
 
25.                Severability. If any part of this Note is construed to be in violation of any law, such part shall be modified to achieve the objective of Borrower and Lender to the fullest extent permitted by law and the balance of this Note shall remain in full force and effect.
 
[Remainder of page intentionally left blank; signature page follows]
 
	 
	10

	

	 

 
IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed as of the Effective Date. 
 
	 
	BORROWER:    
Avant Diagnostics, Inc.
	 

	 	 	 	 
		By:	/s/ Gregg Linn	 

	 
	Name:
	Gregg Linn	 

	 
	Title:
	Chief Executive Officer	 

 
	 
	ACKNOWLEDGED, ACCEPTED AND AGREED:    
LENDER:
 
St. George Investments LLC
 
By: Fife Trading, Inc., Manager
	 

	 	 	 	 
		By:	/s/ John M. Fife	 

	 
	 
	John M. Fife, President	 

  
[Signature Page to Convertible Promissory Note]   

 
	 
	 

	

	 

 
ATTACHMENT 1
DEFINITIONS
 
For purposes of this Note, the following terms shall have the following meanings: 
 
A1.               "Adjusted Outstanding Balance" means the Outstanding Balance of this Note as of the date the applicable Fundamental Default occurred less any Conversion Delay Late Fees included in such Outstanding Balance.
 
A2.               "Approved Stock Plan" means any stock option plan which has been approved by the board of directors of Borrower and is in effect as of the Purchase Price Date, pursuant to which Borrower's securities may be issued to any employee, officer or director for services provided to Borrower.
 
A3.               "Bloomberg" means Bloomberg L.P. (or if that service is not then reporting the relevant information regarding the Common Stock, a comparable reporting service of national reputation selected by Lender and reasonably satisfactory to Borrower).
 
A4.               "Closing Bid Price" and "Closing Trade Price" means the last closing bid price and last closing trade price, respectively, for the Common Stock on its principal market, as reported by Bloomberg, or, if its principal market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of the Common Stock prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if its principal market is not the principal securities exchange or trading market for the Common Stock, the last closing bid price or last trade price, respectively, of the Common Stock on the principal securities exchange or trading market where the Common Stock is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of the Common Stock in the over-the-counter market on the electronic bulletin board for the Common Stock as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for the Common Stock by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for the Common Stock as reported by OTC Markets Group, Inc., and any successor thereto. If the Closing Bid Price or the Closing Trade Price cannot be calculated for the Common Stock on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Trade Price (as the case may be) of the Common Stock on such date shall be the fair market value as mutually determined by Lender and Borrower. If Lender and Borrower are unable to agree upon the fair market value of the Common Stock, then such dispute shall be resolved in accordance with the procedures in Section 16.2. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period.
 
A5.               "Conversion" means a Lender Conversion under Section 3 or an Installment Conversion under Section 8.
 
A6.               "Conversion Factor" means 60%, subject to the following adjustments. If at any time after the Effective Date, Borrower is not DWAC Eligible, then the then-current Conversion Factor will automatically be reduced by 5% for all future Conversions. If at any time after the Effective Date, the Conversion Shares are not DTC Eligible, then the then-current Conversion Factor will automatically be reduced by an additional 5% for all future Conversions. Finally, in addition to the Default Effect, if any Major Default occurs after the Effective Date, the Conversion Factor shall automatically be reduced for all future Conversions by an additional 5% for each of the first three (3) Major Defaults that occur after the Effective Date (for the avoidance of doubt, each occurrence of any Major Default shall be deemed to be a separate occurrence for purposes of the foregoing reductions in Conversion Factor, even if the same Major Default occurs three (3) separate times). For example, the first time Borrower is not DWAC Eligible, the Conversion Factor for future Conversions thereafter will be reduced from 60% to 55% for purposes of this example. Following such event, the first time the Conversion Shares are no longer DTC Eligible, the Conversion Factor for future Conversions thereafter will be reduced from 55% to 50% for purposes of this example. If, thereafter, there are three (3) separate occurrences of a Major Default pursuant to Section 4.1(c), then for purposes of this example the Conversion Factor would be reduced by 5% for the first such occurrence, and so on for each of the second and third occurrences of such Major Default.
 
A7.               "Conversion Floor Price" means $0.10, as the same may be adjusted from time to time pursuant to the terms of this Note.
 
A8.               "Deemed Issuance" means an issuance of Common Stock that shall be deemed to have occurred on the latest possible permitted date pursuant to the terms hereof in the event Borrower fails to deliver Conversion Shares as and when required pursuant to Section 9 of the Note. For the avoidance of doubt, if Borrower has elected or is deemed under Section 8.3 to have elected to pay an Installment Amount in Installment Conversion Shares and fails to deliver such Installment Conversion Shares, such failure shall be considered a Deemed Issuance hereunder even if an Equity Conditions Failure exists at that time or other relevant date of determination.
 
Attachment 1 to Convertible Promissory Note, Page 1
 
	 
	 

	

	 

 
A9.               "Default Effect" means multiplying the Outstanding Balance as of the date the applicable Event of Default occurred by (a) 15% for each occurrence of any Major Default, or (b) 5% for each occurrence of any Minor Default, and then adding the resulting product to the Outstanding Balance as of the date the applicable Event of Default occurred, with the sum of the foregoing then becoming the Outstanding Balance under this Note as of the date the applicable Event of Default occurred; provided that the Default Effect may only be applied three (3) times hereunder with respect to Major Defaults and three (3) times hereunder with respect to Minor Defaults; and provided further that the Default Effect shall not apply to any Event of Default pursuant to Section 4.1(b) hereof.
 
A10.             "DTC" means the Depository Trust Company or any successor thereto.
 
A11.             "DTC Eligible" means, with respect to the Common Stock, that such Common Stock is eligible to be deposited in certificate form at the DTC, cleared and converted into electronic shares by the DTC and held in the name of the clearing firm servicing Lender's brokerage firm for the benefit of Lender.
 
A12.             "DTC/FAST Program" means the DTC's Fast Automated Securities Transfer program.
 
A13.             "DWAC" means the DTC's Deposit/Withdrawal at Custodian system.
 
A14.             "DWAC Eligible" means that (a) Borrower's Common Stock is eligible at DTC for full services pursuant to DTC's operational arrangements, including without limitation transfer through DTC's DWAC system, (b) Borrower has been approved (without revocation) by the DTC's underwriting department, (c) Borrower's transfer agent is approved as an agent in the DTC/FAST Program, (d) the Conversion Shares are otherwise eligible for delivery via DWAC; (e) Borrower has previously delivered all Conversion Shares to Lender via DWAC; and (f) Borrower's transfer agent does not have a policy prohibiting or limiting delivery of the Conversion Shares via DWAC.
 
A15.             "Equity Conditions Failure" means that any of the following conditions has not been satisfied during any applicable Equity Conditions Measuring Period (as defined below): (a) with respect to the applicable date of determination all of the Conversion Shares would be freely tradable under Rule 144 or without the need for registration under any applicable federal or state securities laws (in each case, disregarding any limitation on conversion of this Note); (b) on each day during the period beginning twenty days prior to the applicable date of determination and ending on and including the applicable date of determination (the "Equity Conditions Measuring Period"), the Common Stock is listed or designated for quotation (as applicable) on any of NYSE, NASDAQ, OTCQX, or OTCQB (each, an "Eligible Market") and shall not have been suspended from trading on any such Eligible Market (other than suspensions of not more than two (2) Trading Days and occurring prior to the applicable date of determination due to business announcements by Borrower); (c) on each day during the Equity Conditions Measuring Period, Borrower shall have delivered all shares of Common Stock issuable upon conversion of this Note on a timely basis as set forth in Section 9 hereof and all other shares of capital stock required to be delivered by Borrower on a timely basis as set forth in the other Transaction Documents; (d) any shares of Common Stock to be issued in connection with the event requiring determination may be issued in full without violating Section 12 hereof (Lender acknowledges that Borrower shall be entitled to assume that this condition has been met for all purposes hereunder absent written notice from Lender); (e) any shares of Common Stock to be issued in connection with the event requiring determination may be issued in full without violating the rules or regulations of the Eligible Market on which the Common Stock is then listed or designated for quotation (as applicable); (f) on each day during the Equity Conditions Measuring Period, no public announcement of a pending, proposed or intended Fundamental Transaction shall have occurred which has not been abandoned, terminated or consummated; (g) Borrower shall have no knowledge of any fact that would reasonably be expected to cause any of the Conversion Shares to not be freely tradable without the need for registration under any applicable state securities laws (in each case, disregarding any limitation on conversion of this Note); (h) on each day during the Equity Conditions Measuring Period, Borrower otherwise shall have been in material compliance with each, and shall not have breached any, term, provision, covenant, representation or warranty of any Transaction Document; (i) without limiting clause (j) above, on each day during the Equity Conditions Measuring Period, there shall not have occurred an Event of Default or an event that with the passage of time or giving of notice would constitute an Event of Default; (k) on each Installment Date, the average and median daily dollar volume of the Common Stock on its principal market for the previous twenty (20) Trading Days shall be greater than $5,000.00; (l) the ten (10) day average VWAP of the Common Stock is greater than $0.01; (m) the Common Stock shall be DWAC Eligible as of each applicable Installment Date or other date of determination; and (n) the Market Price shall be greater than or equal to the Conversion Floor Price.
 
Attachment 1 to Convertible Promissory Note, Page 2
 
	 
	 

	

	 

 
A16.             "Excluded Securities" means (a) any shares of Common Stock, options, or convertible securities issued or issuable in connection with any Approved Stock Plan; provided that the option term, exercise price or similar provisions of any issuances pursuant to such Approved Stock Plan are not amended, modified or changed on or after the Purchase Price Date, and (b) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the directors of the Company, provided that any such issuance shall only be to a person which is, itself or through its subsidiaries, an operating company in a business synergistic with the business of the Company and in which the Company receives benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital
 
A17.             "Free Trading" means that (a) the shares or certificate(s) representing the applicable shares of Common Stock have been cleared and approved for public resale by the compliance departments of Lender's brokerage firm and the clearing firm servicing such brokerage, and (b) such shares are held in the name of the clearing firm servicing Lender's brokerage firm and have been deposited into such clearing firm's account for the benefit of Lender.
 
A18.             "Fundamental Default" means that Borrower either fails to pay the entire Outstanding Balance to Lender on or before the Maturity Date or fails to pay the Mandatory Default Amount within three (3) Trading Days of the date Lender delivers any notice of acceleration to Borrower pursuant to Section 4.2 of this Note.
 
A19.             "Fundamental Default Conversion Value" means the Adjusted Outstanding Balance multiplied by the highest Fundamental Default Ratio that occurs during the Fundamental Default Measuring Period.
 
A20.             "Fundamental Default Measuring Period" means a number of months equal to the Outstanding Balance as of the date the Fundamental Default occurred divided by the Installment Amount, with such number being rounded up to the next whole month; provided, however, that if Borrower repays the entire Outstanding Balance prior to the conclusion of the Fundamental Default Measuring Period, the Fundamental Default Measuring Period shall end on the date of repayment. For illustration purposes only, if the Outstanding Balance were equal to $125,000.00 as of the date a Fundamental Default occurred and if the Installment Amount were $28,500.00, then the Fundamental Default Measuring Period would equal five (5) months calculated as follows: $125,000.00/$28,500.00 equals 4.386, rounded up to five (5).
 
A21.             "Fundamental Default Ratio" means a ratio that will be calculated on each Trading Day during the Fundamental Default Measuring Period by dividing the Closing Trade Price for the Common Stock on a given Trading Day by the Lender Conversion Price (as adjusted pursuant to the terms hereof) in effect for such Trading Day.
 
A22.             "Fundamental Liquidated Damages Amount" means the greater of (a) (i) the quotient of the Outstanding Balance on the date the Fundamental Default occurred divided by the then-current Conversion Factor, minus (ii) the Outstanding Balance on the date the Fundamental Default occurred, or (b) the Fundamental Default Conversion Value.
 
A23.             "Fundamental Transaction" means that (a) (i) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, consolidate or merge with or into (whether or not Borrower or any of its subsidiaries is the surviving corporation) any other person or entity, or (ii) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its respective properties or assets to any other person or entity, or (iii) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, allow any other person or entity to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares of voting stock of Borrower (not including any shares of voting stock of Borrower held by the person or persons making or party to, or associated or affiliated with the persons or entities making or party to, such purchase, tender or exchange offer), or (iv) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with any other person or entity whereby such other person or entity acquires more than 50% of the outstanding shares of voting stock of Borrower (not including any shares of voting stock of Borrower held by the other persons or entities making or party to, or associated or affiliated with the other persons or entities making or party to, such stock or share purchase agreement or other business combination), or (v) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, reorganize, recapitalize or reclassify the Common Stock, other than an increase in the number of authorized shares of Borrower's Common Stock, or (b) any "person" or "group" (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act and the rules and regulations promulgated thereunder) is or shall become the "beneficial owner" (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding voting stock of Borrower.
 
Attachment 1 to Convertible Promissory Note, Page 3
 
	 
	 

	

	 

 
A24.             "Installment Amount" means the greater of (a) $28,125.00 ($112,500.00 ÷ 4), plus the sum of any accrued and unpaid interest as of the applicable Installment Date, and accrued and unpaid late charges, if any, under this Note as of the applicable Installment Date, and any other amounts accruing or owing to Lender under this Note as of such Installment Date, and (b) the then Outstanding Balance divided by the number of Installment Dates remaining prior to the Maturity Date.
 
A25.             "Lender Conversion Share Value" means the product of the number of Lender Conversion Shares deliverable pursuant to any Lender Conversion multiplied by the Closing Trade Price of the Common Stock on the Delivery Date for such Lender Conversion.
 
A26.             "Major Default" means any Event of Default occurring under Sections 4.1(a) (payments), 4.1(c) (delivery of Installment Conversion Shares or True-Up Shares), 4.1(l) (Share Reserve), or 4.1(p) (breach of certain covenants) of this Note.
 
A27.             "Mandatory Default Amount" means the greater of (a) the Outstanding Balance divided by the Installment Conversion Price on the date the Mandatory Default Amount is demanded, multiplied by the VWAP on the date the Mandatory Default Amount is demanded, or (b) the Outstanding Balance following the application of the Default Effect.
 
A28.             "Market Capitalization" means the product equal to (a) the average VWAP of the Common Stock for the immediately preceding fifteen (15) Trading Days, multiplied by (b) the aggregate number of outstanding shares of Common Stock as reported on Borrower's most recently filed Form 10-Q or Form 10-K.
 
A29.             "Market Price" means the Conversion Factor multiplied by the lowest Closing Bid Price in the twenty (20) Trading Days immediately preceding the applicable Conversion; provided, however, that in no event shall the Market Price be less than the Conversion Floor Price.
 
A30.             "Minor Default" means any Event of Default that is not a Major Default or a Fundamental Default.
 
A31.             "OID" means an original issue discount.
 
A32.             "Other Agreements" means, collectively, (a) all existing and future agreements and instruments between, among or by Borrower (or an affiliate), on the one hand, and Lender (or an affiliate), on the other hand, and (b) any financing agreement or a material agreement that affects Borrower's ongoing business operations.
 
A33.             "Outstanding Balance" means as of any date of determination, the Purchase Price, as reduced or increased, as the case may be, pursuant to the terms hereof for payment, Conversion, offset, or otherwise, plus the OID, the Transaction Expense Amount, accrued but unpaid interest, collection and enforcements costs (including attorneys' fees) incurred by Lender, transfer, stamp, issuance and similar taxes and fees related to Conversions, and any other fees or charges (including without limitation Conversion Delay Late Fees) incurred under this Note.
 
A34.             "Purchase Price Date" means the date the Purchase Price is delivered by Lender to Borrower.
 
A35.             "Trading Day" means any day on which the New York Stock Exchange is open for trading.
 
A36.             "VWAP" means the volume weighted average price of the Common stock on the principal market for a particular Trading Day or set of Trading Days, as the case may be, as reported by Bloomberg.
 
Attachment 1 to Convertible Promissory Note, Page 4
 
	 
	 

	

	 

 
EXHIBIT A
 
St. George Investments LLC 
303 East Wacker Drive, Suite 1040 
Chicago, Illinois 60601
 
 
	Avant Diagnostics, Inc. 
	Date: __________________ 

Attn: Gregg Linn, CEO 
8561 East Anderson Drive, Suite 104
Scottsdale, Arizona 85225
 
LENDER CONVERSION NOTICE
 

The above-captioned Lender hereby gives notice to Avant Diagnostics, Inc., a Nevada corporation (the "Borrower"), pursuant to that certain Convertible Promissory Note made by Borrower in favor of Lender on January 5, 2016 (the "Note"), that Lender elects to convert the portion of the Note balance set forth below into fully paid and non-assessable shares of Common Stock of Borrower as of the date of conversion specified below. Said conversion shall be based on the Lender Conversion Price set forth below. In the event of a conflict between this Lender Conversion Notice and the Note, the Note shall govern, or, in the alternative, at the election of Lender in its sole discretion, Lender may provide a new form of Lender Conversion Notice to conform to the Note. Capitalized terms used in this notice without definition shall have the meanings given to them in the Note.
 
A. Date of Conversion: ____________
B. Lender Conversion #: ____________
C. Conversion Amount: ____________
D. Lender Conversion Price: _______________ 
E. Lender Conversion Shares: _______________ (C divided by D)
F. Remaining Outstanding Balance of Note: ____________* 
 
* Subject to adjustments for corrections, defaults, interest and other adjustments permitted by the Transaction Documents (as defined in the Purchase Agreement), the terms of which shall control in the event of any dispute between the terms of this Lender Conversion Notice and such Transaction Documents.
 
$_________________of the Conversion Amount converted hereunder shall be deducted from the Installment Amount(s) relating to the following Installment Date(s): _________________.
 
Please transfer the Lender Conversion Shares electronically (via DWAC) to the following account:
 
	Broker:__________________
	 
	Address: 
	 
	 

	DTC#:__________________
	 
	 
	 
	 

	Account #:________________
	 
	 
	 
	 

	Account Name:______________
	 
	 
	 
	 

 
To the extent the Lender Conversion Shares are not able to be delivered to Lender electronically via the DWAC system, deliver all such certificated shares to Lender via reputable overnight courier after receipt of this Lender Conversion Notice (by facsimile transmission or otherwise) to:
 
_____________________________________
_____________________________________
_____________________________________
 
Exhibit A to Convertible Promissory Note, Page 1
 
	 
	 

	

	 

 
	 
	Sincerely,    
Lender: 
 
St. George Investments LLC
 
By: Fife Trading, Inc., Manager
	 

	 	 	 	 
		By:		 

	 
	 
	John M. Fife, President	 

 
Exhibit A to Convertible Promissory Note, Page 2
 
	 
	 

	

	 

 
 
EXHIBIT B
 
Avant Diagnostics, Inc.
8561 East Anderson Drive, Suite 104
Scottsdale, Arizona 85225
 

 
	St. George Investments LLC 
	Date: _____________

Attn: John Fife
303 East Wacker Drive, Suite 1040
Chicago, Illinois 60601
 
INSTALLMENT NOTICE
 
The above-captioned Borrower hereby gives notice to St. George Investments LLC, a Utah limited liability company (the "Lender"), pursuant to that certain Convertible Promissory Note made by Borrower in favor of Lender on January 5, 2016 (the "Note"), of certain Borrower elections and certifications related to payment of the Installment Amount of $_________________ due on ___________, 201_ (the "Installment Date"). In the event of a conflict between this Installment Notice and the Note, the Note shall govern, or, in the alternative, at the election of Lender in its sole discretion, Lender may provide a new form of Installment Notice to conform to the Note. Capitalized terms used in this notice without definition shall have the meanings given to them in the Note.
 
INSTALLMENT CONVERSION AND CERTIFICATIONS
AS OF THE INSTALLMENT DATE
 
A.                 INSTALLMENT CONVERSION
 
A. Installment Date: ____________, 201_
B. Installment Amount: ____________
C. Portion of Installment Amount to be Paid in Cash: ____________
D. Portion of Installment Amount to be Converted into Common Stock: ____________ (B minus C)
E. Installment Conversion Price: _______________ (lower of (i) Lender Conversion Price in effect and (ii) Market Price as of Installment Date)
F. Installment Conversion Shares: _______________ (D divided by E)
G. Remaining Outstanding Balance of Note: ____________ *
 
* Subject to adjustments for corrections, defaults, interest and other adjustments permitted by the Transaction Documents (as defined in the Purchase Agreement), the terms of which shall control in the event of any dispute between the terms of this Installment Notice and such Transaction Documents.
 
B.                 EQUITY CONDITIONS CERTIFICATION
 
1.      Market Capitalization:________________
 
(Check One)
 
2.      _________ Borrower herby certifies that no Equity Conditions Failure exists as of the Installment Date.
 
3.      _________ Borrower hereby gives notice that an Equity Conditions Failure has occurred and requests a waiver from Lender with respect thereto. The Equity Conditions Failure is as follows:
 
Exhibit B to Convertible Promissory Note, Page 1
 
	 
	 

	

	 

 
______________________________________________________________________________________________________________________________________
______________________________________________________________________________________________________________________________________
______________________________________________________________________________________________________________________________________
______________________________________________________________________________________________________________________________________
 
	 
	Sincerely,    
Borrower:
 
Avant Diagnostics, Inc.
	 

	 	 	 	 
		By:		 

	 
	Name:
		 

	 
	Title:
		 

 
	 
	ACKNOWLEDGED AND CERTIFIED BY:    
Lender:
 
St. George Investments LLC
 
By: Fife Trading, Inc., Manager
	 

	 	 	 	 
		By:		 

	 
	 
	John M. Fife, President	 

 
 Exhibit B to Convertible Promissory Note, Page 2
 
	 
	 

	

	 

 
EXHIBIT C
 
St. George Investments LLC 
303 East Wacker Drive, Suite 1040 
Chicago, Illinois 60601
 
 
	Avant Diagnostics, Inc. 
	Date: __________________ 

Attn: Gregg Linn, CEO
8561 East Anderson Drive, Suite 104
Scottsdale, Arizona 85225
 
TRUE-UP NOTICE
 
The above-captioned Lender hereby gives notice to Avant Diagnostics, Inc., a Nevada corporation (the "Borrower"), pursuant to that certain Convertible Promissory Note made by Borrower in favor of Lender on January 5, 2016 (the "Note"), of True-Up Conversion Shares related to _____________, 201_ (the "Installment Date"). In the event of a conflict between this True-Up Notice and the Note, the Note shall govern, or, in the alternative, at the election of Lender in its sole discretion, Lender may provide a new form of True-Up Notice to conform to the Note. Capitalized terms used in this notice without definition shall have the meanings given to them in the Note.
 
TRUE-UPCONVERSION SHARES AND CERTIFICATIONS
 
AS OF THE TRUE-UP DATE
 
1.      TRUE-UP CONVERSION SHARES
 
A.     Installment Date: ____________, 201_
B.      True-Up Date: ____________, 201_
C.      Portion of Installment Amount Converted into Common Stock: _____________
D.     True-Up Conversion Price: _______________ (lower of (i) Lender Conversion Price in effect and (ii) Market Price as of True-Up Date)
E.      True-Up Conversion Shares: _______________ (C divided by D)
F.       Installment Conversion Shares Delivered: ________________
G.     True-Up Conversion Shares to be Delivered: ________________ (only applicable if E minus F is greater than zero)
 
2.      EQUITY CONDITIONS CERTIFICATION (Section to be completed by Borrower)
 
A.     Market Capitalization:________________
 
(Check One)
 
B.      _________ Borrower herby certifies that no Equity Conditions Failure exists as of the applicable True-Up Date.
 
C.      _________ Borrower hereby gives notice that an Equity Conditions Failure has occurred and requests a waiver from Lender with respect thereto. The Equity Conditions Failure is as follows:
 
Exhibit C to Convertible Promissory Note, Page 1
 
	 
	 

	

	 

 
	 
	Sincerely,    
Lender: 
 
St. George Investments LLC
 
By: Fife Trading, Inc., Manager
	 

	 	 	 	 
		By:		 

	 
	 
	John M. Fife, President	 

 
Exhibit C to Convertible Promissory Note, Page 2EX-10.1

 Exhibit 10.1 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2. 
 FINAL
VERSION 
 AMENDED AND RESTATED 

COLLABORATION AGREEMENT 

BY AND BETWEEN 

OREXIGEN THERAPEUTICS, INC. 

AND 
 TAKEDA
PHARMACEUTICAL COMPANY LIMITED 
 DATED 

July 31, 2015 

 FINAL VERSION 

TABLE OF CONTENTS 
  

									
	 	 	 	  	 	  	Page	 
			
	 1.
	 	 DEFINITIONS.
	  	 	2	  
			
	 2.
	 	 DEVELOPMENT
	  	 	17	  
				
		 	 2.1
	  	 Overview.
	  	 	17	  
		 	 2.2
	  	 Development.
	  	 	18	  
			
	 3.
	 	 COMMERCIALIZATION; CO-PROMOTION
	  	 	25	  
				
		 	 3.1
	  	 Commercialization Activities.
	  	 	25	  
		 	 3.2
	  	 Additional Diligence Obligations.
	  	 	25	  
		 	 3.3
	  	 Commercialization.
	  	 	27	  
		 	 3.4
	  	 Regulatory Responsibilities.
	  	 	29	  
		 	 3.5
	  	 Orexigen’s Co-Promote Activities.
	  	 	31	  
		 	 3.6
	  	 Pharmacovigilance.
	  	 	33	  
		 	 3.7
	  	 Recalls and Product Safety.
	  	 	34	  
		 	 3.8
	  	 Trademarks.
	  	 	34	  
			
	 4.
	 	 PRODUCT SUPPLY
	  	 	36	  
				
		 	 4.1
	  	 Manufacturing Services Agreement; Quality Agreement.
	  	 	36	  
		 	 4.2
	  	 Takeda’s Option to Manufacture.
	  	 	36	  
		 	 4.3
	  	 [IntentionallyOmitted.]
	  	 	36	  
		 	 4.4
	  	 Commercial Packaging.
	  	 	36	  
			
	 5.
	 	 GOVERNANCE
	  	 	37	  
				
		 	 5.1
	  	 Joint Steering Committee.
	  	 	37	  
		 	 5.2
	  	 Joint Development Committee.
	  	 	38	  
		 	 5.3
	  	 Joint Commercialization Committee.
	  	 	40	  
		 	 5.4
	  	 Joint Manufacturing Committee.
	  	 	40	  
		 	 5.5
	  	 Additional Committees.
	  	 	41	  
		 	 5.6
	  	 General Committee Procedures.
	  	 	41	  
		 	 5.7
	  	 Committee Decision-Making.
	  	 	42	  
		 	 5.8
	  	 Orexigen’s Membership in Committees.
	  	 	43	  
		 	 5.9
	  	 Alliance Managers.
	  	 	44	  
			
	 6.
	 	 LICENSES
	  	 	44	  
				
		 	 6.1
	  	 Licenses to Takeda for Products.
	  	 	44	  
		 	 6.2
	  	 Sublicensing.
	  	 	45	  
		 	 6.3
	  	 Licenses to Orexigen.
	  	 	45	  
		 	 6.4
	  	 Patent Marking.
	  	 	46	  
		 	 6.5
	  	 No Implied Licenses; Upstream Agreements.
	  	 	46	  

  
 - 1 - 

 FINAL VERSION 

 

									
		 	 6.6
	  	 Parallel Trade.
	  	 	46	  
			
	 7.
	 	 FINANCIAL TERMS
	  	 	46	  
				
		 	 7.1
	  	 Upfront Payment.
	  	 	46	  
		 	 7.2
	  	 Milestone Payments.
	  	 	46	  
		 	 7.3
	  	 Royalty Payments.
	  	 	49	  
		 	 7.4
	  	 Royalty Payment Reports.
	  	 	51	  
		 	 7.5
	  	 Manner of Payment.
	  	 	51	  
		 	 7.6
	  	 Records Retention.
	  	 	52	  
		 	 7.7
	  	 Audits.
	  	 	52	  
		 	 7.8
	  	 Currency Exchange.
	  	 	52	  
		 	 7.9
	  	 Taxes.
	  	 	52	  
		 	 7.10
	  	 Interest Due.
	  	 	53	  
			
	 8.
	 	 REPRESENTATIONS, WARRANTIES, AND COVENANTS;
DISCLAIMERS; LIMITATION OF LIABILITY
	  	 	53	  
				
		 	 8.1
	  	 Mutual Representations and Warranties.
	  	 	53	  
		 	 8.2
	  	 Additional Representations and Warranties of Orexigen.
	  	 	54	  
		 	 8.3
	  	 Additional Representations and Warranties of Takeda.
	  	 	57	  
		 	 8.4
	  	 Mutual Covenants.
	  	 	57	  
		 	 8.5
	  	 Additional Covenants of Orexigen.
	  	 	58	  
		 	 8.6
	  	 Additional Covenants of Takeda.
	  	 	59	  
		 	 8.7
	  	 DISCLAIMERS.
	  	 	61	  
		 	 8.8
	  	 LIMITATION OF LIABILITY.
	  	 	62	  
		 	 8.9
	  	 Knowledge Standard.
	  	 	62	  
			
	 9.
	 	 INTELLECTUAL PROPERTY
	  	 	62	  
				
		 	 9.1
	  	 Ownership of Inventions.
	  	 	62	  
		 	 9.2
	  	 Prosecution of Collaboration Patents.
	  	 	63	  
		 	 9.3
	  	 Enforcement of Collaboration Patents or Product Trademarks Against Infringers.
	  	 	65	  
		 	 9.4
	  	 Patent Term Extension.
	  	 	68	  
		 	 9.5
	  	 Regulatory Patent Listing.
	  	 	68	  
		 	 9.6
	  	 Defense Against Claims of Infringement of Third Party Patents.
	  	 	68	  
		 	 9.7
	  	 Third Party Licenses.
	  	 	69	  
			
	 10.
	 	 CONFIDENTIALITY
	  	 	69	  
				
		 	 10.1
	  	 Nondisclosure.
	  	 	69	  
		 	 10.2
	  	 Exceptions.
	  	 	70	  
		 	 10.3
	  	 Authorized Disclosure.
	  	 	70	  
		 	 10.4
	  	 Terms of this Agreement.
	  	 	71	  
		 	 10.5
	  	 Securities Filings.
	  	 	71	  
		 	 10.6
	  	 Relationship to Confidentiality Agreement.
	  	 	72	  
		 	 10.7
	  	 Publications.
	  	 	72	  

  
 - 2 - 

 FINAL VERSION 

 

									
		 	 10.8
	  	 Publicity.
	  	 	73	  
		 	 10.9
	  	 Third Party Information.
	  	 	73	  
			
	 11.
	 	 INDEMNITY AND INSURANCE
	  	 	73	  
				
		 	 11.1
	  	 Takeda Indemnity.
	  	 	73	  
		 	 11.2
	  	 Orexigen Indemnity.
	  	 	74	  
		 	 11.3
	  	 Indemnification Procedure.
	  	 	74	  
		 	 11.4
	  	 Dante Indemnity.
	  	 	75	  
		 	 11.5
	  	 Insurance.
	  	 	75	  
			
	 12.
	 	 TERM AND TERMINATION
	  	 	75	  
				
		 	 12.1
	  	 Term; Expiration.
	  	 	75	  
		 	 12.2
	  	 Termination for Cause.
	  	 	75	  
		 	 12.3
	  	 Termination for Safety Reasons.
	  	 	76	  
		 	 12.4
	  	 Termination for Insolvency.
	  	 	76	  
		 	 12.5
	  	 Termination for Patent Challenge.
	  	 	77	  
		 	 12.6
	  	 Unilateral Termination by Takeda.
	  	 	77	  
		 	 12.7
	  	 Consequences of Termination.
	  	 	77	  
		 	 12.8
	  	 Consequences of Expiration.
	  	 	80	  
		 	 12.9
	  	 Survival.
	  	 	80	  
		 	 12.10
	  	 No Limitation on Remedies.
	  	 	81	  
			
	 13.
	 	 DISPUTE RESOLUTION
	  	 	81	  
				
		 	 13.1
	  	 Exclusive Dispute Resolution Mechanism.
	  	 	81	  
		 	 13.2
	  	 Resolution by Executive Officers.
	  	 	81	  
		 	 13.3
	  	 Alternative Dispute Resolution.
	  	 	81	  
		 	 13.4
	  	 Survivability.
	  	 	82	  
		 	 13.5
	  	 Preliminary Injunctions.
	  	 	82	  
		 	 13.6
	  	 Patent Disputes.
	  	 	82	  
		 	 13.7
	  	 Confidentiality.
	  	 	82	  
			
	 14.
	 	 MISCELLANEOUS
	  	 	82	  
				
		 	 14.1
	  	 HSR.
	  	 	82	  
		 	 14.2
	  	 Severability.
	  	 	82	  
		 	 14.3
	  	 Notices.
	  	 	82	  
		 	 14.4
	  	 Force Majeure.
	  	 	84	  
		 	 14.5
	  	 Assignment.
	  	 	84	  
		 	 14.6
	  	 Further Assurances.
	  	 	85	  
		 	 14.7
	  	 Waivers, Modifications and Amendments.
	  	 	85	  
		 	 14.8
	  	 Governing Law.
	  	 	86	  
		 	 14.9
	  	 Relationship of the Parties.
	  	 	86	  
		 	 14.10
	  	 Entire Agreement.
	  	 	86	  
		 	 14.11
	  	 Exports.
	  	 	86	  
		 	 14.12
	  	 Interpretation.
	  	 	86	  

  
 - 3 - 

 FINAL VERSION 

 

									
		 	 14.13
	  	 Performance by Affiliates.
	  	 	86	  
		 	 14.14
	  	 Counterparts; Electronic Delivery.
	  	 	87	  

  
 - 4 - 

 FINAL VERSION 

 
 AMENDED AND RESTATED COLLABORATION AGREEMENT 

THIS AMENDED AND RESTATED COLLABORATION
AGREEMENT (the “Agreement”) is made and entered into as of July 31, 2015 (the “Amended and Restated Effective Date”), by and between Orexigen Therapeutics, Inc., a
Delaware corporation located at 3344 N. Torrey Pines Court, Suite 200, La Jolla, California 92037, United States of America (“Orexigen”), and Takeda Pharmaceutical Company Limited, a Japanese corporation with a principal
place of business at 1-1, Doshomachi 4-Chome Chuo-ku, Osaka 540-8645, Japan (“Takeda”). Orexigen and Takeda are sometimes referred to herein individually as a “Party” and collectively as the
“Parties.” 
 RECITALS 

WHEREAS, Orexigen has certain expertise and experience of interest to Takeda relating to certain
pharmaceutical therapeutic molecules; 
 WHEREAS, Takeda has expertise and experience in, and resources
and funding for, the development, manufacture and commercialization of pharmaceutical therapeutic molecules; 

WHEREAS, Orexigen has rights under certain patent, know-how and trademark rights relating to such
pharmaceutical therapeutic molecules, including Orexigen’s therapeutic product, Contrave® (as defined below), and Orexigen has invested substantial resources and funding in developing
Contrave; 
 WHEREAS, Takeda and Orexigen desire to collaborate to continue the conduct of development
and commercialization activities for Contrave, including the investment of resources and funding by Takeda for reimbursement of past research and development expenditures made by Orexigen and to support the future development and commercialization
of Contrave; 
 WHEREAS, Orexigen desires to have the option to Co-Promote (as defined below) Contrave
in the Territory, and Takeda is willing to grant such option as set forth herein; 
 WHEREAS, the
Parties entered into that certain Collaboration Agreement dated as of September 1, 2010 (the “Original Effective Date”), as amended by that certain Amendment Number 1 to the Collaboration Agreement dated September 26, 2013
(the “Amendment No. 1 Effective Date”) between the Parties (collectively, the “Original Collaboration Agreement”); and 

WHEREAS, the Parties have agreed to amend the Original Collaboration Agreement as set forth herein, and,
effective as of the Amended and Restated Effective Date, to replace the Original Collaboration Agreement, in its entirety, including its Exhibits, with this Agreement. 

AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements set forth
below, the Parties agree as follows: 

  
 - 1 - 

 FINAL VERSION 

 

 1. DEFINITIONS. The terms in this Agreement with initial letters
capitalized, whether used in the singular or the plural, shall have the meaning set forth below or, if not listed below, the meaning designated in places throughout this Agreement. 

1.1 “Affiliate” of a Person means any other Person that directly or indirectly is controlled by, controls or is under common
control with such Person. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used with respect to a Person means
(a) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors or (b) in the case of a non-corporate entity, direct or
indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the management and policies of such entity; provided that, if local Laws restrict foreign ownership, control shall be established by
direct or indirect ownership of the maximum ownership percentage that may, under such local Laws, be owned by foreign interests. 
 1.2
“Alliance Manager” has the meaning set forth in Section 5.9. 
 1.3 “Amended and Restated Effective
Date” has the meaning set forth in the first paragraph of this Agreement. 
 1.4 “Bankruptcy Code” has the meaning
set forth in Section 12.4. 
 1.5 “Breaching Party” has the meaning set forth in Section 12.2.1. 

1.6 “Business Day” means a day other than Saturday, Sunday or any day on which commercial banks located in the State of New
York, U.S., or Japan are authorized or obligated by Laws to close. 
 1.7 “Calendar Quarter” means the respective periods
of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Original
Effective Date to the end of the first complete Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement. 

1.8 “Calendar Year” means (a) for the first Calendar Year of the Term, the period beginning on the Original Effective
Date and ending on December 31, 2011, (b) for each Calendar Year of the Term thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31, and (c) for
the last Calendar Year of the Term, the period beginning on January 1 of the Calendar Year in which this Agreement expires or terminates and ending on the effective date of expiration or termination of this Agreement. 

1.9 “Change of Control” means the occurrence of any of the following: 

(a) a Party entering into a merger, consolidation, stock sale or sale or transfer of all or substantially all of its assets, or other
similar transaction or series of related transactions with another entity, unless, following such transaction or transactions, (i) the individuals and entities who were the beneficial owners of the outstanding voting securities of

  
 - 2 - 

 FINAL VERSION 

 

 
such Party immediately prior to such transaction or transactions beneficially own, directly or indirectly, at least fifty percent (50%) of the combined voting power of the then outstanding
voting securities entitled to vote generally in the election of directors or similar governing persons of the corporation or other entity resulting from such transaction or transactions (“Successor”) in substantially the same
proportions as their ownership immediately prior to such transaction or transactions of such outstanding voting securities, and (ii) at least fifty percent (50%) of the members of the Board of Directors or similar governing body of the
Successor were members of the Board of Directors of such Party at the time of the execution of the initial agreement, or the action of the Board of Directors of such Party, governing such transaction or transactions; or 

(b) any transaction or series of related transactions in which any Person or group of Persons acquires beneficial ownership of
securities of a Party representing more than fifty percent (50%) of the combined voting power of the then outstanding securities of such Party; 

provided, however, that notwithstanding subsection (a) or (b) above, a stock sale to underwriters of a
public offering of such Party’s capital stock shall not constitute a Change of Control.  
 1.10 “Clinical
Trial(s)” means any human clinical study of a pharmaceutical product, including Phase IV Trials. 
 1.11 “Clinical Trial
Product Liabilities” means all losses, damages, fees, costs and other liabilities incurred by a Party or its Affiliates and resulting from human use of Product in Clinical Trials during the Term but excluding all losses, damages, fees,
costs and other liabilities that are a result of a Party’s or its Affiliates’ negligence, recklessness, willful misconduct or breach of such Party’s representations and warranties made hereunder. For the avoidance of doubt, Clinical
Trial Product Liabilities include reasonable attorneys’ and experts’ fees and costs relating to any claim or potential claim by any Third Party against a Party or its Affiliates. 

1.12 “Collaboration” means the Development and Commercialization activities conducted by the Parties pursuant to this
Agreement. 
 1.13 “Collaboration Patents” means the Orexigen Patents and the Takeda Patents. 

1.14 “Combination Product” means any pharmaceutical composition, branded or generic, containing the Licensed Compounds in
combination with any other clinically active ingredient(s) that is not a Licensed Compound, whether packaged together or in the same therapeutic formulation. 

1.15 “Commercial Packaging” means all activities after completion of Manufacturing of Product in finished bulk form related
to final packaging and labeling of Product (in commercial packaging presentation) for commercial use, including primary packaging and insertion of materials such as patient inserts, patient medication guides, and

  
 - 3 - 

 FINAL VERSION 

 

 
professional inserts and any other written, printed or graphic materials accompanying Product, considered to be part of the finished packaged Product in accordance with the applicable
specifications and legal requirements, and all testing and release thereof. “Commercial Packaging” shall include stability testing to the extent the right and responsibility to perform stability testing is transferred to Takeda pursuant to
Section 4.4. 
 1.16 “Commercialization” means all activities, whether initiated or conducted prior to or following
receipt of Regulatory Approval for a Product in the Field and in the Territory, undertaken pursuant to the Commercialization Plan in support of the promotion, marketing, sale and distribution (including importing, exporting, transporting, customs
clearance, warehousing, invoicing, handling and delivering Product to customers) of the Product, including: (a) sales force efforts, detailing, advertising, marketing, sales and distribution (as described in Section 3.3.5), pricing,
managed markets and medical affairs, including publications, medical education, medical information, clinical science liaison activities, investigator initiated sponsored research programs and health economics and outcomes research, (b) the
preparation, filing, and maintenance of Regulatory Filings, including the filing of annual updates, but excluding any such activities relating to obtaining the first, and only the first, Regulatory Approval for such Product, and (c) other
similar activities directly relating to the Product in or for the Territory. “Commercialization” shall exclude Development and Manufacturing activities. When used as a verb, “Commercialize” means to engage in
Commercialization activities. 
 1.17 “Commercialization Costs” means the Third Party out-of-pocket costs and expenses
incurred by a Party after the Original Effective Date in connection with Commercialization activities, and any costs and expenses associated with Third Party product liability claims resulting from human use of Products after Regulatory Approval.
Commercialization Costs shall be considered a cost or expense incurred by a Party after the Original Effective Date, even though the actual payment for such cost or expense is made prior to the Original Effective Date, if the corresponding work is
performed after the Original Effective Date, and shall be considered a cost or expense that is not incurred by a Party after the Original Effective Date if the actual payment for such cost or expense is made after the Original Effective Date, but
the corresponding work was performed prior to the Original Effective Date. Commercialization Costs shall also include (a) all Third Party out-of-pocket costs incurred by Orexigen and (b) all internal and Third Party out-of-pocket costs,
including labor costs, material costs and overhead (each without mark-up), incurred by Takeda, in each of (a) and (b) to the extent relating to Manufacture of Product for Commercialization activities. Commercialization Costs do not
include: (i) internal personnel costs, other than as described in subsection (b) above; (ii) certain costs set forth in Exhibit 3.5.3 or in the Co-Promote Agreement, if any; (iii) Clinical Trial Product Liabilities; and
(iv) any losses, damages, fees, costs and other liabilities incurred by a Party as a result of such Party’s negligence, recklessness, willful misconduct or breach of such Party’s representations and warranties made hereunder, and any
such losses, damages, fees, costs and other liabilities will be treated as the sole and exclusive responsibility of the Party whose actions or omissions gave rise to such losses, damages, fees, costs and other liabilities. 

1.18 “Commercialization Plan” means a plan to be agreed upon by the Parties pursuant to Section 3.3.1, that details the
Commercialization activities to be conducted with respect to a Product during the Term, which plan shall describe the strategic Commercialization objectives and activities (including advertising, education, planning, promotion, sales, including

  
 - 4 - 

 FINAL VERSION 

 

 
sales force incentive plans and a PDE frequency call plan by prescription decile, medical affairs, including a publications plan, and managed markets, including a pricing and discounting plan)
for the Product in the Field in the Territory, and the corresponding budget and sales forecast for the Product; provided, further, that following Orexigen’s election to Co-Promote pursuant to Section 3.5, such plan shall also be
updated to include a detailed call target plan, sales force incentive plans, and any other activities to be conducted by Orexigen with respect to the Commercialization of Contrave in the Territory. 

1.19 “Commercially Reasonable Efforts” means, with respect to the efforts to be expended, or considerations to be undertaken,
by a Party or its Affiliate with respect to any objective, activity or decision to be undertaken hereunder, reasonable, good faith efforts to accomplish such objective, activity or decision as such Party would normally use to accomplish a similar
objective, activity or decision under similar circumstances, it being understood and agreed that with respect to the Development or Commercialization of Products, such efforts and resources shall be consistent with those efforts and resources
commonly used by a Party for a similar pharmaceutical product owned by it or to which it has exclusive rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account efficacy,
safety, approved labeling, the competitiveness of alternative products sold by Third Parties in the marketplace, the patent and other proprietary position of the product, the likelihood of regulatory approval given the regulatory structure involved,
the profitability of the product taking into consideration, among other factors, Third Party costs and expenses including the royalties, milestone and other payments payable to Third Party licensors of patent or other intellectual property rights,
and the pricing and reimbursement relating to the product. Commercially Reasonable Efforts shall be determined on an indication-by-indication basis for the Product, and it is anticipated that the level of effort will change over time, reflecting
changes in the status of the Product in the Territory. 
 1.20 “Committee” means each of the JSC, the JDC, the JCC, and the
JMC, or any sub-Committees created pursuant to Section 5.5. 
 1.21 “Competitive Product Infringement” has the meaning
set forth in Section 9.3.1. 
 1.22 “Confidential Information” means all trade secrets, processes, formulae, data,
Know-How, improvements, inventions, chemical or biological materials, chemical structures, techniques, marketing plans, strategies, customer lists, Clinical Trial data (including CVOT PMR Study data) or other confidential or proprietary information
that is disclosed by a Party to the other Party, regardless of whether any of the foregoing are marked “confidential” or “proprietary” or communicated to the other Party by the Disclosing Party in oral, written, graphic, or
electronic form. 
 1.23 “Contrave” means the Orexigen proprietary formulation of bupropion hydrochloride and naltrexone
hydrochloride, formulated in an extended release formulation, as described in NDA No. 20-0063. 
 1.24 “Controlled”
or “Controls” means, when used in reference to Know-How, Confidential Information, Patents or other intellectual property rights, the legal authority or 

  
 - 5 - 

 FINAL VERSION 

 

 
right of a Party (or any of its Affiliates) to grant a license or sublicense of such Know-How or intellectual property rights to the other Party, or to otherwise disclose such Know-How or
Confidential Information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating such Know-How or Confidential Information of a Third Party. 

1.25 “Co-Promote” has the meaning set forth in Section 3.5.1. 

1.26 “Co-Promote Agreement” means the agreement to be entered into by the Parties in the event that Orexigen exercises its
right to Co-Promote as set forth in Section 3.5.1 or 3.5.2. 
 1.27 “Co-Promote Option” has the meaning set forth in
Section 3.5.2. 
 1.28 “Cover(ed)” means, with respect to any Patent and the subject matter at issue, that, but for a
license granted under a Valid Claim in such Patent, the manufacture, use, sale, offer for sale or importation of the subject matter at issue would infringe such Valid Claim, or, in the case of a Patent that is a patent application, would infringe a
Valid Claim in such patent application if it were to issue as a patent. 
 1.29 “Cure Period” has the meaning set forth in
Section 12.2.1. 
 1.30 “CVOT PMR Study” means the randomized, double-blind, placebo-controlled Clinical Trial to
evaluate the effect of long-term treatment with Contrave on the incidence of MACE in obese and overweight subjects with cardiovascular disease that the FDA required in its Regulatory Approval of Contrave dated September 10, 2014, which study
shall meet the following requirements: (a) the primary objective of this Clinical Trial shall be to demonstrate that the upper bound of the 2-sided confidence interval for the estimated risk ratio comparing the incidence of MACE observed with
Contrave to that observed in the placebo group is less than 1.4; (b) the Clinical Trial shall be designed to provide sufficient data to reflect the “on treatment” cardiovascular risk associated with Contrave; (c) the Clinical
Trial shall be designed in a manner that allows for completion in accordance with the timelines set by the FDA; and (d) any other requirements for such Clinical Trial set forth by the FDA or that the Parties mutually agree to include in such
Clinical Trial. 
 1.31 “Dante License” means the License Agreement between Orexigen and Lee Dante, M.D., dated
June 1, 2004, as amended, and “Dante” means Lee Dante, M.D. 
 1.32 “Data Monitoring Committee”
means, with respect to the CVOT PMR Study, the data monitoring committee established and existing under a data monitoring committee charter, which charter may be updated from time to time. [...***...] shall have the right to have
[...***...] representatives present at all open session meetings of the Data Monitoring Committee and shall receive [...***...] copy of all open session meeting materials. 

1.33 “Delivery of Launch Supplies” has the meaning set forth in Section 7.2.1. 

1.34 “Development” means all non-clinical and clinical drug development activities, each to the extent reasonably relating to
the development of Products in or for the 

  
 - 6 - 

 FINAL VERSION 

 

 
Territory. Development shall include toxicology, pharmacology, and other non-clinical efforts, test method development and stability testing, validation batch development, manufacturing process
development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, the conduct of Clinical Trials or other activities, including Development Approval Activities and Development
Post-Approval Activities, relating to obtaining Regulatory Approval, as detailed in the Development Plan for the Product. “Development” shall exclude all Commercialization and Manufacturing activities. When used as a verb,
“Develop” means to engage in Development activities. 
 1.35 “Development Approval Activities” means all
Development activities conducted solely to the extent reasonably necessary to obtain the first, and only the first, Regulatory Approval for the Product for the Initial Indication in the Territory. 

1.36 “Development Costs” means, except as otherwise set forth in this Section 1.36, the Third Party out-of-pocket costs
incurred by a Party after the Original Effective Date in connection with Development activities set forth in the Development Plan and Clinical Trial Product Liabilities. Development Costs shall also include: (a) the cost of preparation, filing,
and maintenance of Regulatory Filings prior to receipt of the first, and only the first, Regulatory Approval for the Product for the Initial Indication in the Territory, and (b)(i) all Third Party out-of-pocket costs incurred by Orexigen and
(ii) all internal and Third Party out-of-pocket costs, including labor costs, material costs and overhead (each without mark-up), incurred by Takeda, in each of (i) and (ii) to the extent relating to Manufacture of Product for
Development activities. For the avoidance of doubt, Development Costs relating to the Manufacture of Product by Orexigen or Takeda shall be split in accordance with Section 2.2.2(b); by way of example, if Orexigen incurs Third Party costs to
Manufacture validation batches of Product for Commercial sale, but such Product is used in a Clinical Trial that is not the CVOT PMR Study, Takeda shall be obligated to pay seventy-five percent (75%) of such Manufacturing costs pursuant to
2.2.2(b)(v). 
 1.37 “Development Plan” means a plan to be agreed upon by the Parties pursuant to Section 2.2.1, that
details the Development activities to be conducted pursuant to this Agreement with respect to a Product during the Term, which plan will outline the strategic Development objectives and activities for each Product in the Territory, and contains a
detailed budget identifying the Development Costs associated with such Development activities. 
 1.38 “Development Post-Approval
Activities” means all Development activities other than Development Approval Activities. For the avoidance of doubt, “Development Post-Approval Activities” includes Product formulation development activities, post-marketing
requirements (e.g., the CVOT PMR Study, Non-CVOT PMRs) and other post-marketing Development activities (e.g., completion of the Light Study, life cycle management activities, and Phase IV Trials). 

1.39 “Disclosing Party” has the meaning set forth in Section 10.1. 

1.40 “Disputes” has the meaning set forth in Section 13.1. 

1.41 “Dollar” means a U.S. dollar, and “$” shall be interpreted accordingly. 

  
 - 7 - 

 FINAL VERSION 

 

 1.42 “EMA” means the European Medicines Agency, or any successor agency
thereto. 
 1.43 “EU” means the European Union. 

1.44 “Executive Officers” has the meaning set forth in Section 5.7.3. 

1.45 “Executive Steering Committee” means with respect to the CVOT PMR Study, the executive steering committee established
and existing under the executive steering committee charter, which charter may be updated from time to time. [...***...] shall have the right to have [...***...] representatives present at all open session meetings of the Executive
Steering Committee and shall receive [...***...] copy of all open session meeting materials. 
 1.46 “FDA” means the
U.S. Food and Drug Administration, or any successor agency thereto. 
 1.47 “Field” means the treatment or prevention of
any and all Indications in humans. 
 1.48 “First Commercial Sale” means, with respect to any Product, the first sale of
such Product invoiced to a Third Party in the Territory after Regulatory Approval of such Product has been granted. 
 1.49 “Force
Majeure” has the meaning set forth in Section 14.4. 
 1.50 “GAAP” means generally accepted accounting
principles in the United States or Japan, consistently applied. 
 1.51 “Generic Competition” means, with respect to all
Products in the Territory, in three (3) consecutive calendar months, if, during such three (3) consecutive calendar month period, one (1) or more Generic Products are sold in the Territory and units of the Generic Product(s) sold
account for more than ten percent (10%) of the sum of: (a) all units of all Products sold in the Territory, and (b) all units of the Generic Products sold in the Territory, in each case based on the average of the monthly IMS data (or
IMS-equivalent data if IMS data is not available) for such units. 
 1.52 “Generic Product” means, on a Product-by-Product
basis, any pharmaceutical product sold by a Third Party in the Territory, other than pursuant to a sublicense from Takeda, which: (a) contains the same active ingredients as the applicable Product in a fixed-dose combination (including a
co-packaged, single prescription product) and in the same dosage form (e.g., oral, injectable, intranasal, etc.) as the applicable Product, or (b) is A/B Rated with respect to such Product in the Territory. For the purposes of this definition,
“A/B Rated” means “therapeutically equivalent” as determined by the FDA, applying the definition of “therapeutically equivalent” set forth in the preface to the then-current edition of the FDA publication
“Approved Drug Products With Therapeutic Equivalence Evaluations”. 

  
 - 8 - 

 FINAL VERSION 

 

 1.53 “Good Clinical Practices” or “GCP” means the
standards, practices and procedures set forth in the International Conference on Harmonization guidelines entitled in “Good Clinical Practice: Consolidated Guideline,” including related regulatory requirements imposed by the FDA and (as
applicable) any equivalent or similar standards in jurisdictions outside the United States, to the extent that such standards are applicable in the jurisdiction in which the relevant Clinical Trial is conducted or required to be followed in the
jurisdiction in which Regulatory Approval of a product will be sought. 
 1.54 “Good Laboratory Practices” or
“GLP” means the regulations set forth in 21 C.F.R. Part 58 and the requirements expressed or implied thereunder imposed by the FDA and (as applicable) any equivalent or similar standards in jurisdictions outside the United States. 

1.55 “Good Manufacturing Practices” or “GMP” means the regulations set forth in 21 C.F.R. Parts
210–211, and the requirements thereunder imposed by the FDA, and, as applicable, any similar or equivalent regulations and requirements in jurisdictions outside the United States. 

1.56 “GSK Field” means the treatment of obesity and disorders of weight management as set forth in the GSK License. 

1.57 “GSK License” means the License Agreement between Orexigen and GSK, effective June 10, 2009, as amended, and
“GSK” means SmithKline Beecham Corporation, doing business as GlaxoSmithKline, a Pennsylvania corporation located at One Franklin Plaza, Philadelphia, PA 19102 and Glaxo Group Limited, a private limited company incorporated in
England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, England UB6 0NN. 
 1.58
“Hatch-Waxman Act” has the meaning set forth in Section 9.4. 
 1.59 “HSR Act” has the meaning set forth
in Section 14.1. 
 1.60 “IFRS” means the International Financial Reporting Standards. 

1.61 “Improvement” means any Invention that is incorporated into, used in connection with, or relates to the Product, whether
or not protected by a Patent. 
 1.62 “IND” means any Investigational New Drug application, as contemplated by
Section 505(i) of the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time, and the regulations promulgated thereunder, filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations,
including any amendments thereto. References herein to IND shall include, to the extent applicable, any comparable filing(s) outside the United States necessary to commence or conduct Clinical Trials. 

1.63 “Indemnification Claim” has the meaning set forth in Section 11.3. 

1.64 “Indemnitee” has the meaning set forth in Section 11.3. 

1.65 “Indemnitor” has the meaning set forth in Section 11.3. 

  
 - 9 - 

 FINAL VERSION 

 

 1.66 “Indication” means any disease or condition which could be listed under
the header “INDICATIONS AND USAGE” or described under the header “CLINICAL STUDIES” of a Product’s label upon Regulatory Approval, or equivalent thereof in the event applicable Laws are modified. 

1.67 “Initial Co-Promote Period” has the meaning set forth in Section 3.5.1. 

1.68 “Initial Indication” means the disease or condition for which Contrave is first approved by the FDA, as described under
the header “INDICATIONS AND USAGE” in the first approved labeling for Contrave. 
 1.69 “Initiation” or
“Initiate” means, when used with respect to Clinical Trials, the dosing of the first human patient with the first dose in such Clinical Trials. 

1.70 “Inventions” has the meaning set forth in Section 9.1.1. 

1.71 “IPR Proceedings” has the meaning set forth in Section 9.2.1. 

1.72 “Joint Invention” has the meaning set forth in Section 9.1.1. 

1.73 “Joint Patent” has the meaning set forth in Section 9.1.1. 

1.74 “JCC” has the meaning set forth in Section 5.3.1. 

1.75 “JDC” has the meaning set forth in Section 5.2.1. 

1.76 “JMC” has the meaning set forth in Section 5.4.1. 

1.77 “JSC” has the meaning set forth in Section 5.1.1. 

1.78 “Know-How” means technical information and know-how, including biological, chemical, pharmacological, and toxicological
information, know-how and trade secrets, and manufacturing data, preclinical data, Clinical Trial data, the specifications of ingredients, the manufacturing processes, formulation, specifications, sourcing information, quality control and testing
procedures, and related know-how and trade secrets. 
 1.79 “Launch Supplies” means the full quantity of Product in
finished bulk form (30 gallon HDPE drums or in such other finished bulk form as agreed to by the Parties), by dosage strength, ordered by Takeda for commercial launch of Product in the Territory, which at the time of Delivery (of Launch Supplies),
will have a minimum of nine (9) months remaining shelf life and will comply with the terms of the Manufacturing Services Agreement. 

1.80 “Laws” means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of
law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign. 
 1.81
“Licensed Compounds” means bupropion hydrochloride and naltrexone hydrochloride, including all drug forms, formulations and salts thereof. 

  
 - 10 - 

 FINAL VERSION 

 

 1.82 “Light Study” means the terminated Orexigen study NB-CVOT which was a
multicenter, double-blind, placebo-controlled study assessing the occurrence of MACE in overweight and obese subjects with cardiovascular risk factors receiving naltrexone SR/bupropion SR. 

1.83 “Losses and Claims” has the meaning set forth in Section 11.1. 

1.84 “MACE” means major adverse cardiovascular events, including non-fatal myocardial infarction, non-fatal stroke, and
cardiovascular death. 
 1.85 “Manufacture” with a correlative meaning for “Manufacturing,” means all
activities related to the manufacturing of a pharmaceutical product, or any ingredient thereof, including manufacturing Product in finished form for Development, manufacturing finished Product for Commercialization, labelling, packaging, in-process
and finished Product testing, validation, process improvement, and process development, release of Product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of Product, ongoing stability tests
and regulatory activities related to any of the foregoing. “Manufacturing” shall include Commercial Packaging. 
 1.86
“Manufacturing Responsibility Transition Plan” has the meaning set forth in Section 4.2. 
 1.87 “Manufacturing
Services Agreement” has the meaning set forth in Section 4.1. 
 1.88 “NDA” means a New Drug Application or
supplemental New Drug Application as contemplated by Section 505(b) of the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time, and the regulations promulgated thereunder, submitted to the FDA pursuant to Part 314
of Title 21 of the U.S. Code of Federal Regulations, including any amendments thereto. 
 1.89 “Net Sales” means, with
respect to a particular time period, the total amounts invoiced to Third Parties by Takeda, its Affiliates or Sublicensees for sale or other distribution of Products made during such time period to Third Parties in the Territory, less the following
deductions to the extent actually allowed or incurred with respect to such sales: 
 (a) sales returns and allowances, including
trade, quantity and cash discounts and any other adjustments, including those granted on account of price adjustments, billing errors, bad debt expense (i.e., non-payment on an account receivable) not to exceed an amount equal to three percent
(3%) of such total amounts invoiced, rebates, chargebacks, fees, reimbursements or similar payments actually granted or given to wholesalers or other distributors, buying groups, healthcare insurance carriers or other institutions, federal,
state, or local government and the agencies, and reimbursers of managed health organizations; 
 (b) credits or allowances actually
granted upon damaged goods, rejections, or returns of such Products, including in connection with recalls; 

  
 - 11 - 

 FINAL VERSION 

 

 (c) freight, postage, shipping, transportation, and insurance charges actually
allowed or paid for delivery of Products, to the extent billed; and 
 (d) taxes (other than income or withholding taxes), duties,
tariffs, or other governmental charges levied on the sale of such Products to the extent billed, including value-added taxes and annual fees paid pursuant to the U.S. Affordable Care Act, dated March 23, 2010 (as amended), net of all
reimbursements and allowances. 
 Notwithstanding the foregoing, amounts billed by Takeda, its Affiliates or Sublicensees for the sale of Products among
Takeda, its Affiliates or Sublicensees for resale shall not be included in the computation of Net Sales hereunder. Net Sales shall be accounted for in accordance with GAAP or IFRS, as applicable. Net Sales shall exclude any samples of Product
transferred or disposed of at no cost for promotional or educational purposes. 
 In the case of any Combination Product in the Territory, Net Sales for
such Combination Product in the Territory shall be calculated as follows: 
 (i) If Product and other clinically active
ingredient(s) each are sold separately in the Territory, Net Sales will be calculated by multiplying the total Net Sales (as described above) of the Combination Product by the fraction A/(A+B), where A is the average invoice price in the Territory
of the Product sold separately in the same formulation and dosage, and B is the sum of the average invoice prices in the Territory of such other clinically active ingredient(s) sold separately in the same formulation and dosage, during the
applicable Calendar Year. 
 (ii) If the Product is sold independently of the other clinically active ingredient(s) therein in the
Territory, but the average invoice price of such other clinically active ingredient(s) cannot be determined, Net Sales will be calculated by multiplying the total Net Sales (as described above) of the Combination Product by the fraction A/C where A
is the average invoice price in the Territory of such Product sold independently and C is the average invoice price in the Territory of the entire Combination Product. 

(iii) If the other clinically active ingredient(s) are sold independently of the Product therein in the Territory, but the average
invoice price of such Product cannot be determined, Net Sales will be calculated by multiplying the total Net Sales (as described above) of the Combination Product by the fraction [1-B/C], where B is the average invoice price in the Territory of
such other clinically active ingredient(s) and C is the average invoice price in the Territory of the entire Combination Product. 
 1.90
“Non-Breaching Party” has the meaning set forth in Section 12.2.1. 
 1.91 “Non-CVOT PMR Study” means
any Clinical Trial or non-clinical study, other than the CVOT PMR Study, that is required by the FDA to maintain Regulatory Approval of Contrave. 

1.92 “OHSU Agreement” means the License Agreement between Orexigen and OHSU, dated June 27, 2003, as amended, and
“OHSU” means the Oregon Health & Science University, having offices at 2525 SW 1st Ave, Portland, Oregon 97201. 

  
 - 12 - 

 FINAL VERSION 

 

 1.93 “Orange Book” has the meaning set forth in Section 9.5.1. 

1.94 “Orexigen Indemnitees” has the meaning set forth in Section 11.1. 

1.95 “Orexigen Intellectual Property” means the Orexigen Patents and the Orexigen Know-How. 

1.96 “Orexigen Invention Patent” has the meaning set forth in Section 9.1.1. 

1.97 “Orexigen Know-How” means all Know-How Controlled by Orexigen or its Affiliates as of the Original Effective Date or at
any time during the Term that is primarily related to or reasonably necessary for the Development or Commercialization. For clarity, the Orexigen Know-How does not include rights with respect to any active ingredient in a Combination Product other
than rights to the Product. 
 1.98 “Orexigen Logo” has the meaning set forth on Exhibit 1.98. 

1.99 “Orexigen Patents” means any and all (a) Patents that are Controlled by Orexigen or its Affiliates as of the
Original Effective Date in the Territory as set forth on Exhibit 1.99, including the Upstream Patents set forth on Exhibit 1.99 (which Upstream Patents are subject to the respective terms and conditions of the applicable Upstream Agreement); and
(b) other Patents that (i) are Controlled by Orexigen or its Affiliates in the Territory during the Term and (ii) Cover a Product. Orexigen Patents include the Orexigen Invention Patents and Orexigen’s interest in Joint Patents.
For clarity, the Orexigen Patents do not include rights with respect to any active ingredient in a Combination Product other than rights to the Product. 

1.100 “Orexigen Trademark” has the meaning set forth in Section 3.8.2. 

1.101 “Original Collaboration Agreement” has the meaning set forth in the recitals of this Agreement. 

1.102 “Original Effective Date” has the meaning set forth in the recitals of this Agreement. 

1.103 “Paragraph IV Certification” has the meaning set forth in Section 9.3.2(c). 

1.104 “Patents” means U.S. patents and patent applications and (a) any foreign counterparts thereof, (b) all
divisionals, continuations, continuations in-part thereof or any other patent or patent application claiming priority directly or indirectly to (i) any such specified patents or patent applications or (ii) any patent or patent application
from which such specified patents or patent applications claim direct or indirect priority, and (c) all patents issuing on any of the foregoing, and any foreign counterparts thereof, together with all registrations, reissues, re-examinations,
renewals, supplemental protection certificates, or extensions of any of the foregoing, and any foreign counterparts thereof; provided, however, that continuations-in-part of the Upstream Patents are only included to the extent that the
subject matter claimed in each such continuation-in-part is described in and enabled by the disclosure of an Upstream Patent to which any particular continuation-in-part claims priority. 

  
 - 13 - 

 FINAL VERSION 

 

 1.105 “Patheon Agreement” means the Manufacturing Services Agreement entered
into as of March 12, 2010 among Patheon Pharmaceuticals Inc., Patheon Inc., and Orexigen, as amended. 
 1.106 “PDE
Term” has the meaning set forth in Section 3.2.1. 
 1.107 “PDE Cost” means sixty percent (60%) of
Takeda’s then-current fully burdened internal cost for each PDE performed by Orexigen, as set forth in paragraph 2 of Exhibit 3.5.3. 

1.108 “Person” means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint
venture, governmental authority, association or other entity. 
 1.109 “Pharmacovigilance Agreement” has the meaning set
forth in Section 3.6. 
 1.110 “Phase IV Trial” means a human clinical trial of a pharmaceutical product Initiated
after receipt of Regulatory Approval in the Territory and that is conducted within the parameters of the Regulatory Approval for the pharmaceutical product. Phase IV Trials may include epidemiological studies, registries, modeling and
pharmacoeconomic studies of pharmaceutical product and post-marketing surveillance studies. 
 1.111 “Primary Detail
Equivalent” or “PDE” means a primary detail equivalent for the Product equal to one (1) P1 Detail or two (2) P2 Details. For the avoidance of doubt, details that are not P1 Details or P2 Details have no Primary
Detail Equivalents. A “P1 Detail” means a detail delivered by a Sales Representative face-to-face to a contact target in which the promotional message involving the Product is the principal topic of discussion during the contact;
and a “P2 Detail” means a detail delivered by a Sales Representative face-to-face to a contact target in which the promotional message involving the Product is emphasized more than any other product during the contact, except for
the product in the P1 Detail. For the avoidance of doubt, electronic and telemarketing details are not Primary Detail Equivalents. 

1.112 “Product” means any pharmaceutical composition, branded or generic, containing the Licensed Compounds, including any
Improvements to such composition. “Product” shall include Contrave. “Product” shall include “Combination Products.” 

1.113 “Product Plan” means the then-current Development Plan together with the then-current Commercialization Plan for a
Product. 
 1.114 “Product Trademarks” has the meaning set forth in Section 3.8.1. 

1.115 “Publication Manager” has the meaning set forth in Section 10.7.1. 

1.116 “Quality Agreement” has the meaning set forth in Section 4.1. 

1.117 “Quarterly Report” has the meaning set forth in Section 2.2.2(c). 

  
 - 14 - 

 FINAL VERSION 

 

 1.118 “Receiving Party” has the meaning set forth in Section 10.1. 

1.119 “Regulatory Approval” means, with respect to any Product in the Territory, approval by a Regulatory Authority of an
NDA. 
 1.120 “Regulatory Authority” means any national or supranational governmental authority, including the FDA, that
has responsibility or authority in the Territory to regulate the development, manufacture, sale or promotion of pharmaceutical products. 

1.121 “Regulatory Filings” means any and all regulatory applications, filings, approvals and associated correspondence
submitted to or received from a Regulatory Authority to further the Development or Commercialization of Products in, or into, the Territory. 

1.122 “Royalty Term” means, on a Product-by-Product basis, the period commencing on the First Commercial Sale of a Product in
the Territory and ending upon the later of: (i) the earliest date upon which both of the following have occurred: (a) the expiration of the last to expire of all Collaboration Patents containing a Valid Claim Covering the composition of
matter or method of manufacture or use of such Product (or any Licensed Compound therein), and (b) the expiration of all applicable exclusivity extensions, including pediatric or data exclusivity, in the Territory with respect to such Product
(such as those periods listed in the FDA’s Orange Book; or (ii) ten (10) years after First Commercial Sale of such Product in the Territory. 

1.123 “Sales Representatives” means sales representatives employed by a Party, or employed or contracted by a Third Party
that is contracted by a Party to provide sales representatives, to detail and promote the Product in the Territory. 
 1.124
“Secondary Co-Promote Period” has the meaning set forth in Section 3.5.2. 
 1.125 “SOPs” has the
meaning set forth in Section 3.7. 
 1.126 “Standstill Period” has the meaning set forth in Section 8.6.3(a).

 1.127 “Sublicense” means a written agreement pursuant to which a Third Party became a Sublicensee. 

1.128 “Sublicensee” means (a) any Third Party granted a sublicense by Takeda of any of the rights licensed to Takeda by
Orexigen under Section 6.1, including any Third Party to whom Takeda has granted the right to promote or distribute a Product if such Third Party is principally responsible for marketing and promotion of such Product in the Territory, or
(b) any Third Party granted a sublicense by Orexigen of any of the rights granted to it by Takeda hereunder. 
 1.129
“Superiority” means, with respect to the CVOT PMR Study, demonstration of a [...***...] reduction in the incidence of [...***...] that, according to FDA, will serve as a [...***...] to establish a [...***...]
for Contrave that includes [...***...]. 

  
 - 15 - 

 FINAL VERSION 

 

 1.130 “Superiority Claim” means Regulatory Approval of a labeled claim for
Contrave that includes an indication for [...***...]. 
 1.131 “Takeda Indemnitees” has the meaning set forth in
Section 11.2. 
 1.132 “Takeda Intellectual Property” means the Takeda Know-How and the Takeda Patent(s). 

1.133 “Takeda Invention Patent” has the meaning set forth in Section 9.1.1. 

1.134 “Takeda Know-How” means all Know-How Controlled by Takeda or its Affiliates as of the Original Effective Date or at any
time during the Term that is primarily related to or reasonably necessary for the composition of matter, method of making or using, or formulation of a Product, other than the Orexigen Know-How. 

1.135 “Takeda Patents” means any and all Patents that are Controlled by Takeda or its Affiliates as of the Original Effective
Date in the Territory or at any time during the Term in the Territory and claim or disclose (a) compositions of matter comprising a Product, or methods of treatment comprising the administration of a Product, or (b) the manufacture,
formulation, delivery, use, sale, offer for sale or importation of a Product. Takeda Patents include the Takeda Invention Patents and Takeda’s interest in Joint Patents. 

1.136 “Takeda Trademark” has the meaning set forth in Section 3.8.3. 

1.137 “Term” has the meaning set forth in Section 12.1. 

1.138 “Territory” means the United States. 

1.139 “Third Party” means any Person other than Takeda, Orexigen, or their respective Affiliates. 

1.140 “Third Party License” has the meaning set forth in Section 9.7.3. 

1.141 “Third Party Manufacturers” has the meaning set forth on Exhibit 8.2.12 of this Agreement, and Section 2.3.1 and
Exhibit 2.3.1 of the Manufacturing Services Agreement, which Exhibit 2.3.1 of the Manufacturing Services Agreement may be updated from time to time. 

1.142 “United States” or “U.S.” means the United States of America and all its territories and possessions.

 1.143 “Upstream Agreements” means (a) the Dante License, (b) the GSK License, and (c) the OHSU Agreement.
For clarity, as of the Amended and Restated Effective Date, the Dante License and the GSK License have expired in accordance with their terms. 

1.144 “Upstream Party” means, respectively, (a) Dante with respect to the Dante License, (b) GSK with respect to
the GSK License, and (c) OHSU with respect to the OHSU Agreement. 

  
 - 16 - 

 FINAL VERSION 

 

 1.145 “Upstream Patents” means the Patents licensed or assigned to Orexigen
under the Upstream Agreements, and any Patents claiming priority therefrom, subject to the provisions regarding continuations-in-part of Upstream Patents as set forth in Section 1.104. 

1.146 “USPTO” has the meaning set forth in Section 8.2.7. 

1.147 “Valid Claim” means a claim within a Patent application filed in or for the Territory or an issued Patent in or for the
Territory, in each case within the Collaboration Patents, that (i) is not expired, lapsed, or abandoned, (ii) is not dedicated to the public, disclaimed, or admitted to be unenforceable or invalid; and (iii) has not been invalidated,
held unenforceable or cancelled by a court or administrative agency of competent jurisdiction in an order or decision from which no appeal has been or can be taken, including through opposition, re-examination, reissue, disclaimer or otherwise. 

1.148 Construction. Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this
Agreement: (a) “include,” “includes” and “including” are not limiting and shall be deemed to be followed by “without limitation”; (b) definitions contained in this Agreement are applicable to the
singular as well as the plural forms of such terms; (c) references to a statute mean such statute as from time to time amended, modified or supplemented; (d) references to a Person are also to its permitted successors and assigns;
(e) captions, the plain meaning of defined terms to the extent different from the definitions provided in Article 1, and other headings to this Agreement are for convenience only, and shall have no force or effect in construing or interpreting
any of the provisions of this Agreement or any other legal effect; (f) references to “Article”, “Section”, or “Exhibit” refer to an Article or Section of, or an Exhibit to, this Agreement, unless otherwise
indicated; (g) the word “will” shall be construed to have the same meaning and effect as the word “shall” and vice versa; and (h) the word “or” has, except where otherwise indicated, the inclusive meaning
represented by the phrase “and/or”. 
 2. DEVELOPMENT 

2.1 Overview. The Parties shall undertake Development in accordance with a Development Plan as provided for herein consisting of
conducting Clinical Trials and other Development activities. 
 2.1.1 Commercially Reasonable Efforts. Each Party shall use
Commercially Reasonable Efforts to Develop each Product in accordance with the Development Plan, including in completion of activities assigned to each Party in the Development Plan. Additionally, and without limiting the foregoing, if the
[...***...] achieves [...***...], Takeda shall use [...***...] to submit for, and obtain, a [...***...]. Each Party will participate in the oversight of Development via membership in the JSC and the JDC.  

2.1.2 Annual Review of Development Progress. On an annual basis, the JDC shall consider the Development progress of the Product,
objectives of the Development Plan and economic factors impacting Product Development and adjust the Development Plan to reflect the then-current conditions. 

  
 - 17 - 

 FINAL VERSION 

 

 2.1.3 Audit Rights. 

(a) Not more than once per Calendar Year, each Party shall have the right to conduct an audit of the other Party’s compliance
with this Section 2.1, including with respect to Development Costs incurred in connection with activities conducted in the execution of the Development Plan, for purposes of confirming the Development Costs reflected in Quarterly Reports
contemplated in Section 2.2.2(c). Such audit shall be conducted during normal business hours, upon not less than fifteen (15) Business Days prior notice, and no more than once with regard to any given Calendar Year. As appropriate, prompt
adjustments to payments made pursuant to Section 2.2.2(c) shall be made by the Parties to reflect the results of such audit. The Party to whom payment is owed will issue an invoice to the other Party. Such invoice will be paid within thirty
(30) days of receipt. The auditing Party shall bear the full cost of such audit unless such audit discloses an over-reporting by the audited Party of more than ten percent (10%) of the amount of Development Costs for a given Calendar
Quarter, in which case, the audited Party shall bear the full cost of such audit. Notwithstanding anything to the contrary contained in this Section 2.1.3, each Party’s audit shall be limited to the review of information directly relating
to Development activities. 
 (b) Each Party shall have the right to conduct an inspection and audit of the other Party’s
compliance with this Section 2.1 and Section 2.2.7, including with respect to any Development activities carried out by subcontractors of a Party. Such inspection and audit shall be conducted during normal business hours, upon not less
than fifteen (15) Business Days prior notice, and not more than once per Calendar Year; provided, however, if an adverse issue arises in connection with the Development activities of the Party to be audited, then such inspection or audit
may be conducted more than once per Calendar Year. The auditing Party shall bear the full cost of such audit. The audited Party shall use Commercially Reasonable Efforts to resolve any material audit findings as promptly as possible. 

2.2 Development. 

2.2.1 Development Plan. The initial Development Plan shall be agreed upon by the Parties within forty-five (45) days after the
Original Effective Date. The Development Plan shall be consistent with the obligations of the Parties under Sections 2.1 and 2.2.2 through 2.2.9. The Development Plan may be updated or amended only as agreed by the Parties in writing through the
JDC, and upon approval of the JSC. The Development Plan will set forth a budget and all Development Costs associated with the Development Plan, consistent with Sections 2.1.2 and 2.2.2. The Parties agree to update the Development Plan to include the
CVOT PMR Study, Non-CVOT PMR Studies, and other Development Post-Approval Activities pursuant to this Section 2.2.1. 
 2.2.2
Development Costs.  
 (a) Orexigen shall bear all Development Costs incurred by either or both of the Parties in the
conduct of Development Approval Activities. 
 (b) The Parties have shared all Development Costs incurred prior to August 1,
2015 by either or both of the Parties in the conduct of Development Post-

  
 - 18 - 

 FINAL VERSION 

 

 
Approval Activities in accordance with Section 2.2.2(b) of the Original Collaboration Agreement. As of August 1, 2015, the Parties shall share all Development Costs incurred from and
after August 1, 2015 by either or both of the Parties in the conduct of Development Post-Approval Activities during the Term as follows: 

(i) Orexigen shall bear all such Development Costs incurred by Takeda (and all Development Costs incurred by Orexigen with respect to
the Manufacture of Product for the CVOT PMR Study by its Third Party Manufacturer(s)) in the conduct of the CVOT PMR Study up to an aggregate amount equal to Two Hundred Ten Million Dollars ($210,000,000). 

(ii) After Orexigen has borne Two Hundred Ten Million Dollars ($210,000,000) of Development Costs incurred by Takeda (and Development
Costs incurred by Orexigen with respect to the Manufacture of Product for the CVOT PMR Study by its Third Party Manufacturer(s)) in the conduct of the CVOT PMR Study, each Party shall bear fifty percent (50%) of such Development Costs incurred
by Takeda (and Development Costs incurred by Orexigen with respect to the Manufacture of Product for the CVOT PMR Study by its Third Party Manufacturer(s)) in the conduct of the CVOT PMR Study. 

(iii) Notwithstanding Section 2.2.2(b)(i) and (ii), if Takeda and Orexigen agree to amend the design of the CVOT PMR Study (and
for clarity, the Development Plan) [...***...]. 
 (iv) Notwithstanding Section 2.2.2(b)(i) and (ii), subject to approval
by the FDA, if the [...***...] approves an amended Development Plan, which includes an amendment to the CVOT PMR Study such that it is designed to achieve Superiority, then in such case, [...***...] 

  
 - 19 - 

 FINAL VERSION 

 

 [...***...]. 

(v) Takeda shall bear seventy-five percent (75%) and Orexigen shall bear twenty-five percent (25%) of such Development Costs
incurred by either or both of the Parties in the conduct of (a) Non-CVOT PMR Studies; (b) life cycle management activities; and (c) Development Post-Approval Activities other than as provided in Section 2.2.2(b)(i), (ii),
(iii) and (iv), and Section 2.2.2(b)(vi). 
 (vi) Takeda shall bear all such Development Costs incurred by Takeda (and all
Development Costs incurred by Orexigen with respect to the Manufacture of Product for the Light Study by its Third Party Manufacturer(s)) in the conduct of activities related to the Light Study. 

(c) Within thirty (30) days after the end of each Calendar Quarter, each Party will provide a written report to the other Party
setting forth in reasonable detail the recorded Development Costs relating to such Calendar Quarter (each, a “Quarterly Report”). Within forty-five (45) days after the end of such Calendar Quarter, the Parties will agree upon
the Development Costs incurred in such Calendar Quarter and any amount required to be paid to give effect to Section 2.2.2(b). Such amount shall be paid within ten (10) days after the Parties agree upon such amount. 

(d) In the event either Orexigen or Takeda discover a need for correction in calculating the amount of Development Costs incurred by
such Party during any previous Calendar Quarter, it will promptly notify the other Party of such discovery. The Parties will then discuss the validity and appropriateness of the correction. If the Parties agree that such correction should be made
and mutually verify the amount to be corrected, then such amounts shall be included in the following quarterly reconciliation between the Parties as set forth in Section 2.2.2(c); provided, however, only corrections for Development Costs
that have occurred in the previous two (2) Calendar Years prior to the date of the notice described in the first sentence of this subsection (d) shall be eligible for correction. If the Parties do not agree on the validity or
appropriateness of the requested correction, the JDC will be responsible for deciding the issue. 
 (e) Each Party will use
Commercially Reasonable Efforts to complete the Development activities contemplated in the Development Plan and related budget, and to do so within the amounts budgeted. The Parties acknowledge that actual expenditures may differ from budgeted
amounts, and accordingly agree that the aggregate amount actually spent by a Party may be up to ten percent (10%) higher than the amount specified in the budget. In the event a Party’s Development Costs in the aggregate exceed the amount
budgeted in any Development Plan by more than ten percent (10%), the JDC shall determine if such excess amount is reasonable under the circumstances. If the JDC determines such excess amounts are reasonable, such amounts shall be deemed Development
Costs; otherwise, the excess shall be borne by the Party that incurred such excess Development Costs. 
 2.2.3 Cooperation. Each
Party will use Commercially Reasonable Efforts to provide the other Party with all reasonable assistance and take all actions reasonably 

  
 - 20 - 

 FINAL VERSION 

 

 
requested by such other Party, without changing the allocation of responsibilities assigned in the Development Plan, that are necessary or desirable to enable the other Party to comply with the
terms and conditions of this Agreement. 
 2.2.4 Development Responsibilities. 

(a) Each Party will perform, on a Calendar Year basis, the Development activities to be conducted by such Party as set forth in the
Development Plan; provided, however, for the avoidance of doubt, during the process of determining which Party will perform the Development activities set forth in the Development Plan, in no event shall a Party be required to perform a
particular Development activity that it does not then possess reasonable resources or capabilities to perform. Except as set forth in Section 2.2.4(b) of this Agreement, Orexigen shall have the right to perform, on a Calendar Year basis, at
least twenty-five percent (25%) of the activities set forth in the applicable Development Plan, as determined based on the percentage of Development Costs associated with such Development activities set forth in the Development Plan for such
Calendar Year. 
 (b) Takeda shall be solely responsible for the performance of, and shall have the sole right to conduct, all
Development activities related to the (i) CVOT PMR Study and (ii) Light Study. The Parties acknowledge and agree that as of the Amended and Restated Effective Date, the current design of the CVOT PMR Study satisfies FDA and, to the
Parties’ knowledge, EMA requirements for, and to support and maintain, Regulatory Approval in the Territory and regulatory approval in the EU. Takeda agrees to consider in good faith amendments to the current design of the CVOT PMR Study
proposed by Orexigen to the extent Takeda deems such proposed amendments as necessary to maintain Orexigen’s regulatory approval in the EU; provided, however, that any such amendment to the current design of the CVOT PMR Study is subject
to approval by the FDA, and any incremental Development Costs related to any such amendment shall be borne solely by Orexigen to the extent provided in Section 2.2.2(b)(iii). For the avoidance of doubt, Takeda has final decision-making
authority pursuant to Section 5.7.3(a)(i) with respect to a Dispute regarding Development Post-Approval Activities, including with respect to the design of the CVOT PMR Study. 

(c) Notwithstanding anything to the contrary in this Agreement, Orexigen shall have the right to conduct in the Territory
(i) Clinical Trial (NB-240) under the Takeda IND for Contrave in the Territory, which Clinical Trial is solely intended to demonstrate the bioequivalence of the Contrave manufactured at Orexigen’s third party manufacturer, Sanofi Winthrop
Industrie, to the Contrave that is Manufactured at Orexigen’s Third Party Manufacturer, Patheon, and (ii) as mutually agreed upon in writing by the Parties, other Clinical Trials under an Orexigen IND in the Territory that cross-references
the Takeda IND for Contrave in the Territory, which Clinical Trials are solely intended to demonstrate bioequivalence. 
 2.2.5
Development Reports. Each Party will provide the JDC with written Development reports or presentations at JDC meetings at the request of the other Party’s JDC members. Each report or presentation shall include the Development activities
accomplished by or on behalf of such Party since the previous JDC meeting, and other relevant matters, including a summary of significant results, information, and data generated, or 

  
 - 21 - 

 FINAL VERSION 

 

 
significant challenges relating to Products, and the status of Development activities as compared to the timelines in the Development Plan. Such reports may also include summaries of the costs
incurred by such Party in the performance of such Development activities prior to the date of such report. Upon request by the JDC, each Party shall provide the JDC with summaries of available Clinical Trial protocols, investigator brochures,
non-clinical protocols and reports (including activities relating to CMC), regulatory submissions and correspondence from Regulatory Authorities with respect to Products. 

2.2.6 Records. In conformity with standard pharmaceutical industry practices and the terms and conditions of this Agreement, each
Party shall prepare and maintain, and shall cause its Affiliates and Sublicensees to prepare and maintain, complete and accurate written records, accounts, notes, reports and data with respect to activities conducted pursuant to the Development Plan
for a minimum of three (3) years following the end of the Calendar Year to which they pertain, or for such longer period of time as required under applicable Laws; provided, further, upon the other Party’s written request, the
non-requesting Party shall provide legible copies of such written records, accounts, notes, reports and data to the requesting Party throughout the Term and for a minimum of three (3) years following the Term, or for such longer period of time
as such written records, accounts, notes, reports and data are required to be maintained under applicable Laws. Upon reasonable advance notice, at the request of the JDC, each Party agrees to make its employees and contractors reasonably available
at their respective places of employment to consult with the other Party on issues arising in connection with Development activities. 

2.2.7 Development Standards. Each Party shall conduct all such Development activities in compliance with applicable Laws, including
GCP, GLP, and all legal and regulatory requirements pertaining to the design and conduct of Clinical Trials. 
 2.2.8
Subcontracting. Each Party may perform any activities in support of its Development under this Agreement through subcontracting to a Third Party contractor or contract service organization; provided that: (a) none of the rights of
the other Party hereunder are materially adversely affected as a result of such subcontracting; (b) any such Third Party subcontractor to whom such Party discloses Confidential Information shall be bound by an appropriate written agreement
obligating such Third Party to obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations in Article 10; (c) such Party will obligate such Third Party to agree in
writing to assign or license (with the right to grant sublicenses) to such Party any inventions (and Patents covering such inventions) made by such Third Party in performing such services for such Party that are necessary for the Development;
(d) such Party shall at all times be responsible for the performance of such subcontractor; and (e) such other Party consents in writing to such subcontract in advance, such consent not to be unreasonably withheld, conditioned or delayed
(it being understood that subcontracting to Takeda’s preferred Third Party contract research organization vendors shall not require the consent of Orexigen in advance). At Orexigen’s request, Takeda shall use Commercially Reasonable
Efforts to arrange for Orexigen to use Takeda’s preferred Third Party contract research organization vendors on the same terms as Takeda. 

2.2.9 Information Sharing. 

  
 - 22 - 

 FINAL VERSION 

 

 (a) Each Party shall provide the other Party with copies of all material
non-clinical, analytical, Manufacturing, and Clinical Trial data (including, for clarity, data sets [...***...] and information relating to the Product generated by such Party in or for the [...***...], or on behalf of such Party by any
Third Party, promptly after such data and information are deemed final in the [...***...] of the Disclosing Party; provided, that (i) Clinical Trial data shall be deemed final only after the Disclosing Party has had a [...***...],
and (ii) when [...***...], the Disclosing Party shall make such [...***...] available to the other Party. Without limiting the foregoing, [...***...] will use [...***...] to provide [...***...] with, and allow
[...***...] to use, [...***...] for the purposes of satisfying [...***...], provided, that, with respect to the [...***...], to the extent that (iii) [...***...] does not have access to such [...***...], the
Data Monitoring Committee grants [...***...] access to such data and information for such purpose, or (iv) [...***...] has access to such [...***...], the Data Monitoring Committee approves the disclosure of such data and
information to [...***...] for such purpose. Notwithstanding the foregoing, [...***...] agrees to provide [...***...] with the Data Monitoring Committee [...***...] to [...***...], the final Data Monitoring Committee
charter and performance metrics as set forth in the performance standards document for the CVOT PMR Study, as such document may be revised from time to time, promptly after it is available to Takeda. The information sharing provisions in this
Section 2.2.9 are in addition to provisions regarding sharing of information by the Committees in Article 5 and publications in Section 10.7. 

(b) Without limiting the foregoing Section 2.2.9(a), with respect to any Clinical Trial of a Product: 

(i) that is conducted by either Party for the Territory (i.e., either in or outside the Territory) pursuant to this Agreement under an
IND for Contrave, the Party conducting such Clinical Trial will provide the other Party with the opportunity to [...***...] for such Clinical Trial [...***...] such [...***...] being deemed final by the Parties, and such Party will
give [...***...] to any comments provided by the other Party; 
 (ii) that is conducted by either Party for the Territory
(i.e., either in or outside the Territory) pursuant to this Agreement which is not required to be conducted under an IND for Contrave, each Party shall provide the other Party with (A) [...***...]; and (B) [...***...]; 

  
 - 23 - 

 FINAL VERSION 

 

 (iii) that is conducted by Orexigen in the Territory, for outside the Territory,
under an Orexigen IND for Contrave, [...***...] shall provide to [...***...] (A) the opportunity to [...***...], and [...***...]; and (B) copies of the [...***...]; and 

(iv) that is conducted by Orexigen outside the Territory, for outside the Territory, under an Orexigen IND for Contrave,
[...***...] shall provide to [...***...] copies of the [...***...] for [...***...]. 
 (c) For clarity,
information regarding adverse events and serious adverse events shall be provided in accordance with the Pharmacovigilance Agreement. Each Party understands and acknowledges that the other Party and its Affiliates, licensees, sublicensees, and
subcontractors, as applicable, may need to utilize and include certain data and certain summary and general information regarding the demonstration of efficacy and safety of the Product generated by such Party (for example, adverse event reports and
tabulated data summaries) as such Party reasonably determines is required in its filings for regulatory approvals for the Product inside or outside the Territory, as requested by regulatory authorities inside or outside the Territory, and/or through
communications with regulatory authorities inside or outside the Territory. Orexigen shall have the right to share any and all such data, information, and other regulatory materials received from Takeda with Orexigen’s Affiliates, licensees,
sublicensees [...***...] for use in [...***...] a Product outside the Territory. Takeda shall have the right to share any and all such data [...***...] and other regulatory materials received from Orexigen with Takeda’s
Affiliates [...***...] for use in [...***...] a Product in or outside the Territory for the Territory and in [...***...] Regulatory Approval or Commercializing a Product in the Territory. 

(d) All non-clinical, analytical, Manufacturing, and Clinical Trial data and associated reports disclosed by one Party to the other
under this Agreement shall be deemed Confidential Information of the Disclosing Party; provided that, except as otherwise set forth in this Agreement, the Receiving Party (or its Affiliates, licensees or sublicensees) may use such data solely
for the purpose of developing, obtaining and [...***...] regulatory approval, [...***...] or commercializing a Product in its respective territory, including pursuant to Orexigen’s right to Co-Promote pursuant to Section 3.5.
For the avoidance of doubt, any and all [...***...] relating to the [...***...] shall be deemed [...***...]. 

(e) Except as provided for in Section 2.2.9(c), [...***...] shall not receive access to [...***...] (as contemplated
in Section 2.2.9(a)). However, to the extent that [...***...] receives [...***...] (e.g., for purposes of its regulatory filings outside the Territory, inadvertent disclosure, etc.), except as set forth in Section 10.3.4,
[...***...] agrees not to [...***...] 

  
 - 24 - 

 FINAL VERSION 

 

 
[...***...], without [...***...]. 
 3.
COMMERCIALIZATION; CO-PROMOTION 
 3.1 Commercialization Activities. Takeda shall be
responsible for Commercializing Products in the Field in the Territory, subject to the terms and conditions of this Agreement and in compliance in all material respects with applicable Laws. Takeda shall be responsible for paying all
Commercialization Costs set forth in the Commercialization Plan approved by the JCC. Takeda shall use Commercially Reasonable Efforts to Commercialize Products in the Field in the Territory in accordance with the Commercialization Plan and the terms
of this Agreement, subject to Orexigen’s Commercialization of Contrave pursuant to Section 3.5 and the terms of any Co-Promote Agreement. Upon exercise of its right to Co-Promote pursuant to Section 3.5, Orexigen shall use
Commercially Reasonable Efforts to Commercialize Contrave in the Territory in accordance with the Commercialization Plan, the terms of this Agreement and the Co-Promote Agreement, and in compliance in all material respects with applicable Laws.
Except as otherwise provided for in Section 3.5 and any Co-Promote Agreement, Takeda, its Affiliates or Sublicensees, as the case may be, shall have the sole right and responsibility for all activities relating to Commercialization of all
Products in the Field in the Territory including: (a) booking all sales of Products; (b) determining the price of all Products; (c) sale and distribution of all Products as described in Section 3.3.5 below; (d) conducting
all Product marketing activities; (e) creating and approving all marketing programs and promotional materials; and (f) conducting all Product medical affairs activities, including field based medical liaison activities, investigator
initiated sponsored research, publications, medical education, health economics outcomes research and medical information. 
 3.2
Additional Diligence Obligations. In addition to the general responsibilities set forth in Section 3.1, Takeda shall have the following specific diligence obligations: 

3.2.1 Commencing on the First Commercial Sale of Contrave in the Initial Indication in the Territory and ending on the third
(3rd) anniversary of such date (the “PDE Term”), Takeda shall, in accordance with the Commercialization Plan and this Section 3.2.1, provide at least the following Primary Detail Equivalents for such Product:
(i) during the first consecutive twelve (12) month period following such First Commercial Sale, Eight Hundred Thousand (800,000) Primary Detail Equivalents, of which at least Four Hundred Eighty Thousand (480,000) shall be P1
Details; (ii) during each of the following two (2) consecutive twelve (12) month periods thereafter, Six Hundred Thousand (600,000) Primary Detail Equivalents, of which at least Three Hundred Thousand (300,000) shall be P1
Details (pro-rated for any partial twelve (12) month period). Takeda shall provide its PDE requirements with the goal of achieving the call plan described in Section 3.2.2, and in accordance with the following: (a) during each
Calendar Quarter, at least eighty percent (80%) of its PDE requirement under the call plan; and (b) during each Calendar Year, at least ninety percent (90%) of its PDE requirement under the call plan. If Takeda fails to achieve eighty
percent (80%) of its PDE 

  
 - 25 - 

 FINAL VERSION 

 

 
requirement under the call plan in a Calendar Quarter, it must exceed ninety percent (90%) of its PDE requirement under such call plan in the following Calendar Quarter by the number of PDEs
that Takeda failed to achieve in the prior Calendar Quarter (i.e., that caused it to achieve less than eighty percent (80%) of its PDE requirement). If Takeda fails to achieve ninety percent (90%) of its PDE requirement under the call plan
in any Calendar Year, it must exceed ninety percent (90%) of its PDE requirement under the call plan in the following two (2) Calendar Quarters by the number of PDEs that Takeda failed to achieve under the call plan in the prior Calendar
Year (i.e., that caused it to achieve less then ninety percent (90%) of its PDE requirement under the call plan). Any failure by Takeda to correct a PDE shortfall (i.e., achieving less than eighty percent (80%) of its PDE requirement under
the call plan in a Calendar Quarter or ninety percent (90%) of its PDE requirement under the call plan in a Calendar Year) in the timeframe specified above shall be a material breach of this Agreement; provided, however, for the
avoidance of doubt, (1) if Takeda achieves the PDE requirements as set forth above, including through the correction of any shortfall, it may not be held in material breach for failure to achieve one hundred percent (100%) of the PDE
requirements under the call plan and (2) details that are not P1 Details or P2 Details shall have no Primary Detail Equivalent value. Upon expiration of the PDE Term, (x) the JCC shall consider the market conditions on an annual basis and
adjust the Commercialization Plan (including the PDE requirements and the number of P1 Details and P2 Details for the Product) to reflect the then-current market conditions and (y) this Section 3.2.1 (other than, for clarity, subsections
(i) and (ii)) shall remain in full force and effect. 
 3.2.2 The Parties shall establish a Primary Detail Equivalent call plan
for Contrave, which shall be supported by a commensurate incentive plan that is aligned with each Sales Representative’s individual call plan, and designed to facilitate achievement of the overall PDE requirements, including as set forth in
Section 3.2.1. By way of example, and without limitation, if a Takeda Sales Representative is directed to sell the Product and other Takeda product(s) that are not the Product such that sixty percent (60%) of such Takeda Sales
Representative’s PDEs are for the Product and forty percent (40%) of such Takeda Sales Representative’s PDEs are for such other Takeda product(s), then in any incentive plan for the Takeda Sales Representatives, such Product would
receive a sixty percent (60%) incentive weighting and such other Takeda product(s) would receive a forty percent (40%) incentive weighting. For the avoidance of doubt, the incentive weighting for the Product is not required to be greater
than or equal to the incentive weighting for such other Takeda product(s). 
 3.2.3 Commencing on the Original Effective Date and
ending on the First Commercial Sale of Contrave in the Initial Indication in the Territory, Takeda shall, in accordance with the Commercialization Plan, incur at least Fifteen Million Dollars ($15,000,000) in Commercialization Costs (excluding any
costs and expenses incurred in connection with Manufacturing activities) for pre-launch activities associated with such Product. During the PDE Term, Takeda shall incur the following Commercialization Costs (excluding any costs and expenses incurred
in connection with Manufacturing activities) for promotion of such Product: (i) during the first twelve (12) month period during the PDE Term, Seventy-Five Million Dollars ($75,000,000); and (ii) during each of the following two
(2) twelve (12) month periods during the PDE Term, Fifty Million Dollars ($50,000,000) (pro-rated for any partial twelve (12) month period). Thereafter, the JCC shall consider the market conditions on an annual basis and adjust

  
 - 26 - 

 FINAL VERSION 

 

 
the amount of Commercialization Costs to be incurred by Takeda for such Product to reflect the then-current market conditions. 

3.2.4 Not more than once per Calendar Year, and no more than one (1) time for each Calendar Year, Orexigen shall have the right
to conduct an inspection and audit of information relating to PDEs, incentive plans, and promotional budget expenditures directly relating to the Product, to confirm Takeda’s compliance with Sections 3.2.1 and 3.2.3. Such inspection and audit
shall be conducted at Orexigen’s expense during normal business hours, and upon not less than thirty (30) days prior written notice to Takeda. 

3.3 Commercialization. 

3.3.1 Commercialization Plan. The initial Commercialization Plan for Contrave in the Territory shall be agreed upon by the Parties
within sixty (60) days after the Original Effective Date. To the extent that the Commercialization Plan includes other Products in the Territory, such Commercialization Plan shall also be mutually agreed upon by the Parties. Notwithstanding the
exercise by Orexigen of its right to Co-Promote the Product, all Products in the Field in the Territory shall be sold, and all sales shall be booked, by Takeda, its Affiliates and Sublicensees, as the case may be, and Takeda shall pay milestones and
royalties to Orexigen in accordance with Article 7 with respect thereto. 
 3.3.2 Updates to Commercialization Plan. The
Commercialization Plan for the Territory shall be updated or amended by the JCC on an annual basis, or more frequently as necessary, including promptly after Orexigen exercises its right to Co-Promote pursuant to Section 3.5. Updates and
amendments to the Commercialization Plan shall be subject to the approval of the JSC pursuant to Section 5.1.2(c), and, if Orexigen exercises its right to Co-Promote, made in accordance with the last sentence in Sections 3.2.1 and 3.2.3. Each
Calendar Year, the JCC will prepare an update to the Commercialization Plan, and submit it in advance to the JSC in order to obtain approval from the JSC no later than November 1st. 

3.3.3 JCC Commercialization Information and Reports. Each Party shall provide the other Party, upon request, with copies of all
material Product-specific information relating to Commercialization of the Product generated by such Party, or on behalf of such Party by any Third Party, including market research and other information generated in connection with the conduct of
promotional efficiency and other Commercialization activities; provided, however, for the avoidance of doubt, neither Party shall be obligated to disclose information that relates to products outside the scope of this Collaboration. Each
Party will provide the JCC with written Commercialization reports or presentations at JCC meetings. Each such report or presentation shall include the Commercialization activities accomplished by or on behalf of such Party since the previous JCC
meeting, and other relevant matters, including a summary of Primary Detail Equivalents broken out on a monthly basis, a copy of all then-current incentive plans relating to the Products, and the status of Commercialization activities as compared to
the timelines in the then-existing Commercialization Plan. The Commercialization reports shall also include the reports set forth on Exhibit 3.3.3, and summaries of the costs incurred by each Party in the performance of its Commercialization
activities prior to the date of such report. The JCC shall provide to the JSC copies of the information provided under this Section 3.3.3. Takeda shall provide any reports referred to in this Section 3.3.3 and received

  
 - 27 - 

 FINAL VERSION 

 

 
from Third Parties to Orexigen promptly, but in no event later than thirty (30) days after receipt of such report from such Third Party. 

3.3.4 Commercialization Costs. 

(a) Except as otherwise expressly provided in this Agreement, Takeda shall bear all Commercialization Costs incurred by either Party
in accordance with the Commercialization activities, and corresponding budgeted costs, set forth in the Commercialization Plan approved by the JSC. 

(b) Takeda shall reimburse Orexigen, on a quarterly basis in arrears, for all PDE Costs incurred by Orexigen during the prior Calendar
Quarter. After the end of each Calendar Quarter, Orexigen shall submit to Takeda an itemized invoice for PDE Costs incurred by Orexigen in accordance with the activities assigned to it in the Commercialization Plan during such Calendar Quarter, and
Takeda shall pay to Orexigen an amount equal to such PDE Costs within thirty (30) days after delivery of such invoice. Notwithstanding the foregoing, if Takeda disputes all or any portion of the PDE Costs submitted to it by Orexigen, Takeda
shall not be required to pay such disputed PDE Costs within thirty (30) days after delivery of the invoice to Takeda, and the Parties shall use good faith efforts to discuss and resolve such disputed amount. 

3.3.5 Sales and Distribution. Notwithstanding the exercise by Orexigen of its right to Co-Promote Contrave pursuant to
Section 3.5, Takeda shall have the sole right and responsibility for handling all sales and distribution activities, including returns, order processing, invoicing and collection, distribution (including importing, exporting, transporting,
customs clearance, warehousing, invoicing, handling and delivering Products to customers), and inventory and receivables for the Products in the Field in the Territory. Orexigen shall not accept orders for the purchase of a Product from Third
Parties, or make sales of Product to Third Parties in the Field in the Territory for its own account or for Takeda’s account. If Orexigen receives any order for a Product in the Field in the Territory, it shall refer such orders to Takeda for
acceptance or rejection. Takeda shall have the sole right and responsibility for: (i) negotiating, establishing or modifying the terms and conditions regarding the sale of the Product in the Field in the Territory, including any terms and
conditions relating to or affecting (a) the price at which the Product shall be sold, (b) discounts available to any Third Party payers (including managed care providers, indemnity plans, unions, self insured entities, and government
payer, insurance or contracting programs such as Medicare, Medicaid, or the U.S. Department of Veterans Affairs), (c) discounts attributable to payments on receivables, (d) distribution of the Product, and (e) credits, price
adjustments, or other discounts and allowances to be granted or refused; and (ii) all activities relating to government price reporting with respect to any Product in the Field in the Territory. 

3.3.6 Bundling. Takeda hereby agrees that it will not, nor, to the extent permitted under applicable Laws, shall it allow its
Affiliates or Sublicensees to, provide a discount on Products as part of a multiple product offering with any other products or services that: (i) are not a normal and customary discount that Takeda would provide on other products in its
portfolio; or (ii) are unreasonably disproportionate to discounts Takeda has provided on other products in its portfolio. 

  
 - 28 - 

 FINAL VERSION 

 

 3.4 Regulatory Responsibilities. 

3.4.1 Prior to receipt of Regulatory Approval in the Territory for the Initial Indication for Contrave: (a) Orexigen shall
prepare, file, maintain, and own all Regulatory Filings, including the IND and the NDA for Contrave in the Territory, and related submissions with respect to Contrave in the Territory; and (b) Orexigen shall promptly notify Takeda of all
material Regulatory Filings with respect to Contrave that it proposes to submit to Regulatory Authorities, or that it receives from Regulatory Authorities, in the Territory (including all substantive correspondence with such Regulatory Authorities,
responses from such Regulatory Authorities, requests for information from such Regulatory Authorities, briefing documents and other materials relating to interactions with such Regulatory Authorities, and summaries of outputs resulting from
substantive correspondence/conversations or meetings with such Regulatory Authorities), and shall promptly provide Takeda with a copy (which may be wholly or partly in electronic form) of such Regulatory Filings for review by Takeda. Takeda shall
provide any comments promptly, but in no event later than three (3) Business Days after receiving such Regulatory Filings, Orexigen shall reasonably consider and give due consideration to any such comments provided by Takeda, and, as necessary,
it shall discuss such comments with Takeda, and each Party shall use good faith efforts to mutually agree on the content of any communications that relate to or contain commitments made or to be made by Orexigen to Regulatory Authorities for the
purpose of obtaining Regulatory Approvals; provided, however, (i) Orexigen shall retain the right to make any final decisions with respect to the content of any such communications, which shall be compliant with the Development Plan,
this Agreement and applicable Law, and (ii) in the event any interaction with a Regulatory Authority is time-sensitive, Orexigen shall have the right to communicate with such Regulatory Authority within the time frame requested by such
Regulatory Authority. Orexigen shall provide Takeda with reasonable advance notice of any scheduled meeting with any Regulatory Authority relating to the Product or any Regulatory Approval in the Territory, and Takeda shall have the right to have up
to two (2) individuals attend and participate in any such meeting; provided, however, Orexigen will retain the lead role and responsibility in any such meetings. 

3.4.2 The Parties acknowledge and agree that as of the Amended and Restated Effective Date, Orexigen has transferred all Regulatory
Filings relating to Contrave in the Territory, including the IND and the NDA for Contrave in the Territory, into the name of Takeda and provided Takeda with a copy of all such Regulatory Filings. Takeda is responsible for (a): preparing, filing,
maintaining and owning all Regulatory Filings and related submissions, including the IND and the NDA for Contrave in the Territory, with respect to Products in all Indications in the Territory, and (b) leading discussions and meetings with all
Regulatory Authorities regarding Products in all Indications in the Territory; provided, however, two (2) representatives of Orexigen shall be entitled to participate in any such discussions and meetings with Regulatory Authorities, and,
if an appropriate Orexigen representative(s) is requested by Takeda to attend a discussion or meeting with a Regulatory Authority regarding the Products in the Indications in the Territory, Orexigen will use Commercially Reasonable Efforts to
arrange for such individual(s) to participate in such discussions or meetings. 
 3.4.3 Upon request, Takeda will provide the JSC
with copies of all Regulatory Filings and related material correspondence submitted to Regulatory Authorities or received from Regulatory Authorities with respect to Products in all Indications in the Territory.

  
 - 29 - 

 FINAL VERSION 

 

 
Takeda will promptly furnish, but in no event later than five (5) Business Days after receipt or generation, Orexigen with copies of all such Regulatory Filings (including all substantive
correspondence with such Regulatory Authorities, responses from such Regulatory Authorities, requests for information from such Regulatory Authorities, briefing documents and other materials relating to interactions with such Regulatory Authorities,
and summaries of outputs resulting from substantive correspondence/conversations or meetings with such Regulatory Authorities). In addition, prior to making a Regulatory Filing relating to Contrave or responding to any such Regulatory Authority
correspondence or interactions, except to the extent impracticable with respect to expedited safety reports, timelines imposed by Regulatory Authorities, Takeda SOPs and other similar time-sensitive issues, Takeda shall provide to the JDC and JSC a
complete draft copy for its review and comment. Takeda shall give due consideration to any comments of the JDC and JSC with respect thereto. 

3.4.4 Notwithstanding any transfer of Regulatory Filings or ownership thereof to Takeda, Orexigen shall have, on behalf of itself, its
Affiliates, and licensees and sublicensees, the right to access and reference data and information contained in any Regulatory Filings to the extent useful or necessary in connection with (a) Product regulatory filings outside the Territory
and/or (b) any Clinical Trial of a Product conducted in the Territory by Orexigen or its Affiliates, licensees, and sublicensees for the Territory or for outside the Territory. Orexigen hereby grants to Takeda, its Affiliates and Sublicensees,
the right to access and reference data and information contained in any of Orexigen’s, or its Affiliates’, licensees’ and sublicensees’ Product regulatory filings outside the Territory to the extent useful or necessary in
connection with Regulatory Filings in or for the Territory. Each Party agrees to provide letters of authorization and take any other actions as reasonably necessary for the other Party to exercise its right to access and reference data and
information as permitted under this Section 3.4.4. 
 3.4.5 If a Regulatory Authority desires to conduct an inspection or audit
of, or sends a communication to, Takeda or Orexigen or any Third Party engaged by either Party to perform activities under the Development Plan or Commercialization Plan with regard to any Product or this Agreement, Takeda and Orexigen each agrees
to cooperate with the Regulatory Authority and the other Party during such inspection or audit, including by allowing, to the extent practicable, a representative of the other Party to be present during the applicable portions of such inspection or
audit. Following receipt of the inspection or audit observations of the Regulatory Authority (a copy of which the responsible Party will immediately provide to the other Party), the responsible Party will prepare the response to any observation that
concerned this Agreement. The other Party agrees to fully cooperate when it prepares such a response, including by providing to the responsible Party, within two (2) Business Days after its request, such information and documentation in the
Party’s possession as may be necessary for the responsible Party to prepare such response. Before submitting the response to the Regulatory Authority, the responsible Party agrees to give the other Party a reasonable opportunity to comment on
it. 
 3.4.6 Each Party (and its Third Party subcontractors) shall notify the other Party within one (1) Business Day of
receipt of notification from a Regulatory Authority of the intention of such Regulatory Authority to audit or inspect a Party’s facilities with respect to any Product, including facilities being used for Manufacture of any Product. Each Party
(and its Third Party subcontractors) shall also provide the other Party with copies of any written 

  
 - 30 - 

 FINAL VERSION 

 

 
communications received from Regulatory Authorities with respect to such facilities within [...***...] ([...***...]) Business Days of receipt. Such Party shall provide the other Party
with an opportunity to review and provide input on any proposed response by such Party (or Third Party subcontractor) to such communications. 

3.5 Orexigen’s Co-Promote Activities. 

3.5.1 Initial Co-Promote Period. During the period commencing on the date of the First Commercial Sale of Contrave in the Territory
for the Initial Indication and ending on the third (3rd) anniversary of such date (the “Initial Co-Promote Period”), Orexigen shall have the right to participate in the
Commercialization of the Product by promoting or detailing the Product in the Field in the Territory (“Co-Promote”), Orexigen shall have the right to provide up to one hundred twenty-six thousand (126,000) Primary Detail
Equivalents per year, of which at least sixty percent (60%) shall be P1 Details during the first year, and fifty percent (50%) shall be P1 Details in each year thereafter. Orexigen shall perform its Primary Detail Equivalents only through
Orexigen’s Sales Representatives (in accordance with Section 3.5.5) and exclusively targeting obstetricians and gynecologists or other targets approved by the JCC. Takeda shall be required to pay Orexigen the PDE Costs incurred by Orexigen
in connection with such Co-Promote activities under this Section 3.5.1 as provided in Section 3.3.4(b). Orexigen shall provide Takeda with prior written notice of its intention to Co-Promote in accordance with this Section 3.5.1.
Orexigen may provide written notice to Takeda of its intention to Co-Promote under this Section 3.5.1 at any time during the first three Calendar Quarters of any Calendar Year during the Initial Co-Promote Period, in which case Orexigen shall
be permitted to begin its Co-Promote activities on April 1st of the following Calendar Year. For example, if Orexigen provides written notice to Takeda of its intention to Co-Promote under
this Section 3.5.1 at any time from January 1, 2015 to September 30, 2015, then Orexigen may begin its Co-Promote activities on April 1, 2016. 

3.5.2 Secondary Co-Promote Period. Except as otherwise provided in Section 3.5.4, during the period commencing on the third (3rd) anniversary of the date of the First Commercial Sale of Contrave in the Territory for the Initial Indication and ending upon expiration or termination of the Term (the “Secondary
Co-Promote Period”), Orexigen shall have the exclusive option (the “Co-Promote Option”) to Co-Promote such Product in the Field in the Territory. Orexigen may exercise the Co-Promote Option by providing written notice to
Takeda at any time prior to October 1st during each Calendar Year during the Secondary Co-Promote Period, in which case Orexigen shall be permitted to: (a) begin its Co-Promote
activities on April 1st of the following Calendar Year, (b) perform up to Two Hundred Fifty Thousand (250,000) Primary Detail Equivalents in the twelve (12) month period
following the start of its Co-Promote activities (i.e., April 1st through March 31st after exercise of the Co-Promote Option),
(c) perform up to Five Hundred Thousand (500,000) Primary Detail Equivalents in each twelve (12) month period thereafter (i.e., after the twelve (12) month period referenced in Section 3.5.2(b)), and (d) only through
Orexigen’s Sales Representatives (in accordance with Section 3.5.5), target any physicians approved by the JCC in the Commercialization Plan, including physicians that are not obstetricians and gynecologists. Upon exercise of the
Co-Promote Option by Orexigen, and during the Secondary Co-Promote Period, Takeda shall not be obligated to compensate Orexigen for any portion of Orexigen’s PDE Costs. In addition, notwithstanding anything to the contrary contained in this
Agreement: (1) Takeda 

  
 - 31 - 

 FINAL VERSION 

 

 
shall have the right to reduce the number of Primary Detail Equivalents to be performed by Takeda during each Calendar Year from and after Orexigen exercises its Co-Promote Option based on the
increase in Primary Detail Equivalents to be performed by Orexigen, provided that the total number of Primary Detail Equivalents to be performed by Orexigen and Takeda is not less than the total number of Primary Detail Equivalents in the
then-current Commercialization Plan, and (2) Orexigen shall compensate Takeda for all reasonable Third Party costs and internal personnel costs not to exceed Two Hundred Fifty Thousand Dollars ($250,000), incurred by Takeda in support of
Orexigen’s implementation activities necessary to begin Co-Promoting the Product. 
 3.5.3 Promptly after exercise of the
earlier of Orexigen’s exercise of its right under Section 3.5.1 or the Co-Promote Option under Section 3.5.2, the JCC will amend the Commercialization Plan to address the transition of promotional activities from Takeda to both of the
Parties. In addition, promptly thereafter (and in all events prior to the commencement of any Co-Promotion activities by Orexigen), the Parties shall diligently and in good faith negotiate and enter into a Co-Promote Agreement for the
Commercialization of the Product in the Field in the Territory by Orexigen and Takeda, on mutually agreeable terms, including the terms set forth in Article 3 and Exhibit 3.5.3; provided, however, if the Parties fail to enter into a
Co-Promote Agreement within the timeframe contemplated in this Section 3.5.3, the terms set forth in Article 3 and Exhibit 3.5.3 shall govern the Commercialization of the Product as if the Parties had entered into a Co-Promote Agreement. 

3.5.4 Notwithstanding anything to the contrary contained in Section 3.5.1 or Section 3.5.2, Orexigen’s Successor shall
have the right to Co-Promote the Product in accordance with this Agreement and the Co-Promote Agreement by providing Takeda with twelve (12) months prior written notice if such right is exercised during the Initial Co-Promote Period, or six
(6) months prior written notice if such right is exercised during the Secondary Co-Promote Period. If Orexigen’s Successor exercises such Co-Promote right, (a) Orexigen’s Successor shall have the right to perform up to Five
Hundred Thousand (500,000) Primary Detail Equivalents during each Calendar Year thereafter in accordance with a JCC approved Commercialization Plan, but at no cost to Takeda (including no PDE Cost), (b) during the Initial Co-Promote
Period, if Orexigen’s Successor elects to conduct more than One Hundred Twenty-Six Thousand (126,000) Primary Detail Equivalents, Takeda shall have the right to reduce the number of Primary Detail Equivalents it is obligated to perform by
the number of Primary Detail Equivalents Orexigen’s Successor elects to perform, provided that the total combined Primary Detail Equivalents to be performed by Orexigen’s Successor and Takeda is not less than Takeda’s Primary
Detail Equivalent obligation, including the P1 Details obligation, pursuant to Section 3.2.1(i) and (ii), (c) during the Secondary Co-Promote Period, Takeda shall have the right to reduce the number of Primary Detail Equivalents it is
obligated to perform based on the increase in Primary Detail Equivalents to be performed by Orexigen’s Successor, provided that the total number of Primary Detail Equivalents to be performed by Orexigen’s Successor and Takeda is not
less than the total number of Primary Detail Equivalents in the then-current Commercialization Plan, (d) Orexigen shall compensate Takeda for all reasonable Third Party costs and internal personnel costs not to exceed Two Hundred Fifty Thousand
Dollars ($250,000), incurred by Takeda in support of the implementation activities necessary for Orexigen’s Successor to begin Co-Promoting the Product, (e) Orexigen’s Successor shall be subject to the terms and conditions of the
Co-Promote Agreement, provided that relevant terms 

  
 - 32 - 

 FINAL VERSION 

 

 
and conditions of the Co-Promote Agreement shall be modified through mutual agreement to address the rights and obligations of Takeda and Orexigen’s Successor contained in this
Section 3.5.4, and (f) the Primary Detail Equivalent targets for Orexigen’s Successor shall be discussed at the JCC; provided, further, the JCC shall take into account the following when selecting Orexigen’s
Successor’s call targets with the objective of reasonably balancing the unnecessary disruption to Orexigen’s Successor and maximizing PDE call targets, (1) avoiding call target over-saturation by the Parties, (2) efficient use of
resources, (3) minimizing re-targeting, and (4) providing call targets in other therapeutic areas. 
 3.5.5 With respect
to Orexigen’s Co-Promote activities, Orexigen’s Sales Representatives shall be either employees of Orexigen or employees or contractors of a contract sales organization that (i) [...***...], and (ii) [...***...]. 

3.6 Pharmacovigilance. Orexigen and Takeda entered into a pharmacovigilance agreement effective as of September 10, 2014 (as may
be amended by the Parties in accordance with its terms, the “Pharmacovigilance Agreement”) concerning all matters relating to management and exchange of safety information on terms no less stringent than those required by ICH
guidelines. Takeda shall be responsible, at its own expense, for the establishment and maintenance of the global safety database for Products in all Indications in the Territory. Each Party shall cooperate (at its sole cost and expense), and shall
cause its Affiliates, licensees, and sublicensees to cooperate, in implementing a pharmacovigilance mutual alert process with respect to the Products and to comply with all applicable Laws. Generally, (a) prior to transfer of the Regulatory
Filings as set forth in Section 3.4.2, Orexigen shall be responsible for submitting all required IND safety reports contemplated by 21 C.F.R. 312.32, and post-marketing reports of adverse drug experiences contemplated by 21 C.F.R. 314.80, or
the foreign equivalent in the Territory, relating to Products to the appropriate Regulatory Authorities in the Territory, in accordance with applicable Laws; (b) following transfer of the Regulatory Filings as set forth in Section 3.4.2,
and with respect to any other Regulatory Filings, Takeda shall be responsible for reporting all adverse drug reaction experiences required to be reported to the appropriate Regulatory Authorities in the Territory in which such Product is being
Developed or Commercialized, in accordance with Laws; and (c) Orexigen, its Affiliates or licensees or sublicensees shall be responsible for submitting all regulatory filings, including any post-marketing reports of adverse drug experiences,
relating to Products and required to be reported to the appropriate regulatory authorities outside of the Territory, in accordance with the Laws of the relevant countries. Orexigen shall have the right to share any and all information received from
Takeda under this Section 3.6, or the Pharmacovigilance Agreement, with Orexigen’s Affiliates and licensees and sublicensees outside the Territory. Takeda shall have the right to share any and all information received from Orexigen under
this Section 3.6 or the Pharmacovigilance Agreement with Takeda’s Affiliates and Sublicensees in the Territory. The JSC shall review from time to time Takeda’s and Orexigen’s pharmacovigilance policies and procedures. The
Pharmacovigilance Agreement identifies the responsibilities of each Party regarding the information to be exchanged and the timeframes for such exchange, regulatory reporting, literature review, risk management, and labeling. 

  
 - 33 - 

 FINAL VERSION 

 

 3.7 Recalls and Product Safety. The Parties shall exchange their internal standard
operating procedures (“SOPs”) for conducting product recalls reasonably in advance of the First Commercial Sale of any Product in the Territory, and shall discuss and resolve any conflicts between such SOPs and issues relating
thereto promptly after such exchange. If either Party becomes aware of information relating to any Product that indicates that a unit or batch of Product may not conform to the specifications therefor, or that potential adulteration, misbranding, or
other issues have arisen that relate to the safety or efficacy of Products, it shall promptly so notify the other Party. The JSC shall meet to discuss such circumstances and to consider appropriate courses of action, which shall be consistent with
the internal SOP of the Party having the right to control such recall pursuant to this Section 3.7. Takeda shall have the right and responsibility to control any product recall, field correction, or withdrawal of any Product in the Territory
that is required by Regulatory Authorities in the Territory, and the allocation of expenses incurred in connection with such recall between the Parties is set forth in the Manufacturing Services Agreement. In addition, Takeda shall have the right,
at its discretion, to conduct any product recall, field correction, or withdrawal of any Product in the Territory that is not so required by such Regulatory Authorities but that Takeda deems to be appropriate, with the allocation of expenses
incurred in connection with such recall between the Parties set forth in the Manufacturing Services Agreement. As between the Parties, Orexigen shall have the right, at its expense, to control all recalls, field corrections, and withdrawals of any
Product outside the Territory; provided, however, Orexigen shall provide Takeda with at least five (5) days prior written notice before taking any such action. Takeda shall maintain complete and accurate records of any recall in the
Territory for such periods as may be required by Laws, but in no event for less than three (3) years. 
 3.8 Trademarks. 

3.8.1 Product Trademarks. All packaging, promotional materials, package inserts, and labeling for each Product shall bear one or more
Trademark(s) that pertain specifically to such Product, including the Trademark(s) set forth on Exhibit 3.8.1 (“Product Trademark”). Orexigen shall be the sole and exclusive owner of all Product Trademarks. Orexigen shall bear the
full costs and expense of and be responsible for filing, prosecuting, and maintaining, including searching and policing, any and all Product Trademarks, and conducting litigation with respect thereto. Except as expressly permitted by Orexigen,
Takeda shall make no use of the Product Trademarks or any Trademark that includes any of the Product Trademarks, or is confusingly similar thereto, on or in connection with any product or service anywhere in the world. Without limiting the
generality of the foregoing, Takeda shall not use any Trademark that is the same as, or similar to (so as to cause confusion in consumers), the Product Trademarks. The foregoing shall not be construed as restricting Takeda from making factual
references to the Product Trademarks in its Regulatory Filings under this Agreement or to satisfy its legal and regulatory obligations. If the Product Trademarks in existence as of the Original Effective Date are not eligible for trademark
protection or for use in connection with the Products in the Territory, then the JCC shall identify alternative trademarks owned, registered or to be registered by Orexigen and to be used for the Products in the Territory, for Takeda final selection
from among such trademarks identified by the JCC, and the Parties shall amend this Agreement to identify such marks and include them as Product Trademarks for the Territory. 

  
 - 34 - 

 FINAL VERSION 

 

 3.8.2 Orexigen Trademarks. All packaging, promotional materials, package inserts, and
labeling for each Product shall bear one or more house Trademark(s) chosen and owned by Orexigen, including the Orexigen name and Orexigen Logo (“Orexigen Trademark”). Orexigen shall be the sole and exclusive owner of all Orexigen
Trademarks. Orexigen shall bear the full costs and expense of and be responsible for filing, prosecuting, and maintaining, including searching and policing, any and all Orexigen Trademarks, and conducting litigation with respect thereto. Except as
expressly permitted by Orexigen, Takeda shall make no use of the Orexigen Trademarks or any Trademark that includes any of the Orexigen Trademarks, or is confusingly similar thereto, or any of Orexigen’s or its Affiliates’ Trademarks, on
or in connection with any product or service anywhere in the world. Without limiting the generality of the foregoing, Takeda shall not use any Trademark that is the same as, or similar to (so as to cause confusion in consumers), the Orexigen
Trademarks. The foregoing shall not be construed as restricting Takeda from making factual references to the Orexigen Trademarks in its Regulatory Filings under this Agreement or to satisfy its legal and regulatory obligations. 

3.8.3 Takeda Trademarks. All packaging, promotional materials, package inserts, and labeling for each Product shall bear one or more
house Trademark(s) chosen and owned by Takeda, including the Takeda name and logo (“Takeda Trademark”). Takeda shall be the sole and exclusive owner of all Takeda Trademarks. Takeda shall bear the full costs and expense of and be
responsible for filing, prosecuting, and maintaining, including searching and policing, any and all Takeda Trademarks, and conducting litigation with respect thereto. Except as expressly permitted by Takeda, Orexigen shall make no use of the Takeda
Trademarks or any Trademark that includes any of the Takeda Trademarks, or is confusingly similar thereto, or any of Takeda’s or its Affiliates’ Trademarks, on or in connection with any product or service anywhere in the world. Without
limiting the generality of the foregoing, Orexigen shall not use any Trademark that is the same as, or similar to (so as to cause confusion in consumers), the Takeda Trademarks. The foregoing shall not be construed as restricting Orexigen from
making factual references to the Takeda Trademarks in its Regulatory Filings under this Agreement or to satisfy its legal and regulatory obligations. 

3.8.4 Quality Control. Each Party agrees to (a) conduct its business in a manner that will not damage the reputation or integrity
of the Trademarks of the other Party, (b) conduct its business in a manner that will not damage in any way the goodwill associated with the Trademarks of the other Party, (c) use the Trademarks of the other Party in a manner that will not
cause a negative impact upon the good name of such other Party, (d) conduct its business in compliance with all applicable trademark Laws and (e) to use the other Party’s Trademarks only in accordance with this Agreement. 

3.8.5 Product Marking. To the extent permitted under Laws, the packaging, promotional materials, package inserts, and labeling for
Products will bear both the Takeda name and Takeda logo and the Orexigen name and Orexigen Logo, and such names and logos will be presented in a manner agreed to by the Parties. Orexigen will be responsible for registering and policing the Orexigen
Logo in order to enable Takeda to appropriately mark any packaging with the Orexigen Logo, to the extent permitted or required by Laws. Except as set forth in this Section 3.8 and Sections 6.1.2 and 6.1.3, no right or license, express or
implied, is granted to Takeda to use any trademark, trade name, trade dress, or service mark Controlled by Orexigen or any of its Affiliates. No right or license, express or implied, is granted to Orexigen

  
 - 35 - 

 FINAL VERSION 

 

 
under this Agreement to use any trademark, trade name, trade dress or service mark Controlled by Takeda or any of its Affiliates. 

4. PRODUCT SUPPLY 

4.1 Manufacturing Services Agreement; Quality Agreement. The Parties entered into a manufacturing services agreement, dated as of
September 2, 2014 (as may be amended by the Parties in accordance with its terms, the “Manufacturing Services Agreement”), which governs the Manufacture and supply of the Product. The Parties entered into a quality agreement,
dated as of September 24, 2014 (as may be amended by the Parties in accordance with its terms, the “Quality Agreement”), which governs quality roles and responsibilities with respect to the Manufacture and supply of the Product
under the Manufacturing Services Agreement. 
 4.2 Takeda’s Option to Manufacture. At any time during the Term, Takeda may
elect, subject to the provisions of Section 14.1, to assume the exclusive right and responsibility to Manufacture or have Manufactured the Product for the Territory by notifying the JSC and the JMC. Within thirty (30) days after such
notice, the JMC shall begin working on a transition plan for transferring responsibility for Manufacturing activities for Products in the Territory from Orexigen to Takeda within a commercially reasonable timeframe (the “Manufacturing
Responsibility Transition Plan”). The Manufacturing Responsibility Transition Plan will be subject to approval by the JSC. Prior to such transfer, Orexigen shall have the sole right to make and have made Products in accordance with the
Manufacturing Services Agreement for Takeda’s or Orexigen’s use in Development or Commercialization activities under this Agreement. The Manufacturing Responsibility Transition Plan will reasonably take into account Orexigen’s
obligation, if any, to supply the Product for use outside the Territory for purposes unrelated to the Parties’ activities under this Agreement. Each Party shall use Commercially Reasonable Efforts to perform its responsibilities under the
Manufacturing Responsibility Transition Plan. Upon transfer of Manufacturing to Takeda in accordance with the Manufacturing Responsibility Transition Plan, as between the Parties, Takeda shall assume the sole and exclusive right and responsibility
to Manufacture Products for the Territory, itself or through Third Party Manufacturers. Orexigen acknowledges and agrees that following transfer of Manufacture of the Product to Takeda, Takeda will have no obligation to supply the Product for any
use outside the Territory that is unrelated to the Parties’ activities under this Agreement. Upon Takeda’s assumption of such responsibility, the Manufacturing Services Agreement shall automatically terminate. Orexigen shall continue to
have the sole right and obligation to supply Takeda its requirements of Products in the Territory until any such transfer of Manufacturing is successfully achieved in accordance with the Manufacturing Responsibility Transition Plan and approved by
appropriate Regulatory Authorities. 
 4.3 [Intentionally Omitted.] 

4.4 Commercial Packaging. Takeda, itself and/or through one or more of its Affiliates and/or through one or more subcontractors, shall
have the sole right and responsibility 

  
 - 36 - 

 FINAL VERSION 

 

 
to perform Commercial Packaging in the Territory; provided, however, that Orexigen shall have the sole right and responsibility to perform stability testing on Products; provided
further, however, that the Parties may mutually agree, at any time during the Term, to transfer to Takeda the right and responsibility to perform stability testing for Product in connection with Commercial Packaging. At the time of such
transfer, stability testing for Product in final packaged form will be included in the term “Commercial Packaging.” Prior to any such transfer, Takeda shall provide Orexigen, at Orexigen’s request, with sufficient amounts of Product
after Takeda has completed Commercial Packaging for such Product to enable Orexigen to complete stability testing for purposes of compliance with any and all regulatory requirements in the Territory. For the avoidance of doubt, prior to the transfer
of the right and responsibility for Manufacturing activities pursuant to Section 4.2 for Product in the Territory from Orexigen to Takeda, Orexigen shall retain the sole right and responsibility for all Manufacturing activities other than
Commercial Packaging, including manufacturing Product in finished form for Development. Section 3.4.6 shall apply with respect to Takeda’s, its Affiliates’, and/or subcontractors’ performance of any Commercial Packaging
activities. 
 5. GOVERNANCE 

5.1 Joint Steering Committee. 

5.1.1 Formation and Purpose. Within fifteen (15) days after the Original Effective Date, the Parties shall establish a joint
steering committee (the “JSC”) to oversee the Collaboration and to make certain decisions regarding the Development and Commercialization activities of the Parties during the Term as set forth in this Section 5.1. The JSC shall
have review and oversight responsibilities for all Development and Commercialization activities. The JSC shall also provide a forum for sharing advice, progress and results relating to such activities and shall attempt to facilitate the resolution
of any Disputes between the Parties, as described in Section 5.7. The JSC shall have access to all Development Plans and Commercialization Plans and related budgets and shall be briefed by the Parties regarding the content, execution and
results achieved by the respective Parties thereunder. Each Party, through its representatives on the JSC, shall be permitted to provide advice and commentary with respect to the Development Plans and Commercialization Plans and related budgets. As
applicable, each Party shall take such advice and commentary into good faith consideration. 
 5.1.2 Specific Responsibilities of the
JSC. In addition to its general responsibilities set forth in Section 5.1.1, the JSC shall, in particular, have responsibility to: 

(a) oversee and coordinate the Development activities; 

(b) review, provide comments relating to, and approve each Development Plan, and any modifications thereof or amendments thereto, to
ensure that the Development Plan is designed to meet the Development diligence objectives set forth in Section 2.1; 
 (c)
review, provide comments relating to, and approve each Commercialization Plan, and any modifications thereof or amendments thereto, to ensure that the 

  
 - 37 - 

 FINAL VERSION 

 

 
Commercialization Plan is designed to meet the Commercialization diligence objectives set forth in Sections 3.1 and 3.2; 

(d) review and provide comments to the pricing strategy for each Product (as included in the Commercialization Plan), subject to the
provisions of Section 3.1 and applicable Law; 
 (e) review the overall progress under the Product Plans; 

(f) provide a forum for the Parties to discuss and attempt to resolve Disputes; and 

(g) such other responsibilities as the Parties may allocate to the JSC. 

5.1.3 Membership of the JSC. The JSC shall consist of three (3) representatives having appropriate decision-making authority
(e.g., at least the Vice President position) designated by each of Orexigen and Takeda, and shall operate by consensus with each Party having one (1) vote. Additional representatives having relevant expertise may from time to time be invited to
attend JSC meetings; provided, however, any such representatives who are not employees of a Party or its Affiliates shall be subject to such representative’s written agreement to comply with the requirements of this Agreement. 

5.1.4 Meetings of the JSC. The JSC shall meet at least four (4) times annually during the Term or at such other frequency as
mutually agreed by the Parties. The JSC shall meet on such dates and at such times as agreed to by Orexigen and Takeda, with all scheduled in-person meetings to alternate between an Orexigen site and a Takeda site as designated by the respective
Party prior to such meeting, or at other locations as determined by the JSC. Meetings may be held by audio or video conference with the consent of each Party. Each Party shall be responsible for its own expenses for participating in each JSC.
Meetings of the JSC shall be effective only if a majority of the representatives of each Party are present or participating. 
 5.2 Joint
Development Committee. 
 5.2.1 Formation and Purpose. Within fifteen (15) days after the Original Effective Date, the
Parties shall establish a joint development committee (the “JDC”), which shall perform the primary function of designing, implementing, monitoring, reviewing and discussing the Development Plan and Development budget for the
Product, including progress and performance thereunder, and for proposing updates or amendments to the Development Plan and Development budget for approval by the JSC. 

5.2.2 Specific Responsibilities of the JDC. In addition to its general responsibilities set forth in Section 5.2.1, the JDC
shall, in particular, have responsibility for: 
 (a) facilitating cooperation and coordination between the Parties regarding
Development matters; 

  
 - 38 - 

 FINAL VERSION 

 

 (b) preparing and proposing, for JSC approval, amendments to the then-current
Development Plan and the corresponding Development budget and proposing such Development Plan and Development budget for approval by the JSC. Any amended Development Plan shall cover the next Calendar Year (and additional periods as reasonably
determined by the Parties) and shall contain a corresponding Development budget; 
 (c) monitoring, reviewing, coordinating, and
discussing the overall progress of Development under this Agreement; 
 (d) facilitating the flow of information with respect to
Development activities being conducted for Products in or for the Territory, including through the review of data, reports, or other information submitted by either Party with respect to Development activities conducted by or on behalf of such
Party; 
 (e) assigning lead parties for specific tasks or activities identified in the Development Plan; 

(f) reviewing, discussing and proposing appropriate Third Party subcontractors to engage for the purpose of supporting the Development
activities to be carried out by each of the Parties; 
 (g) coordinating communications by the Parties with the Regulatory
Authorities with respect to Products in accordance with this Agreement; and 
 (h) reviewing, coordinating, discussing and proposing
the overall strategy for Regulatory Filings for approval by the JSC, except to the extent impracticable with respect to expedited safety reports. 

5.2.3 Membership of the JDC. The JDC shall consist of three (3) representatives designated by each of Orexigen and Takeda and
shall operate by consensus with each Party having one (1) vote. Additional representatives having relevant expertise may from time to time be invited to attend JDC meetings; provided, however, any such representatives who are not
employees of a Party or its Affiliates shall be subject to such representative’s written agreement to comply with the requirements of this Agreement. 

5.2.4 Meetings of the JDC. The JDC shall meet at least four (4) times annually during the Term or at such other frequency as
mutually agreed by the Parties. The JDC shall meet on such dates and at such times as agreed to by Orexigen and Takeda, with all scheduled in-person meetings to alternate between an Orexigen site and a Takeda site as designated by the respective
Party prior to such meeting, or at other locations as determined by the JDC. Meetings may be held by audio or video conference with the consent of each Party. Each Party shall be responsible for its own expenses for participating in each JDC.
Meetings of the JDC shall be effective only if a majority of the representatives of each Party are present or participating. 

  
 - 39 - 

 FINAL VERSION 

 

 5.3 Joint Commercialization Committee. 

5.3.1 Formation and Purpose. Within fifteen (15) days after the Original Effective Date, the Parties shall establish a joint
commercialization committee (the “JCC”), which shall perform the primary functions of: 
 (a) facilitating
cooperation and coordination between the Parties regarding Commercialization matters; 
 (b) designing, implementing, monitoring,
reviewing and discussing the Commercialization Plan and Commercialization budget for the Product, including progress and performance thereunder, and for proposing updates or amendments to the Commercialization Plan and Commercialization budget for
approval by the JSC; 
 (c) monitoring, reviewing, coordinating, and discussing the overall progress of Commercialization under this
Agreement; and 
 (d) providing regular updates, and making recommendations (as appropriate), to the JSC regarding the foregoing
matters. 
 5.3.2 Membership of the JCC. The JCC shall consist of three (3) representatives designated by each of Orexigen and
Takeda and shall operate by consensus with each Party having one (1) vote. Additional representatives having relevant expertise may from time to time be invited to attend JCC meetings; provided, however, any such representatives who are
not employees of a Party or its Affiliates shall be subject to such representative’s written agreement to comply with the requirements of this Agreement. 

5.3.3 Meetings of the JCC. The JCC shall meet at least four (4) times annually during the Term or at such other frequency as
mutually agreed by the Parties. The JCC shall meet on such dates and at such times as agreed to by Orexigen and Takeda, with all scheduled in-person meetings to alternate between an Orexigen site and a Takeda site as designated by the respective
Party prior to such meeting, or at other locations as determined by the JCC. Meetings may be held by audio or video conference with the consent of each Party. Each Party shall be responsible for its own expenses for participating in meetings of the
JCC. Meetings of the JCC shall be effective only if a majority of the representatives of each Party are present or participating. 
 5.4
Joint Manufacturing Committee. 
 5.4.1 Formation and Purpose. Within fifteen (15) days after the Original Effective Date,
the Parties shall establish a joint manufacturing committee (the “JMC”) which will have strategic oversight of the manufacture and distribution of the Products in and for the Territory, including receiving updates from Orexigen
regarding the Third Party Manufacturers, and monitoring the production capabilities of the Third Party Manufacturers in order that Takeda may forecast when Takeda demand for the Products in a given Calendar Quarter exceed (or are likely to exceed)
the maximum production capability of the Third Party Manufacturers in such Calendar Quarter; and overseeing the arrangements for the distribution of Products which are to be delivered as specified on the relevant binding order. 

  
 - 40 - 

 FINAL VERSION 

 

 5.4.2 Membership of the JMC. The JMC shall consist of three (3) representatives
designated by each of Orexigen and Takeda and shall operate by consensus with each Party having one (1) vote. Additional representatives having relevant expertise may from time to time be invited to attend JMC meetings; provided,
however, any such representatives who are not employees of a Party or its Affiliates shall be subject to such representative’s written agreement to comply with the requirements of this Agreement. 

5.4.3 Meetings of the JMC. The JMC shall meet at least four (4) times annually during the Term or at such other frequency as
mutually agreed by the Parties. The JMC shall meet on such dates and at such times as agreed to by Orexigen and Takeda, with all scheduled in-person meetings to alternate between an Orexigen site and a Takeda site as designated by the respective
Party prior to such meeting, or at other locations as determined by the JMC. Meetings may be held by audio or video conference with the consent of each Party. Each Party shall be responsible for its own expenses for participating in meetings of the
JMC. Meetings of the JMC shall be effective only if a majority of the representatives of each Party are present or participating. 
 5.5
Additional Committees. The Parties shall discuss such other committees as the Parties deem necessary or desirable for the management of the Collaboration. Any Committee may establish and delegate duties to other committees or sub-Committees on
an “as-needed” basis to oversee particular projects or activities. Each such sub-Committee shall be constituted and shall operate as the establishing Committee determines; provided that each Party shall have the right to equal
representation on any such sub-Committee. Sub-Committees may be established on an ad hoc basis for purposes of a specific project, or on such other basis as the applicable Committee may determine. Each sub-Committee and its activities shall be
subject to the oversight, review and approval of, and shall report to, the Committee that established such sub-Committee. In no event shall the authority of the sub-Committee exceed that specified for the relevant Committee in this Article 5. 

5.6 General Committee Procedures. 

5.6.1 General Responsibilities. The Committees will be responsible in the first instance for developing mutual agreement between the
Parties on matters within the Committee’s jurisdiction, and for making recommendations to the JSC. After approval by the JSC, the designated lead Party will implement the plan, subject to the oversight of the relevant Committee. 

5.6.2 Chairperson. Each Committee will be led by a representative of one of the Parties (the “Chairperson”),
appointed as follows: (a) Orexigen shall select from its representatives a Chairperson for each of the JDC for the period commencing on the Original Effective Date and ending on December 31, 2011 and Takeda shall select from its
representatives a Chairperson for the JDC for the period commencing on January 1, 2012 and ending on December 31, 2012, and (b) Takeda shall select from its representatives a Chairperson for the JSC for the period commencing on the
Original Effective Date and ending on December 31, 2011 and Orexigen shall select from its representatives a Chairperson for the JSC for the 

  
 - 41 - 

 FINAL VERSION 

 

 
period commencing on January 1, 2012 and ending on December 31, 2012. Thereafter, selection of the Chairperson for such Committees will alternate between the Parties on a Calendar Year
basis. A Takeda representative shall be the Chairperson of the JCC throughout the Term. An Orexigen representative shall be the Chairperson of the JMC unless or until Manufacturing responsibilities are transferred to Takeda pursuant to
Section 4.2; and thereafter a Takeda representative shall be the Chairperson of the JMC. 
 5.6.3 Responsibilities. The
Chairperson shall have only those responsibilities set forth in this Section 5.6.3. The Chairperson of each Committee shall be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of such Committee,
provided that a Chairperson shall call a meeting of the applicable Committee promptly upon the written request of either Party to convene such a meeting. In addition, each Chairperson shall bear the responsibility for preparing written draft
minutes of that Committee’s meetings in reasonable detail and for distributing such draft minutes to all members of that Committee for comment and review within twenty (20) days after the relevant meeting. The members of the Committee
shall have ten (10) days to provide comments. Each Chairperson shall incorporate timely received comments and distribute revised minutes to all members of that Committee for their final review and approval within forty-five (45) days after
the relevant meeting. 
 5.6.4 Membership on Committees. Each representative of a Party may serve on more than one Committee as
appropriate in view of the individual’s expertise and may be substituted by another person with notice to the other Party. 
 5.6.5
Limitations of Committee Powers. Each Committee shall have only such powers as are specifically delegated to it hereunder and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no Committee
shall have any power to amend this Agreement. Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 14.7. 

5.6.6 Authority. The Parties agree that, in voting on matters as described in this Article 5, it shall be conclusively presumed that
each voting member of the JSC or other Committee has the authority and approval of such member’s respective senior management in casting his or her vote. 

5.7 Committee Decision-Making. 

5.7.1 Consensus; Good Faith; Action Without Meeting. Subject to the terms of this Section 5.7, each Committee will take action by
consensus, assuming a quorum for such Committee is present, with each Party having one (1) vote. The members of each Committee shall act in good faith to cooperate with one another to reach agreement with respect to issues to be decided by the
Committee. Action that may be taken at a meeting of a Committee also may be taken without a meeting if a written consent setting forth the action so taken is signed by all of the Committee representatives of each Party. 

5.7.2 Failure to Reach Consensus by a Committee. In the event that any matter before a Committee that is required to be resolved by
mutual agreement of the 

  
 - 42 - 

 FINAL VERSION 

 

 
members thereof is unable to be resolved and agreed within fifteen (15) days of its initial consideration (or such other time period as mutually agreed by the Parties), then such matter
shall be escalated to and resolved by the JSC; provided that such Committee may escalate the matter to the JSC prior to the expiration of such period with the consent of both Parties. 

5.7.3 Failure to Reach Consensus by the JSC. If the JSC cannot reach consensus within fifteen (15) days (or such other time
period as mutually agreed by the Parties) with respect to any Dispute escalated from another Committee or within fifteen (15) days of such Dispute arising at the JSC, with the exception of Disputes related to the safety of a Product, the JSC
shall submit the respective positions of the Parties with respect to such Dispute for discussion in good faith and resolution by the Chief Executive Officer of Orexigen, or such other person with
decision-making authority designated by Orexigen from time to time, and the Chief Executive Officer of Takeda’s Affiliate, Takeda Pharmaceuticals U.S.A., Inc., or such other person with decision-making authority designated by Takeda from time to time (collectively, the “Executive Officers”). The Executive Officers shall meet promptly to discuss the Dispute submitted and to
determine a resolution. If the Executive Officers are unable to resolve the Dispute within ten (10) days of submission of such Dispute to the Executive Officers (or such other time period as mutually agreed by the Parties), then,
(a) Takeda shall have the final decision-making authority and the right to solely decide the Dispute if such Dispute is related to (i) Development Post-Approval Activities (provided that, for clarity, Takeda shall not have the right
to limit Orexigen’s rights under Section 2.2.4 without mutual agreement of the Parties); (ii) Commercialization (provided that, for clarity, Takeda shall not have the right to, without mutual agreement of the Parties,
(1) limit Orexigen’s rights under Section 3.5, (2) reduce Takeda’s PDE requirements under Section 3.2.1 or Commercial Costs obligations under Section 3.2.3, or (3) reduce the number of PDEs Orexigen has the
right to perform under Sections 3.5.1 or 3.5.2); (iii) [...***...] and (b) Orexigen shall have the final decision-making authority and the right to solely decide the Dispute if such Dispute is related to (i) Development Approval
Activities; or (ii) Manufacturing [...***...] for so long as Orexigen retains responsibility to manufacture and supply Product [...***...]. 

5.8 Orexigen’s Membership in Committees. Orexigen’s membership in any Committee shall be at its sole discretion, as a matter
of right and not obligation, for the sole purpose of participation in governance, decision-making, and information exchange with respect to activities within the jurisdiction of such Committee. At any time during the Term, Orexigen shall have
the right to withdraw from membership in any or all of the Committees upon thirty (30) days’ prior written notice to Takeda, which notice shall be effective as to the relevant Committee upon the expiration of such thirty (30) day
period. Following the issuance of such notice for a given Committee, (a) Orexigen’s membership in such Committee shall be terminated and (b) Orexigen shall have the right to continue to receive the data, plans, reports, and
information it would otherwise be entitled to receive under this Agreement. If, at any time, following issuance of such a notice, Orexigen wishes to resume participation in any Committee, Orexigen shall notify Takeda in writing and, thereafter,
Orexigen’s representatives to such Committee shall be entitled to attend 

  
 - 43 - 

 FINAL VERSION 

 

 
any subsequent meeting of such Committee and to participate in the activities of, and decision-making by, such Committee as provided in this Article 5 as if such notice had not been issued by
Orexigen pursuant to this Section 5.8. If the JSC is disbanded, then any data, plans, reports, and information originally to be disclosed through the JSC shall be provided by such Party directly to the other Party. 

5.9 Alliance Managers. Promptly after the Original Effective Date, each Party shall appoint an individual (other than an existing
member of the JSC) to act as the alliance manager for such Party (each, an “Alliance Manager”). Each Alliance Manager shall thereafter be permitted to attend meetings of any Committee as a nonvoting observer. The Alliance Managers
shall be the primary point of contact for the Parties regarding the Collaboration activities contemplated by this Agreement and shall facilitate communication regarding all activities hereunder. The Alliance Managers shall lead the communications
between the Parties and shall be responsible for following-up on decisions made by the JSC. The name and contact information for such Alliance Manager, as well as any replacement(s) chosen by Orexigen or Takeda, in their sole discretion, from time
to time, shall be promptly provided to the other Party in accordance with Section 14.3. 
 6. LICENSES 

6.1 Licenses to Takeda for Products. 

6.1.1 Subject to the terms and conditions of this Agreement, Orexigen hereby grants to Takeda (a) an exclusive (even as to
Orexigen, except to the extent set forth in Article 4 and Sections 2.2, 2.2.4(c), 3.5, and 6.3), nontransferable (except as provided in Section 14.5) license in the Field in the Territory, with the right to grant sublicenses solely in
accordance with Section 6.2, under the Orexigen Intellectual Property, to make and have made (except to the extent set forth in Article 4), use, sell, offer to sell, import, and otherwise Develop and Commercialize all Products during the Term;
and (b) a non-exclusive license, with the right to grant sublicenses solely in accordance with Section 6.2, under the Orexigen Intellectual Property to (i) make and have made (except to the extent set forth in Article 4) Product
outside the Territory for use or sale solely inside the Territory, and (ii) conduct Clinical Trials outside the Territory for the purpose of submitting Regulatory Filings in the Territory. 

6.1.2 Subject to the terms and conditions of this Agreement, Orexigen hereby grants to Takeda an exclusive (even as to Orexigen,
except to the extent set forth in Section 3.5), nontransferable (except as provided in Section 14.5) license in the Field in the Territory, with the right to grant sublicenses solely in accordance with Section 6.2, under the Product
Trademarks, to use and display the Product Trademarks in connection with Commercialization, as provided under and in accordance with this Agreement. 

6.1.3 Subject to the terms and conditions of this Agreement, Orexigen hereby grants to Takeda a non-exclusive, nontransferable (except
as provided in Section 14.5) license in the Field in the Territory, with the right to grant sublicenses solely in accordance with Section 6.2, under the Orexigen Trademarks, to use and display the Orexigen Trademarks in connection with
Commercialization, as provided under and in accordance with Section 3.8.2. 

  
 - 44 - 

 FINAL VERSION 

 

 6.2 Sublicensing. Takeda shall have the right to grant sublicenses through multiple
tiers with respect to the rights licensed to Takeda under Section 6.1 to any Affiliate of Takeda solely in accordance with Sections 6.2.1 through 6.2.5. Takeda shall not have the right to grant Sublicenses with respect to the rights licensed to
Takeda under Section 6.1 to any Third Party without the prior written consent of Orexigen, which shall not to be unreasonably withheld, conditioned, or delayed. In the event Orexigen consents to the grant of such a Sublicense, such Sublicense
shall be granted solely in accordance with Sections 6.2.1 through 6.2.5: 
 6.2.1 such Sublicense shall refer to this Agreement and
shall be subordinate to and consistent with the terms and conditions of this Agreement, and shall not limit either the ability of Takeda (individually or through the activities of its Sublicensee) to fully perform all of its obligations under this
Agreement or Orexigen’s rights under this Agreement; 
 6.2.2 in such Sublicense, the Sublicensee shall agree in writing to be
bound to Takeda by terms and conditions substantially similar to, or less favorable to the Sublicensee than, the corresponding terms and conditions of this Agreement; 

6.2.3 promptly after execution of the Sublicense, and specifically excluding any sublicenses granted to an Affiliate of Takeda, Takeda
shall provide a complete and correct copy of such Sublicense to Orexigen; 
 6.2.4 Takeda shall remain responsible for the
performance of this Agreement and the performance of its Sublicensees hereunder, and shall cause such Sublicensee to enable Takeda to comply with all applicable terms and conditions of this Agreement; and 

6.2.5 each Sublicense shall terminate immediately upon the termination of this Agreement (in whole or only with respect to the rights
that are subject to such Sublicense). 
 For clarity, any references to Sublicense or Sublicensee in Sections 6.2.1 through 6.2.5 shall also mean sublicense
or sublicensee, as the case may, be with respect to Takeda’s Affiliates. 
 6.3 Licenses to Orexigen. 

6.3.1 Subject to the terms and conditions of this Agreement, Takeda hereby grants to Orexigen a non-exclusive, royalty-free,
non-transferable (except as provided in Section 14.5) license in the Field in the Territory, with the right to grant sublicenses solely in accordance with Section 6.2, under the Takeda Intellectual Property solely as and to the extent
necessary to enable Orexigen to perform Development and Commercialization activities under this Agreement, and/or other development activities as contemplated in Section 2.2.4(c), with respect to Products. 

6.3.2 Subject to the terms and conditions of this Agreement, Takeda hereby grants to Orexigen a non-exclusive, nontransferable (except
as provided in Section 14.5) license in the Field in the Territory, with the right to grant sublicenses solely in accordance with Section 6.2, under the Takeda Trademarks, to use and display the Takeda Trademarks in

  
 - 45 - 

 FINAL VERSION 

 

 
connection with Orexigen’s Co-Promotion of the Products in the Field throughout the Territory, as provided under and in accordance with Section 3.8.3. 

6.4 Patent Marking. The packaging for each Product Commercialized by Takeda under this Agreement shall be marked (to the extent not
prohibited by Laws) with a notice that such Product is sold under a license from Orexigen. 
 6.5 No Implied Licenses; Upstream
Agreements. 
 6.5.1 No Implied Licenses. No license or other right is or shall be created or granted hereunder by implication,
estoppel, or otherwise. All licenses and rights are or shall be granted only as expressly provided in this Agreement. All rights not expressly granted by Orexigen under this Agreement are reserved by Orexigen and may not be used by Takeda for any
purpose. 
 6.5.2 Upstream Agreements. Takeda’s rights under this Agreement with respect to the Upstream Patents are expressly
subject to the applicable terms and conditions of the applicable Upstream Agreements as set forth below in this Section 6.5.2. Without limiting the foregoing, Takeda acknowledges and agrees that: 

(a) the license granted in Section 6.1.1 is non-exclusive with respect to the Patents licensed to Orexigen pursuant to the GSK
License, and the grant to any and all such Patents is limited to the GSK Field; 
 (b) Takeda’s right to sublicense under
Section 6.2, with respect to the GSK License is subject to delivery of notice to GSK pursuant to Section 2.1(ii) of the GSK License; and 

(c) under the OHSU Agreement, OHSU retains the right to use the “Assigned Therapeutic Patent Rights” (as defined in the OHSU
Agreement) for educational and research purposes. 
 6.6 Parallel Trade. Orexigen shall use Commercially Reasonable Efforts to cause
Orexigen’s and its Affiliates’, licensees’ and sublicensees’ advertising, promotional or other commercialization activities with respect to a Product not to result in sales of the Product from Canada (including its provinces and
territories) and Mexico into the Territory. 
 7. FINANCIAL TERMS 

7.1 Upfront Payment. As reimbursement for research and development of Products conducted by Orexigen, Takeda has paid to Orexigen a
payment of Fifty Million Dollars ($50,000,000) within ten (10) Business Days after the Original Effective Date. Such payment shall not be refundable or returnable in any event, nor shall it be creditable against royalties or other payments.

 7.2 Milestone Payments. As reimbursement for research and development of Products conducted by Orexigen, Takeda has made each of
the milestone payments to Orexigen described in Section 7.2.1 and shall make milestone payments to Orexigen described in 

  
 - 46 - 

 FINAL VERSION 

 

 
Section 7.2.2. Such milestone payments shall not be refundable or returnable in any event, nor shall they be creditable against royalties or other payments. 

7.2.1 Development Milestones. The Parties acknowledge and agree that as of the Amended and Restated Effective Date, Takeda has made
each of the development milestone payments set forth in the table in this Section 7.2.1, below, to Orexigen with respect to the first and only the first achievement of each of the corresponding milestone events set forth in the table in this
Section 7.2.1, below, within thirty (30) days after the date of achievement of the applicable milestone event. 
  

					
	Milestone Event	  	Payment	 
		
	 Regulatory Approval in the Territory
	  	$	20 million	  
	The later to occur of (i) Delivery of Launch Supplies; or (ii) Regulatory Approval in the Territory	  	$	10 million	  
		
	 First Commercial Sale in the Territory
	  	$	70 million	  

 For purposes of this Section 7.2.1, “Delivery of Launch Supplies” shall be deemed to occur if and only
if the Launch Supplies are available and at the disposal of Takeda at Orexigen’s or Orexigen’s Third Party Manufacturer’s manufacturing site not later than the delivery date specified in Takeda’s purchase order issued to Orexigen
on November 26, 2013. 
 7.2.2 Net Sales Milestones. Takeda shall pay, in accordance with Section 7.4, to Orexigen the
applicable Net Sales threshold milestone payments set forth in the table in this Section 7.2.2, below, the first and only the first time during the Term that the total aggregate Net Sales of all Products (including all Indications and
formulations of such Products) in any Calendar Year by Takeda, its Affiliates and its Sublicensees in the Territory reach or exceed the relevant amounts set forth in the table in this Section 7.2.2, below. 

 

					
	 Annual Calendar Year Net Sales for Products in the Territory

in all Indications
	  	Payment	 
		
	 Net Sales in one Calendar Year are greater than $400 million
	  	$	40 million	  
		
	 Net Sales in one Calendar Year are greater than $600 million
	  	$	60 million	  
		
	 Net Sales in one Calendar Year are greater than $800 million
	  	$	80 million	  
		
	 Net Sales in one Calendar Year are greater than $1 billion
	  	$	100 million	  

  
 - 47 - 

 FINAL VERSION 

 

					
		
	 Net Sales in one Calendar Year are greater than $1.5 billion
	  	$	150 million	  
		
	 Net Sales in one Calendar Year are greater than $2 billion
	  	$	200 million	  
		
	 Net Sales in one Calendar Year are greater than $2.5 billion
	  	$	250 million	  

 7.2.3 Anniversary Milestones. Takeda shall pay to Orexigen a milestone payment of Fifteen Million
Dollars ($15,000,000) on each of: (a) the first (1st) anniversary of Regulatory Approval in the Territory, (b) the second
(2nd) anniversary of the First Commercial Sale, and (c) the third (3rd) anniversary of the First Commercial Sale. Such milestone
payments shall not be refundable or returnable in any event, nor shall they be creditable against royalties or other payments. 
 7.2.4
Superiority Milestones. Takeda shall make the following milestone payments to Orexigen within thirty (30) days after the corresponding milestone dates set forth in the table in this Section 7.2.4 below; provided that each of the
following conditions is satisfied as of each such milestone date in order for the corresponding milestone payment to be due: (i) a Superiority Claim [...***...]; (ii) there is no [...***...]; (iii) if such milestone date
is [...***...] or earlier, the aggregate Net Sales for the [...***...] period preceding such milestone date shall have been at least $[...***...]; and (iv) if such milestone date is after [...***...], the aggregate Net
Sales for the [...***...] period preceding such milestone date shall have been at least $[...***...]. The Parties agree that Takeda will provide such Net Sales information to Orexigen in accordance with Section 7.4. For the
avoidance of doubt, if as of a milestone date, any of the foregoing applicable conditions are not satisfied, then no payment shall be required for such milestone date. 
  

			
	Milestone Date	  	Payment
	 [...***...]
	  	$[...***...]
	 [...***...]
	  	$[...***...]
	 [...***...]
	  	$[...***...]
	 [...***...]
	  	$[...***...]
	 [...***...]
	  	$[...***...]
	 [...***...]
	  	$[...***...]

 For clarity, [...***...] acknowledges and agrees that, as of [...***...], it is not [...***...], or to
[...***...]. 
 For example, if [...***...] 

  
 - 48 - 

 FINAL VERSION 

 

 [...***...]. 

7.3 Royalty Payments. 

7.3.1 Running Royalties. Subject to Sections 7.3.2 through 7.3.5 and in accordance with Section 7.4, Takeda shall pay to Orexigen
incremental royalties on aggregate Net Sales by Takeda, its Affiliates and its Sublicensees of all Products in the Territory during a Calendar Year in the amounts set forth in the table in this Section 7.3.1, below. 

 

					
	 Portion of Annual Net Sales for Products in the Territory in all

Indications
	  	Royalty Rate	 
		
	 Up to $400 million
	  	 	20	% 
		
	 Over $400 million and up to $600 million
	  	 	25	% 
		
	 Over $600 million and up to $1 billion
	  	 	30	% 
		
	 Over $1 billion
	  	 	35	% 

 7.3.2 Royalty Duration. All royalties payable under Section 7.3.1 shall be payable for the
duration of the Royalty Term for such Product in the Territory subject to the provisions of Sections 7.3.3 through 7.3.5. Such royalties are due and payable with respect to the substantial value provided to Takeda through access to the information,
assistance, materials and data made available to or provided to Takeda pursuant to this Agreement and Orexigen’s substantial expertise applied to research and Development of the Product. Following the Royalty Term, Takeda shall continue to pay
Orexigen a royalty of three percent (3%) of aggregate Net Sales of the Product by Takeda for as long as Takeda continues to use the Product Trademarks. 

7.3.3 Royalty Reduction – Generic Competition. In the event a Product is subject to Generic Competition in the Territory, then,
beginning in the calendar month following the three (3) calendar month period during which Generic Competition has been determined to exist in accordance with Section 1.51 at the applicable level noted below, the royalty rates set forth in
Section 7.3.1 (without giving effect to any reduction under Section 7.3.5) shall be reduced in the Territory: (a) by twenty-five percent (25%) if the units of such Generic Product(s) sold during the applicable three
(3) month period exceed ten percent (10%) and are not more than twenty-five percent (25%) of the Product’s unit volume in the Territory; 

  
 - 49 - 

 FINAL VERSION 

 

 
(b) by fifty percent (50%) if the units of such Generic Product(s) sold during the applicable three (3) month period exceed twenty-five percent (25%) and are not more than fifty
percent (50%) of the Product’s unit volume in the Territory; (c) by seventy-five percent (75%) if the units of such Generic Product(s) sold during the applicable three (3) month period exceed fifty percent (50%) and are
not more than seventy-five percent (75%) of the Product’s unit volume in the Territory; and (d) to three percent (3%) of Net Sales if the units of such Generic Product(s) sold during the applicable three (3) month period
exceed seventy-five percent (75%) of the Product’s unit volume in the Territory. For clarity, the Product’s unit volume shall be determined in accordance with Section 1.44(a) and (b). Such reduction shall be first applied with
respect to the Territory starting with sales in the calendar month following the first three (3) calendar month period where the sales of the Generic Product(s) in the Territory exceed the applicable level noted above of the unit sales volume
of the applicable Product, and shall expire on the day after the last day of the calendar month in which such Generic Competition ceases to exist or, if earlier, the expiration of the Royalty Term; provided, however, following the Royalty
Term Takeda shall continue to pay Orexigen a royalty of three percent (3%) of aggregate Net Sales of the Product by Takeda for as long as Takeda continues to use the Product Trademarks. As an example, in the case where Takeda has total annual
Net Sales for two Products of over $400 million and less than $600 million in the Territory and Generic Competition is established for either or both of the Products such that units of Generic Products have exceeded ten percent (10%), but are less
than twenty-five percent (25%), of the sum of all units of all Products and all units of Generic Products sold in the Territory, then the royalty rate of twenty-five percent (25%) for aggregate Net Sales of both Products will be reduced by
twenty-five (25%) to a royalty rate of eighteen point seventy-five percent (18.75%). For the avoidance of doubt, if the royalty rate set forth in Section 7.3.1 has already been reduced pursuant to Section 7.3.4, then the royalty
reduction set forth in Section 7.3.4 shall no longer apply and the royalty reduction set forth in this Section 7.3.3 shall take precedence. 

7.3.4 Royalty Reduction – Patent Expiry or Sole Takeda Patent. 

(a) Expiration of All Valid Claims Prior to End of Royalty Term. In the event the expiration of the last to expire Collaboration
Patent containing a Valid Claim Covering a Product in the Territory occurs prior to the expiration of the Royalty Term in the Territory, the royalty rate set forth in Section 7.3.1 (without giving effect to any reduction under
Section 7.3.5) for such Product in the Territory shall be reduced by twenty-five percent (25%) for the remainder of the applicable Royalty Term. Such royalty reduction shall become effective on the day after the last day of the Calendar
Quarter in which such last to expire Valid Claim expires. 
 (b) Royalty Term Based Solely on Takeda Patent. With respect to a
Product in the Territory, if all of the events described in the following subsections (i) through (iv) occur, then the royalty rate set forth in Section 7.3.1 (without giving effect to any reduction under Section 7.3.5) for such
Product shall be reduced by fifty percent (50%) until the expiration of the last to expire Takeda Patent containing a Valid Claim Covering such Product in the Territory: (i) all applicable exclusivity extensions, including pediatric
or data exclusivity, in the Territory with respect to such Product (such as those periods listed in the FDA’s Orange Book) have expired; (ii) it is after ten (10) years after First Commercial Sale of such Product in the Territory;
(iii) all Orexigen Patents and Joint Patents containing a Valid Claim Covering such 

  
 - 50 - 

 FINAL VERSION 

 

 
Product in the Territory have expired; and (iv) there is a Takeda Patent containing a Valid Claim Covering such Product in the Territory. Such royalty reduction shall become effective on the
day after the last day of the Calendar Quarter in which the events described in subsections (i) through (iv) occur. 
 7.3.5
Royalty Reduction – Anti-Stacking. Takeda may offset a total of fifty percent (50%) of any royalty payments based on Net Sales paid by Takeda to a Third Party pursuant to any necessary Third Party License against any royalty payments
due to Orexigen under Section 7.3.1; provided, however, that in no event shall the total royalty payable to Orexigen on any Product as a result of such offset be less than fifty percent (50%) of the royalty otherwise payable under
Section 7.3.1. In the event that fifty percent (50%) of such Third Party payments exceeds the amount of payments withheld by Takeda under this Section 7.3.5 in any Calendar Quarter, the excess may be carried over as a credit on the
same basis into succeeding Calendar Quarters. 
 7.4 Royalty Payment Reports. After the First Commercial Sale of a Product and
throughout the Royalty Term for such Product, Takeda shall furnish to Orexigen a written report, within forty-five (45) days after the end of each Calendar Quarter (or portion thereof if this Agreement terminates during a Calendar Quarter),
showing the amount of royalty or Net Sales milestone payments due for such Product for such Calendar Quarter (or portion thereof). Royalty or Net Sales milestone payments for each Calendar Quarter shall be due at the same time as such written report
for the Calendar Quarter. With each quarterly payment, Takeda shall deliver to Orexigen a full and accurate accounting to include at least the following information: (a) the gross sales for the applicable Product by Takeda, its Affiliates and
Sublicensees in the currency in which sales were made and in Dollars after application of the exchange rate during the reporting period as reported in subsection (e) below; (b) the deductions by category of permitted deductions set forth
in the Net Sales definition; (c) the Net Sales for the applicable Product by Takeda, its Affiliates, and Sublicensees in the currency in which sales were made and in Dollars after the application of the exchange rate during the reporting period
as reported in subsection (e) below; (d) the royalties or Net Sales milestone payments payable in Dollars which shall have accrued hereunder in respect of such Net Sales and the basis for calculating those royalties; (e) the exchange
rates and other methodology used in converting into Dollars, from the currencies in which sales were made; and (f) withholding taxes, if any, required by Laws to be deducted in respect of such royalties. In addition, Takeda will send to
Orexigen no later than fifteen (15) days following the end of each Calendar Quarter a preliminary statement setting forth the actual Net Sales for the first two (2) months of such Calendar Quarter and estimated Net Sales for the third (3rd) month of such Calendar Quarter, the calculation of royalties or Net Sales milestone payments due (based on such actual and estimated Net Sales in the Territory) and, if applicable, the
exchange rate to be utilized by Takeda to convert a local currency payment to Dollars. 
 7.5 Manner of Payment. All payments to be
made by Takeda hereunder shall be made in Dollars by wire transfer of immediately available funds to such U.S. bank account as shall be designated by Orexigen. Late payments shall bear interest at the rate provided in Section 7.10. 

  
 - 51 - 

 FINAL VERSION 

 

 7.6 Records Retention. Commencing with the First Commercial Sale of a Product by
Takeda, Takeda shall keep, and shall cause each of its respective Affiliates, and Sublicensees, if any, to keep, full, true, and accurate books of accounting in accordance with IFRS or GAAP, as applicable, containing all particulars that may be
necessary for the purpose of calculating all royalties payable to Orexigen under this Article 7, for a period of five (5) years after the Calendar Year in which such sales occurred, in sufficient detail to permit Orexigen to confirm the
accuracy of royalties paid hereunder. 
 7.7 Audits. During the Term and for a period of three (3) years thereafter, at the
request and expense of Orexigen under this Article 7, Takeda shall permit an independent, certified public accountant of nationally recognized standing appointed by Orexigen, and reasonably acceptable to Takeda, at reasonable times and upon
reasonable notice, but in no case more than once per Calendar Year thereafter, to examine such records as may be necessary for the sole purpose of verifying the calculation and reporting of Net Sales and the correctness of any royalty payment made
under this Agreement for any period within the preceding three (3) Calendar Years. Results of any such examination shall be made available to both Takeda and Orexigen. The independent, certified public accountant shall disclose to Orexigen only
the royalty amounts which the independent auditor believes to be due and payable hereunder to Orexigen, details concerning any discrepancy from the amount paid and the amount due, and shall disclose no other information revealed in such audit. Any
and all records examined by such independent accountant shall be deemed Takeda’s Confidential Information which may not be disclosed by said independent, certified public accountant to any Third Party other than a party to an Upstream Agreement
as required under the Upstream Agreements. If, as a result of any inspection of the books and records of Takeda, it is shown that payments received by Orexigen under this Agreement were less than the amount which should have been received, then
Takeda shall make all payments required to be made to eliminate any discrepancy revealed by said inspection within sixty (60) days. Orexigen shall pay for such audits, except that in the event that Takeda underpaid royalty payments by more than
five percent (5%) during the period in question as per the audit, Takeda shall pay the reasonable costs of the audit. Takeda acknowledges and agrees that Dante shall have the right to audit Orexigen’s books in accordance with this
Section 7.7. 
 7.8 Currency Exchange. All payments under this Agreement shall be payable, in full, in Dollars. For the purposes
of computing Net Sales in a currency other than Dollars, such currency shall be converted into Dollars as calculated using the monthly average exchange rate between each currency of origin and Dollars as reported by Bloomberg or an equivalent
resource as agreed by the Parties. 
 7.9 Taxes. 

7.9.1 Cooperation and Coordination. The Parties acknowledge and agree that it is their mutual objective and intent to appropriately
calculate and minimize, to the 

  
 - 52 - 

 FINAL VERSION 

 

 
extent feasible and legal, taxes payable with respect to any payments under this Agreement and that they shall use Commercially Reasonable Efforts to cooperate and coordinate with each other to
achieve such objective. Without limiting the generality of the foregoing, the Parties shall use Commercially Reasonable Efforts to cooperate and coordinate with each other in completing and filing documents required under the provisions of any
applicable Laws (including treaties) in connection with the making of any required tax payment or withholding payment, in connection with a claim of exemption from, or entitlement to, a reduced or zero rate of withholding or in connection with any
claim to a refund of or credit for any such payment. 
 7.9.2 Payment of Tax. All payments made by Takeda to Orexigen pursuant to
this Agreement shall be made without reduction for any taxes, charges or remittance fees. If applicable Laws require that taxes be deducted and withheld from a payment made pursuant to this Agreement, the remitting Party shall (a) deduct those
taxes from the payment; (b) pay the taxes to the proper taxing authority; and (c) send evidence of the obligation together with proof of payment to the other Party promptly following that payment. Orexigen shall pay any and all taxes that
are due and payable by Orexigen on payments made to the Orexigen under this Agreement. 
 7.9.3 Tax Residence Certificate. A Party
(including any entity to which this Agreement may be assigned, as permitted under Section 14.5) receiving a payment pursuant to this Agreement shall provide the remitting Party appropriate certification from relevant governmental authorities
that such Party is a tax resident of that jurisdiction, if such receiving Party wishes to claim the benefits of an income tax treaty to which that jurisdiction is a party. Upon the receipt thereof, any deduction and withholding of taxes shall be
made at the appropriate treaty tax rate. 
 7.9.4 Assessment. Either Party may, at its own expense, protest any assessment, proposed
assessment, or other claim by any governmental authority for any taxes, interest or penalties or seek a refund of such amounts paid if permitted to do so by applicable Laws. The Parties shall cooperate with each other in any protest or refund by
providing records and such additional information as may reasonably be necessary for a Party to pursue such protest or refund. 
 7.10
Interest Due. Without limiting any other rights or remedies available to Orexigen, Takeda shall pay Orexigen interest on any payments that are not paid on or before the date such payments are due under this Agreement at a rate equal to the
lesser of (a) one percent (1%) per month or (b) the maximum applicable legal rate, calculated on the total number of days payment is delinquent. 

8. REPRESENTATIONS, WARRANTIES, AND COVENANTS; DISCLAIMERS;
LIMITATION OF LIABILITY 
 8.1 Mutual Representations and Warranties. Each Party
hereby represents and warrants to the other Party, (i) as of the Original Effective Date (with references to “this Agreement” in this Section 8.1 being deemed references to the Original Collaboration Agreement) and (ii) as
of the Amended and Restated Effective Date 

  
 - 53 - 

 FINAL VERSION 

 

 
(with references to “this Agreement” in this Section 8.1 being deemed references to this Amended and Restated Collaboration Agreement), that: 

8.1.1 such Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and
has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; 
 8.1.2 execution of
this Agreement and the performance by such Party of its obligations hereunder have been duly authorized; 
 8.1.3 this Agreement has
been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof; 

8.1.4 the performance of this Agreement by it does not create a material breach or default under any other agreement to which it is a
party; 
 8.1.5 the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Law or regulation of any court, governmental body or administrative or other agency having jurisdiction over such Party; 

8.1.6 no government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental
department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Laws currently in effect, is or will be necessary for, or in connection with, the transaction contemplated by this Agreement or any other agreement or
instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such other agreements except as may be required to obtain clearance under the HSR Act; and 

8.1.7 neither such Party, nor any of its employees, officers, subcontractors, or consultants who have rendered services relating to
the Products: (a) has ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be debarred by the FDA under 21 U.S.C. Section 335a or (b) has ever been under indictment for a crime for
which a person or entity could be so debarred. 
 8.2 Additional Representations and Warranties of Orexigen. Orexigen hereby
represents and warrants to Takeda, as of the Original Effective Date, that: 
 8.2.1 Orexigen owns or otherwise Controls the
Orexigen Patents set forth in Exhibit 1.99; 
 8.2.2 all of its employees and officers involved in Development are obligated to
assign to Orexigen all inventions made during the course of and as a result of their association with Orexigen that are materially related to the Product and to maintain as confidential the Confidential Information of Orexigen; 

  
 - 54 - 

 FINAL VERSION 

 

 8.2.3 Orexigen has not granted any right or license to any Third Party under the
Orexigen Intellectual Property that would materially conflict or interfere with any of the rights or licenses granted to Takeda hereunder; 

8.2.4 to its knowledge, Orexigen has no reason to believe that the patents within the Orexigen Patents that are listed on Exhibit 1.99
as of the Original Effective Date are invalid or unenforceable; 
 8.2.5 subject to the provisions of the Upstream Agreements,
Orexigen’s right, title and interest to all the Orexigen Patents set forth in Exhibit 1.99 are free of any lien or security interest; 

8.2.6 Orexigen has made available to Takeda all agreements between Orexigen and any Third Party relating to any Clinical Trial or
other material Development activities that relate to Contrave in the Territory; 
 8.2.7 to its knowledge, no Third Party
(a) is infringing any Orexigen Patents or has misappropriated any Orexigen Know-How or (b) has challenged the ownership, scope, duration, validity, enforceability, priority or right to use any Orexigen Patents (including, by way of
example, through the institution of or written threat of institution of interference, reexamination, protest, opposition, nullity or similar invalidity proceeding before the United States Patent and Trademark Office (“USPTO”) or any
analogous foreign entity) or any Orexigen Know-How; 
 8.2.8 to its knowledge, except as otherwise disclosed in writing to Takeda by
letter dated as of the Original Effective Date, the manufacture, use, offer for sale, sale or importation of Contrave in the Territory, including Development and Commercialization of Contrave, by Orexigen or Takeda (or their respective Affiliates or
Sublicensees) does not infringe any Patent of any Third Party and does not misappropriate any technology of any Third Party; 
 8.2.9
Orexigen has disclosed to Takeda all Third Party issued patents identified as material by counsel to Orexigen in any freedom to operate or patentability searches or opinions relating to Contrave in the Territory, and Orexigen has received no
notice from a Third Party regarding, nor has any knowledge that any Third Party intends to assert, any claim that the Development or Commercialization of Contrave infringes the intellectual property rights of a Third Party; 

8.2.10 prior to the Original Effective Date, Contrave has been developed, manufactured, stored, labeled, distributed and tested by
Orexigen and its Affiliates and, to its knowledge, by any Third Parties acting on behalf of Orexigen, in compliance in all material respects with all applicable Laws; 

8.2.11 except as otherwise disclosed in writing to Takeda by letter dated as of the Original Effective Date, the Upstream Patents
listed in Exhibit 1.99 are licensed or assigned to Orexigen under the Upstream Agreements and are included in the Orexigen Patents licensed to Takeda under this Agreement; and other than the Patents listed in Exhibit 1.99,

  
 - 55 - 

 FINAL VERSION 

 

 
Orexigen does not Control, as of the Original Effective Date, any Patents claiming the Products or their methods of use; 

8.2.12 (a) except as set forth on Exhibit 8.2.12 and except for the Upstream Agreements, there are no written licenses or other
agreements to which Orexigen or any of its Affiliates is a party that relate in any material respect to (i) the Products in the Territory or (ii) any Patents relating to the Products in the Territory; (b) the Upstream Agreements
delivered by Orexigen to Takeda were true, accurate and complete copies of such agreements on the date of delivery and have not been modified, supplemented or amended since the date of delivery; (c) each of the Upstream Agreements is in full
force and effect; (d) Orexigen is not in material breach of any Upstream Agreement, and, to Orexigen’s knowledge, no other party to any Upstream Agreement is in material breach thereof, in each respect in, any manner that would give an
Upstream Party the right to terminate such Upstream Agreement; (e) except as otherwise disclosed in writing to Takeda by letter dated as of the Original Effective Date, no party to any Upstream Agreement has notified in writing any other party
thereto of any material breach thereof; (f) Dante has executed and delivered to Orexigen written amendment to the Dante License, which gives Orexigen the right to grant sublicenseable licenses under the Dante License to Takeda under this
Agreement; (g) there was no government funding of the research conducted under the OHSU Agreement, and Section 5 of the OHSU Agreement, which purports to grant the U.S. Government certain rights, has no force or effect; and (h) except
as otherwise disclosed in writing to Takeda by letter dated as of the Original Effective Date, no approval holder of a bupropion sustained release product under license from GSK in the Territory has the right to prevent or in any way impede the
approval of Products by a Regulatory Authority in the Territory, or upon approval, prevent or impede the right to make, have made, use, sell, import or otherwise Develop Products in the Territory; 

8.2.13 Orexigen has made available to Takeda a true, accurate and complete copy of NDA No. 20-0063, as updated as of the Original
Effective Date; 
 8.2.14 Orexigen has made available to Takeda all material written correspondence exchanged between Orexigen and
the FDA prior to the Original Effective Date regarding Contrave in the Territory; 
 8.2.15 except for filings pursuant to the HSR
Act, if any, neither the execution and delivery of this Agreement nor the performance hereof by Orexigen requires Orexigen to obtain any permits, authorizations or consents from any governmental authority or from any other person, firm or
corporation, and such execution, delivery and performance will not result in the breach of or give rise to any right of termination, rescission, renegotiation or acceleration under, or trigger any other rights under, any agreement or contract to
which Orexigen is a party or to which it may be subject that relates to the Orexigen Intellectual Property or the Products; 
 8.2.16
to Orexigen’s knowledge, there is no written suit, proceeding, arbitration, or litigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending against Orexigen, any of its Affiliates or Upstream Party, in
each case in connection with the Orexigen Intellectual Property, Products or the Upstream Agreements; 

  
 - 56 - 

 FINAL VERSION 

 

 8.2.17 Orexigen has conducted audits of its Third Party Manufacturers and Third Party
contract research organizations in accordance with GCP, GLP, and GMP, as applicable, and has found no circumstances that it believes would be likely to have a material adverse effect on the Development, Manufacturing and/or Commercialization of the
Products in the Territory as contemplated by this Agreement; and 
 8.2.18 Orexigen is not aware of any information not disclosed to
Takeda with respect to Contrave which could materially adversely affect (i) the Development, Manufacturing and/or Commercialization of the Products in the Territory, or (ii) Orexigen’s Third Party Manufacturers’ ability or
capacity to Manufacture the Products in sufficient quantities to launch the Product in the Territory as soon as practicable following receipt of Regulatory Approval in the Territory. 

8.3 Additional Representations and Warranties of Takeda. Takeda hereby represents and warrants to Orexigen, as of the Original
Effective Date, that, to its knowledge: 
 8.3.1 Takeda does not Control any intellectual property rights that relate to the
Products; 
 8.3.2 Takeda has not granted any right or license to any Third Party under the Takeda Intellectual Property or other
intellectual property rights Controlled by Takeda that would materially conflict or interfere with any of the rights or licenses granted to Orexigen hereunder; and 

8.3.3 Except for filings pursuant to the HSR Act, if any, neither the execution and delivery of this Agreement nor the performance
hereof by Takeda requires Takeda to obtain any permits, authorizations or consents from any governmental authority or from any other person, firm or corporation, and such execution, delivery and performance will not result in the breach of or give
rise to any right of termination, rescission, renegotiation or acceleration under, or trigger any other rights under, any agreement or contract to which Takeda is a party or to which it may be subject that relates to the Takeda Intellectual Property
or Products. 
 8.4 Mutual Covenants. Each Party hereby covenants to the other Party that: 

8.4.1 all employees and officers of such Party or its Affiliates working under this Agreement shall be under the obligation to assign
all right, title and interest in and to their Inventions, whether or not patentable, if any, to such Party as the sole owner thereof, and under the obligation to maintain as confidential the Confidential Information of such Party; 

8.4.2 such Party shall perform its activities pursuant to this Agreement in compliance with GLP, GCP, and GMP, in each case as
applicable under the Laws and regulations of the country and the state and local government wherein such activities are conducted, and with respect to the care, handling and use in research and Development activities hereunder of any non-human
animals by or on behalf of such Party, shall at all times comply 

  
 - 57 - 

 FINAL VERSION 

 

 
(and shall ensure compliance by any of its subcontractors) with all Laws, and also with the standards in the pharmaceutical industry for the development and commercialization of pharmaceutical
products; 
 8.4.3 neither Party shall employ (or, to its knowledge, use any contractor or consultant that employs) any individual
or entity debarred by the FDA (or subject to a similar sanction of a Regulatory Authority), or, to its knowledge, any individual who or entity which is the subject of an FDA debarment investigation or proceeding (or similar proceeding of a
Regulatory Authority), in the conduct of its activities under this Agreement, and each contractor or consultant used by a Party in connection with the conduct of Clinical Trials under this Agreement shall be subject to a covenant that is the same or
substantially the same as the foregoing covenant; and 
 8.4.4 neither Party shall, during the Term, grant any right or license to
any Third Party relating to any of the intellectual property rights it Controls which would conflict or interfere with any of the rights or licenses granted to the other Party hereunder. 

8.4.5 Competing Products. For the period commencing on the Original Effective Date and ending on May 1, 2016, each of Takeda and
Orexigen shall not, and shall ensure that their respective Affiliates and sublicensees do not, (whether directly or through a Third Party), commercialize in the Territory any pharmaceutical product, other than (a) the Products or (b) any
product owned or Controlled by either Party as of the Original Effective Date, for sale for the treatment of obesity or weight management. For the avoidance of doubt, this Section 8.4.5 shall apply to any Successor of either Party. 

8.5 Additional Covenants of Orexigen. 

8.5.1 Restrictions on Transfers and Liens. Orexigen covenants that it shall not license, sell, assign or otherwise transfer to any
person (including any Affiliate of Orexigen) any Orexigen Patents or any Orexigen Know-How, or assign or otherwise transfer any of the Upstream Agreements or any of its rights or obligations thereunder to any person (including any Affiliate of
Orexigen) (or agree to do any of the foregoing) in any manner that would have a material adverse impact on the rights granted to Takeda under this Agreement, except to the extent permitted by, and in compliance with, Section 14.5. In addition,
Orexigen hereby covenants and agrees that after the Original Effective Date Orexigen shall not incur or permit to exist (and shall cause each of its Affiliates not to incur or permit to exist), with respect to any Orexigen Patents or Orexigen
Know-How, any lien, encumbrance, or security interest (including in connection with any indebtedness) in any manner that would have a material adverse impact on the rights granted to Takeda under this Agreement, except to the extent permitted by,
and in compliance with, Section 14.5. 
 8.5.2 Upstream Agreements. Orexigen covenants that it shall not (a) execute or
otherwise permit, and shall cause its Affiliates to refrain from executing or otherwise permitting, any amendment, modification or waiver to any of the Upstream Agreements in any manner that would have a material adverse impact on the rights granted
to Takeda under this Agreement without the prior written consent of Takeda, such consent not to be unreasonably withheld, conditioned, or delayed, or (b) materially breach any Upstream Agreement if such

  
 - 58 - 

 FINAL VERSION 

 

 
material breach would give rise to a termination right by the counterparty to such Upstream Agreement or materially adversely impact the rights granted to Takeda under this Agreement. 

8.6 Additional Covenants of Takeda. 

8.6.1 Compliance with Laws. Takeda covenants that it shall not engage in any activities that use the Orexigen Intellectual Property in
a manner that is outside the scope of the license rights granted to it hereunder or knowingly infringe the intellectual property rights of any Third Party in connection with its activities pursuant to this Agreement. 

8.6.2 Intellectual Property. Takeda shall not practice or exploit the Orexigen Intellectual Property except to the extent expressly
permitted under the terms and conditions of this Agreement. 
 8.6.3 Standstill. 

(a) Takeda agrees that, for a period of three (3) years from the Original Effective Date (the “Standstill
Period”), neither it nor any of its Affiliates will, without the prior written consent of Orexigen or the Orexigen Board of Directors: 

(i) acquire, offer to acquire, or agree to acquire, directly or indirectly, by purchase or otherwise: (A) any voting securities
or direct or indirect rights to acquire any voting securities of Orexigen or any subsidiary if, after the completion of such acquisition or proposed acquisition, Takeda would beneficially own more than five percent (5%) of the outstanding
shares of common stock of Orexigen (the “Common Stock”), or (B) any asset of Orexigen or any subsidiary or division thereof; 

(ii) make, or in any way participate in, directly or indirectly, any “solicitation” of “proxies” (as such terms
are used in the rules of the Securities and Exchange Commission) to vote, or seek to advise or influence any Person with respect to the voting of, any voting securities of Orexigen; 

(iii) submit or publicly announce a proposal for, or offer to enter into (with or without conditions) any merger, business combination
or similar extraordinary transaction involving Orexigen or its securities or assets; 
 (iv) form, join or in any way participate in
any “group” (as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended) in connection with any of the foregoing; or 

(v) request that Orexigen amend or waive any provision of this Section 8.6.3. 

(b) Notwithstanding the provisions of Section 8.6.3(a), Takeda’s obligations under this Section 8.6.3 shall
automatically terminate upon the earliest to occur of: 

  
 - 59 - 

 FINAL VERSION 

 

 (i) the acquisition by any Third Party of beneficial ownership of more than twenty
percent (20%) of the outstanding Common Stock (other than by stockholders of Orexigen as of the Original Effective Date); 
 (ii)
the commencement by any Person or Group of a tender offer or exchange offer to acquire securities of Orexigen; 
 (iii) Orexigen
publicly announces its execution of any agreement related to a transaction described in (A) or (B) of this Section 8.6.3(b)(iii) or publicly announces its Board of Directors’ authorization or recommendation of such execution of
any such agreement, or Orexigen publicly announces the consummation of any transaction involving (A) the sale of all or substantially all of the assets of Orexigen and its subsidiaries taken as a whole, or (B) a merger, business
combination, restructuring, recapitalization or similar transaction of or with Orexigen and any of its subsidiaries taken as a whole; 

(iv) Orexigen or any of its Affiliates becomes the subject of any bankruptcy, insolvency or similar proceeding (except for any
involuntary proceeding that is dismissed within sixty (60) days); or 
 (v) The public announcement by Orexigen or any other
Person of any of the foregoing. 
 (c) Notwithstanding the provisions of Section 8.6.3(a), it is understood and agreed that
Takeda shall not be prohibited from entering into an agreement and having discussions with legal, accounting or financial advisors for the limited purposes of evaluating any of the transactions contemplated in this Section 8.6.3 and Takeda may
initiate private discussions with, and submit proposals confidentially to, the Executive Officer of Orexigen regarding a transaction otherwise prohibited by this Section 8.6.3; provided that any such proposal shall be expressly
conditioned on approval of Orexigen’s Board of Directors and shall by its terms not require public disclosure. Further, notwithstanding the provisions of Section 8.6.3(a), Orexigen agrees that during the Standstill Period, if the Orexigen
Board of Directors has approved the commencement of the solicitation of bids for any transaction within the scope of Section 8.6.3(b)(iii), Orexigen will promptly notify Takeda of, and in good faith permit Takeda to participate in, such bidding
process. 
 (d) The provisions of this Section 8.6.3 shall not apply to any investment by Takeda or an Affiliate of Takeda in
Third-Party mutual funds or other similar passive investment vehicles that hold interests in securities of Orexigen or any of its Affiliates (and any such interests in securities shall not be taken into account for the purpose of
Section 8.6.3(a) including the five percent (5%) exception contained therein), provided that the provisions of this Section 8.6.3(d) shall apply with respect to any such fund or vehicle only for so long as such fund or vehicle
satisfies the requirements of paragraphs (i) and (ii) of Rule 13d-1(b)(1) promulgated under the Securities Exchange Act of 1934, as amended, with respect to any Orexigen securities held by such fund or vehicle. 

  
 - 60 - 

 FINAL VERSION 

 

 (e) The termination or expiration of the Standstill Period will not terminate or
otherwise affect any of the provisions of this Agreement other than this Section 8.6.3. 
 8.6.4 Covenant Not to Challenge Patents.
Takeda covenants: (a) not to challenge the validity, scope or enforceability of or otherwise oppose any Patent included in the Orexigen Patents or any foreign counterparts thereof; (b) that it shall include in all of its Sublicenses
the obligation binding on the Sublicensee under such Sublicense not to challenge the validity, scope or enforceability of or otherwise oppose any such Patent; (c) that is shall include provisions in all Sublicenses providing that if the
Sublicensee challenges the validity or enforceability of or otherwise opposes any such Patent, Takeda may terminate its Sublicense agreement with such Sublicensee; and (d) if any such Sublicensee challenges the validity, scope or enforceability
of or otherwise opposes any such Patent, Takeda shall terminate such Sublicense, and such Sublicensee shall no longer have any rights under any such Patent. In the event that all or any portion of this Section 8.6.4 is invalid, illegal or
unenforceable, then the Parties will use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s). 

8.7 DISCLAIMERS. 

8.7.1 EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, OREXIGEN MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE OREXIGEN INTELLECTUAL PROPERTY, ANY OREXIGEN CONFIDENTIAL INFORMATION OR ANY LICENSE GRANTED BY OREXIGEN UNDER ITS
INTELLECTUAL PROPERTY RIGHTS HEREUNDER, OR WITH RESPECT TO ANY PRODUCTS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, OREXIGEN MAKES NO REPRESENTATIONS OR WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE OREXIGEN PATENTS ARE
VALID OR ENFORCEABLE OR THAT USE OF THE OREXIGEN INTELLECTUAL PROPERTY CONTEMPLATED HEREUNDER DOES NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT NOTHING IN
THIS AGREEMENT (OR THE ORIGINAL COLLABORATION AGREEMENT) SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT USE OF THE OREXIGEN CONFIDENTIAL INFORMATION CONTEMPLATED HEREUNDER DOES NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY
RIGHTS OF ANY THIRD PARTY. 
 8.7.2 EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, TAKEDA MAKES NO REPRESENTATIONS OR WARRANTIES
OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE TAKEDA INTELLECTUAL PROPERTY ANY TAKEDA CONFIDENTIAL INFORMATION OR ANY LICENSE GRANTED BY
TAKEDA UNDER ITS INTELLECTUAL PROPERTY RIGHTS HEREUNDER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, TAKEDA MAKES NO REPRESENTATIONS OR 

  
 - 61 - 

 FINAL VERSION 

 

 
WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE TAKEDA PATENTS ARE VALID OR ENFORCEABLE OR THAT USE OF THE TAKEDA INTELLECTUAL PROPERTY CONTEMPLATED HEREUNDER DOES NOT
INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT NOTHING IN THIS AGREEMENT (OR THE ORIGINAL COLLABORATION AGREEMENT)
SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT USE OF THE TAKEDA CONFIDENTIAL INFORMATION CONTEMPLATED HEREUNDER DOES NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. 

8.8 LIMITATION OF LIABILITY. EXCEPT FOR A BREACH OF ARTICLE 10, OR FOR CLAIMS OF A THIRD PARTY THAT ARE SUBJECT TO INDEMNIFICATION
UNDER ARTICLE 11, NEITHER PARTY SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT (OR THE ORIGINAL COLLABORATION AGREEMENT), WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY,
FOR ANY INCIDENTAL, INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS, LOSS OF USE, DAMAGE TO GOODWILL, OR LOSS OF BUSINESS). 

8.9 Knowledge Standard. “Knowledge” means, as applied to a Party in this Article 8, that such Party shall be deemed to have
knowledge of a particular fact or other matter to the extent that a reasonably prudent person with experience in or with the pharmaceutical industry and with primary responsibility for the applicable subject matter would know of such fact or other
matter upon reasonably diligent inquiry. For the avoidance of doubt, this knowledge standard is intended to apply on each occasion that the term “knowledge” (lower case), or any other formulation thereof, is used throughout this Agreement.

 9. INTELLECTUAL PROPERTY 

9.1 Ownership of Inventions. 

9.1.1 Inventorship of inventions conceived or reduced to practice solely by either Party or jointly by the Parties (a) in the
course of activities performed under or contemplated by this Agreement or in the exercise of the rights licensed under this Agreement or (b) relating to the composition of matter, methods of making, methods of using (including methods of
treatment or administration), or formulations of Products (“Inventions”) shall be determined by application of U.S. patent Laws pertaining to inventorship. If an Invention is jointly invented by one or more employees, consultants,
or contractors of each Party, such Invention shall be jointly owned by the Parties (each such Invention, a “Joint Invention”), and if one or more claims included in an issued Patent or pending Patent application that is filed in a
patent office in the Territory claim such Joint Invention, such issued Patent or such pending Patent application shall be jointly owned by the Parties (each such patent application or patent, a “Joint Patent”). If an Invention is
solely invented by an employee, consultant, or contractor of a Party, such Invention shall be solely owned by such Party, and any Patent application filed 

  
 - 62 - 

 FINAL VERSION 

 

 
claiming such solely owned Invention shall also be solely owned by such Party. Any such Patent application owned solely by Orexigen and any Patent issuing therefrom shall be an “Orexigen
Invention Patent”, and any such Patent application owned solely by Takeda and any Patent issuing therefrom shall be a “Takeda Invention Patent”. 

9.1.2 Subject to the rights granted under this Agreement, each Party shall have the right to practice and exploit Joint Inventions and
Joint Patents, without any obligation to account to the other for profits, or to obtain any approval of the other Party to license, assign, or otherwise exploit Joint Inventions and Joint Patents, by reason of joint ownership thereof, and each Party
hereby waives any right it may have under the Laws of any jurisdiction to require any such approval or accounting; and to the extent there are any applicable Laws that prohibit such a waiver, each Party will be deemed to so consent. Each Party
agrees to be named as a party, if necessary, to bring or maintain a lawsuit involving a Joint Invention or Joint Patent. 
 9.1.3
Each Party shall promptly disclose to the other Party in writing, and shall cause its Affiliates, licensees and Sublicensees to so disclose, the conception of any Invention. Each Party shall cause its Sublicensees and Affiliates, and their
respective employees, consultants, agents, or independent contractors to so assign to such Party, such person’s or entity’s right, title and interest in and to any Inventions, and intellectual property rights therein, as is necessary to
enable such Party to fully effect the ownership of such Inventions, and intellectual property rights therein. Each Party shall also include provisions in its relevant agreements with Third Parties performing activities on its behalf pursuant to this
Agreement, that effect the intent of this Article 9. Each Party hereby appoints the other Party as attorney-in-fact of such Party to execute and deliver all documents reasonably required to evidence or record any assignment pursuant to this
Agreement if such Party is unable, after making reasonable inquiry, to obtain assistance of such other Party with respect to any such document. Each Party shall, and shall cause its Sublicensees and Affiliates, and their respective employees,
consultants, agents, or independent contractors to, cooperate with the other Party and take all reasonable additional actions and execute such agreements, instruments and documents as may be reasonably required to perfect such other Party’s
right, title and interest in and to Inventions, and intellectual property rights therein, as set forth in this Section 9.1. 
 9.2
Prosecution of Collaboration Patents. 
 9.2.1 Filing, Prosecution and Maintenance of Collaboration Patents. Takeda shall be
responsible for the preparation, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of Takeda Patents. Orexigen shall be responsible for the preparation, prosecution (including any interferences,
reissue proceedings and reexaminations) and maintenance of Orexigen Patents. The Party bringing any action or proceeding as described in Section 9.3.2 to enforce or defend any Collaboration Patent shall be further responsible for any inter
partes review proceedings at the USPTO (the “IPR Proceedings”) relating to such Collaboration Patents. Each Party shall reasonably consult with the other Party, and shall take any comments of the other Party into good faith
consideration, with respect to the preparation, prosecution and maintenance of such Patents. Each Party shall provide to the other Party copies of any papers relating to the filing, prosecution or maintenance of such Patents promptly upon their
being filed or received. The Parties shall discuss and 

  
 - 63 - 

 FINAL VERSION 

 

 
evaluate Joint Inventions and confer with each other regarding the advisability of filing patent applications covering Joint Inventions and, if either Party requests that a patent application be
filed covering a Joint Invention, the other Party shall not unreasonably withhold, condition, or delay its consent to such filing. The Parties shall agree to whether Orexigen or Takeda have the first right to control and manage the Joint Patents,
and an appropriate allocation of expenses related thereto, using a mutually acceptable independent patent counsel, and reasonably consult with the other Party, and shall take any comments of the other Party into good faith consideration, with
respect to the preparation, prosecution and maintenance of such Joint Patents. Each Party shall provide to the other Party copies of any papers relating to the filing, prosecution or maintenance of such Joint Patents promptly upon their being filed
or received. The Parties shall share equally all expenses incurred with respect to the preparation, prosecution and maintenance of any and all Collaboration Patents. Within forty-five (45) days after the end of each Calendar Quarter, each Party
shall report to the other Party and the JSC all expenses incurred by such Party under this Section 9.2.1 for such Calendar Quarter. Any payments due to such Party as specified in such report shall be paid within forty-five (45) days after
receipt of such report. The reports and payments due pursuant to this Section 9.2.1 for each Calendar Quarter shall include any reconciliations and adjustments with respect to the prior Calendar Quarter necessary to effect the sharing of
expenses as set forth in Section 9.2.1. 
 9.2.2 Abandonment of Collaboration Patents. In no event will a Party permit a
Collaboration Patent under its Control to be abandoned in the Territory, or elect not to file a new Patent application claiming priority to a Patent application within such Patents either before such Patent application’s issuance or within the
time period required for the filing of an international (i.e., Patent Cooperation Treaty), regional or national Patent application, in each case other than to optimize overall Patent protection of claimed inventions, without the other Party first
being given an opportunity to assume full responsibility for the continued prosecution and maintenance of such Patents, or the filing of such new Patent application included in such Patents. Each Party shall provide the other Party with notice of
the allowance and expected issuance date of any Patent within the Collaboration Patents, and any of the aforementioned filing deadlines, and each Party shall provide the other Party with prompt notice as to whether it desires to file such new Patent
application. In the event that a Party decides either (a) not to continue the prosecution or maintenance of a Patent application or Patent within the Collaboration Patents under its control in the Territory or (b) not to file such new
Patent application requested to be filed by the other Party, in each case other than to optimize overall Patent protection of claimed inventions, the Party shall provide the other Party with notice of this decision at least thirty (30) days
prior to any pending lapse or abandonment thereof. In such event, the Party shall provide the other Party with an opportunity to assume responsibility for all costs reasonably associated with the filing or further prosecution and maintenance of such
Patent application and any Patent issuing thereon (such filing to occur prior to the issuance of the Patent to which the application claims priority or expiration of the applicable filing deadline, as set forth above). In the event that the other
Party assumes such responsibility for such filing, prosecution and maintenance costs, the other Party shall have the right to transfer the responsibility for such filing, prosecution and maintenance of such Patent applications and Patents to patent
counsel selected by it and reasonably acceptable to the Party. In such case, Section 9.2.1 shall apply to such Patent applications and Patents mutatis mutandis. Such Patent applications and Patents shall otherwise continue to be subject to all
of the terms and conditions of this Agreement in the same manner and to the same extent as the other Collaboration Patents. 

  
 - 64 - 

 FINAL VERSION 

 

 9.2.3 Upstream Agreements. Notwithstanding Section 9.2.1 and 9.2.2, Takeda
acknowledges that: (a) Orexigen is obligated, under Section 6.01 of the Dante License, to (i) inform Dante of the status of, and to consult with Dante regarding, prosecution of any Orexigen Patents licensed pursuant to the Dante
License, (ii) not to abandon prosecution of any of such Orexigen Patents or any of the claims of such Orexigen Patents without first notifying Dante in a timely manner of Orexigen’s intention and reason therefore, and providing Dante with
reasonable opportunity to assume responsibility for prosecution and maintenance of such Orexigen Patents, and (iii) inform Dante in a timely manner (no less than thirty (30) days prior to the appertaining filing deadlines) that
Orexigen will not pursue patents in any non-U.S. country so that Dante may pursue such Patents if it so desires in which case from the date of such filing of such Patent applications by Dante shall not be considered Orexigen Patents and Orexigen
shall be deemed to have forfeited all rights under the Dante License to such Patent applications and resulting Patents; (b) all decisions with respect to the prosecution of such Orexigen Patents by Orexigen pursuant to Section 6.01 of the
Dante License shall be made by Orexigen, subject to the approval of Dante which approval shall not be unreasonably withheld, conditioned, or delayed; (c) GSK has sole responsibility for preparation, prosecution and maintenance of the Patents
licensed under the GSK License, and Orexigen has no rights with respect to such preparation, prosecution and maintenance; and (d) if Orexigen elects to abandon any national stage Patent application of the Assigned Therapeutic Patent Rights (as
defined in the OHSU Agreement), OHSU has the right to continue prosecuting or maintaining such Patent, and Orexigen is required to alert OHSU and give OHSU one hundred and fifty (150) days to decide whether OHSU desires to continue the Patent
prosecution or maintenance at OHSU’s sole expense. 
 9.3 Enforcement of Collaboration Patents or Product Trademarks Against
Infringers. 
 9.3.1 Notice. In the event that Orexigen or Takeda become aware of a suspected infringement of any Collaboration
Patent by means of the manufacture, use, or sale of a product substantially similar to or the same as a Product (a “Competitive Product Infringement”), or any such Collaboration Patent is challenged in any action or proceeding
(other than any oppositions, cancellations, interferences, reissue proceedings or reexaminations, which are addressed above), or either Party becomes aware of the infringement of any rights in a Product Trademark, such Party shall notify the other
Party promptly, and following such notification, the Parties shall confer. 
 9.3.2 Enforcement of Collaboration Patents and Product
Trademarks. 
 (a) Takeda will have the first right, but not an obligation to, bring any action or proceeding, at its own
expense, to enforce or defend, as applicable, any Collaboration Patent or Product Trademark in its own name and entirely under its own direction and control, subject to the following. Orexigen shall reasonably assist Takeda (at Takeda’s
expense) in any such action or proceeding if so requested, and shall lend its name to such actions or proceedings if requested by Takeda or required by Laws. Orexigen shall have the right to participate and be represented in any such suit by its own
counsel at its own expense. No settlement of any such action or proceeding will be entered into by Takeda without the prior 

  
 - 65 - 

 FINAL VERSION 

 

 
written consent of Orexigen, which consent shall not be unreasonably withheld, conditioned, or delayed. Takeda shall consult with Orexigen and take any Orexigen comments into good faith
consideration with respect to the infringement, claim construction, or defense of the validity or enforceability of any claim in any Collaboration Patent or Product Trademark. Takeda shall provide to Orexigen copies of any papers relating to the
infringement or validity litigation of any such involved Collaboration Patent or Product Trademark promptly upon their being filed or received. 

(b) If Takeda elects not to settle, or bring any action or proceeding as described in Section 9.3.2(a) within ninety
(90) days after first notifying Orexigen or being notified by Orexigen with respect thereto, then at any time during the Term, Orexigen may bring such action or proceeding at its own expense, in its own name and entirely under its own direction
and control, subject to the following. Takeda will reasonably assist Orexigen (at Orexigen’s expense) in any such action or proceeding if so requested, and will lend its name to such actions or proceedings if requested by Orexigen or required
by Laws. Takeda shall have the right to participate and be represented in any such suit by its own counsel at its own expense with respect to a Competitive Product Infringement. No settlement of any such action or proceeding which restricts the
scope, or adversely affects the enforceability, of any Collaboration Patent or Product Trademark shall be entered into by Orexigen without the prior written consent of Takeda, which consent shall not be unreasonably withheld, conditioned, or
delayed. Orexigen shall not knowingly take any action during such litigation of any Collaboration Patent or Product Trademark that would materially adversely affect them, without consultation with Takeda. 

(c) Notwithstanding Section 9.3.2(b), each Party shall notify and provide the other Party with copies, received by such Party, of
any allegations of alleged patent invalidity, unenforceability, or non-infringement of a Collaboration Patent pursuant to a paragraph IV patent certification under 21 C.F.R. §§ 314.94 and 314.95 by a Third Party filing an Abbreviated New
Drug Application under § 505(j), a New Drug Application under § 505(b)(2), or other similar patent certification by a Third Party, and any foreign equivalent thereof, in each case that concerns a Product (“Paragraph IV
Certification”). Such notification and copies shall be provided as soon as practicable and at least within five (5) days (including, for clarity, non-Business Days) after the Party receives such certification (in view of the forty-five
(45) day period during which litigation should be brought so as to afford a thirty (30) month stay of approval under § 505, and shall be sent by facsimile and overnight courier to the address set forth in Section 14.3. Takeda
shall have the first right to institute (or defend, as applicable), prosecute, and control such litigation brought by a Third Party where Takeda is a named defendant, or by Takeda where Takeda is a named plaintiff, in both cases irrespective of
whether Orexigen is also named as a defendant or plaintiff. If Takeda decides not to institute (or defend, as applicable) such litigation, Takeda will give notice to Orexigen of its decision within ten (10) days after receipt of notification of
the Paragraph IV Certification (or, if the remaining time period permitted by Law for Takeda to commence such action is less than twenty (20) days, within half of the time period permitted by Law). Orexigen may then, but is not required to,
institute (or defend, as applicable), prosecute, and control such litigation. Each Party shall cooperate fully with the other Party in such litigation and shall provide reasonable assistance (including making available to such other Party documents
possessed by such Party that are reasonably required by such other Party and making available personnel for interviews and testimony) in any actions reasonably undertaken in accordance with this Section 9.3.2(c) to

  
 - 66 - 

 FINAL VERSION 

 

 
contest any such Paragraph IV Certification. At either Party’s request, the other Party agrees to join any such litigation to enforce such Collaboration Patent against the Third Party(ies)
that made such Paragraph IV Certification. Each Party shall have the right to approve any settlement that would adversely affect the Collaboration Patents or such Party’s rights under this Agreement or result in any liability or admission on
behalf of such Party, such approval not to be unreasonably withheld, conditioned, or delayed. Any recovery, by settlement or otherwise, realized as a result of such litigation shall be allocated in accordance with Section 9.3.3. 

(d) Notwithstanding Sections 9.3.2(a), (b), and (c), Takeda acknowledges and agrees that, under Section 8.03 of the Dante
License, (i) in the event that Orexigen or its Sublicensee undertakes the enforcement or defense of the Orexigen Patents licensed pursuant to the Dante License by litigation, including any declaratory judgment action, any recovery of damages by
Orexigen as a result of such action shall be applied first in satisfaction of any unreimbursed expenses and attorneys’ fees of Orexigen relating to the action, and second in satisfaction of unreimbursed legal expenses and attorneys’ fees
of Dante, if any, relating to the action, (ii) if applicable, Orexigen shall receive an amount equal to its lost profits, a reasonable royalty on sales of the infringer, or other measure of damages the court shall have applied, less a
reasonable approximation of the royalties that Orexigen would have owed to Dante on Net Sales (as defined in the Dante License) that may have been made by Orexigen but, instead, were lost to the infringer, which amount shall be promptly paid by
Orexigen to Dante, (iii) any balance remaining from such recovery shall be distributed between Orexigen and Dante, with Orexigen receiving seventy-five percent (75%) and Dante receiving twenty-five percent (25%), and (iv) if Orexigen
does not undertake action to prevent the infringing activity within three (3) months of having been made aware and notified thereof, Dante shall have the right, but not the obligation, to prosecute at his own expense any such infringements of
the Patent Rights, as defined in the Dante License. 
 9.3.3 Damages. In the event that either Party exercises the rights conferred
in this Section 9.3 and recovers any damages or other sums in such action, suit or proceeding or in settlement thereof, such damages or other sums recovered shall first be subject to Section 9.3.2(d) if such damages relate to the Patents
licensed under the Upstream Agreements, and then shall be applied to all out-of-pocket costs and expenses incurred by the Parties in connection therewith, including attorneys’ fees. If such recovery is insufficient to cover all such costs and
expenses of both Parties, it shall be shared in proportion to the total of such costs and expenses incurred by each Party. If after such reimbursement any funds remain from such damages or other sums recovered, seventy-five percent (75%) of
such funds shall be retained by the Party that controlled the action or proceeding under this Section 9.3 and such other Party shall receive twenty-five percent (25%) of such funds. 

9.3.4 Upstream Limitations. Each Party’s rights to enforce a Collaboration Patent pursuant to this Section 9.3, or to defend
against a challenge in any action or proceeding described in Section 9.3.1, shall be subject to the applicable provisions of any agreements between the Party Controlling such Patents and its licensor. In the event of any conflict between this
Section 9.3 and such other agreements, the provisions of the other agreements shall control. 

  
 - 67 - 

 FINAL VERSION 

 

 9.4 Patent Term Extension. Orexigen and Takeda shall each cooperate with one another
and shall use Commercially Reasonable Efforts in obtaining any available marketing exclusivity and patent term extension (including any pediatric exclusivity as may be available) under the Drug Price Competition and Patent Term Restoration Act of
1984 (the “Hatch-Waxman Act”) and the Federal Food, Drug, and Cosmetic Act or supplemental protection certificates with respect to Patents claiming the Products, as applicable. If elections with respect to obtaining such patent term
extensions and marketing exclusivity are to be made, Takeda shall have the right to elect to seek patent term extension, marketing exclusivity or supplemental protection; provided that such election will be made so as to maximize the period
of marketing exclusivity for the Product. For such purpose, for all Regulatory Approvals, Takeda shall provide Orexigen with written notice of any expected Regulatory Approval at least thirty (30) days prior to the expected date of Regulatory
Approval, as well as notice within three (3) Business Days of receiving each Regulatory Approval confirming the date of such Regulatory Approval. 

9.5 Regulatory Patent Listing. 

9.5.1 To the extent required by or permitted by Law, at all times prior to transfer of the Regulatory Filings to Takeda during the
Term, Orexigen will use Commercially Reasonable Efforts to promptly, accurately and completely provide to the applicable Regulatory Authorities, all applicable Patents for any Product that has become the subject of a marketing application owned by
Orexigen and submitted to FDA, for listing in FDA’s Approved Products with Therapeutic Equivalence Determinations (“Orange Book”) in accordance with the Hatch-Waxman Act. 

9.5.2 To the extent required by or permitted by Law, at all times after transfer of the Regulatory Filings to Takeda during the Term,
Takeda will use Commercially Reasonable Efforts to promptly, accurately and completely provide to the applicable Regulatory Authorities, all applicable Patents for any Product that has become the subject of a marketing application owned by Takeda
and submitted to FDA, for listing in the Orange Book in accordance with the Hatch-Waxman Act. 
 9.5.3 Prior to any listing under
Section 9.5.1 or 9.5.2, the Parties will meet to evaluate, identify all applicable Patents to be listed. Orexigen shall have the right to finally determine the Patents to be listed under Section 9.5.1 and Takeda shall have the right to
finally determine the Patents to be listed under Section 9.5.2. 
 9.6 Defense Against Claims of Infringement of Third Party
Patents. If a Third Party asserts that a Patent or other right owned by it is or has been infringed by the manufacture, use, sale, offer for sale, or import of a Product in the Territory, the Party first obtaining knowledge of such a claim shall
immediately provide the other Party notice of such claim through the JSC along with the related facts in reasonable detail. In such event, unless the Parties otherwise agree, Takeda shall have the obligation, at its expense, to control such defense
with respect to such Product. Orexigen shall cooperate with Takeda, at Takeda’s reasonable request and expense, and shall have the right to be represented separately by counsel of its own choice. Takeda shall also control settlement of such
claim; provided, however, that no settlement shall be entered into without the prior consent of Orexigen if such settlement would adversely 

  
 - 68 - 

 FINAL VERSION 

 

 
affect the rights and benefits of, or impose or adversely affect any obligations on, Orexigen, such consent not being unreasonably withheld, conditioned, or delayed. 

9.7 Third Party Licenses. 

9.7.1 If either Party reasonably determines that any Third Party intellectual property rights, are necessary for the Development,
manufacture, or Commercialization of a Product, where such Third Party intellectual property rights are necessary for use of any Product, or for any license that may be required for the use or exploitation of Orexigen Intellectual Property as
contemplated under this Agreement for the discovery, research, manufacture, or use of Products, then such Party will notify the JSC. 

9.7.2 If the JSC determines that it needs to obtain one or more licenses from one or more Third Parties for such activities, the JSC
will determine which Party will negotiate the most favorable license. The chosen Party shall obtain a license to such Third Party intellectual property, with the right to sublicense, in order to permit both Parties to conduct their obligations under
this Agreement. Subject to the foregoing, the terms and conditions involved in obtaining such rights shall be determined at such chosen Party’s sole discretion. If such chosen Party elects not to obtain rights to such Third Party intellectual
property, or is unsuccessful in obtaining such rights, then the other Party shall have the right (but not the obligation) to negotiate and obtain rights from such Third Party at its sole discretion and expense. 

9.7.3 In the event that Takeda determines, in its reasonable commercial judgment, that a license, sublicense or similar right from one
or more Third Parties is necessary in order to make, have made, use, offer to sell, sell or import a Product, then Takeda or its Affiliates may acquire such a license, sublicense or similar right. In accordance with Section 7.3.5, each Party
shall bear fifty percent (50%) of the payments owed pursuant to any Third Party licenses under intellectual property rights that are necessary for the exploitation of, and cover the composition of matter or method of use of, Products in the
Field and in the Territory, other than pursuant to the Upstream Agreements (a “Third Party License”). Orexigen shall be responsible for all royalties and other payment obligations owed pursuant to any Upstream Agreement. 

10. CONFIDENTIALITY 

10.1 Nondisclosure. Each Party agrees that, during the Term and for a period of ten (10) years thereafter, a Party (the
“Receiving Party”) receiving Confidential Information of the other Party (the “Disclosing Party”) shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving
Party uses to maintain in confidence its own confidential or proprietary information of similar kind and value, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except
for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this Section 10.1(c) shall not create or imply any rights or
licenses not expressly granted under this Agreement). Notwithstanding anything to the contrary in the foregoing, the obligations of confidentiality and 

  
 - 69 - 

 FINAL VERSION 

 

 
non-use with respect to any trade secret within such Confidential Information shall survive such ten (10) year period for so long as such Confidential Information remains protected as a
trade secret under applicable Laws. 
 10.2 Exceptions. The obligations in Section 10.1 shall not apply with respect to any
portion of the Confidential Information that the Receiving Party can show by competent proof: 
 10.2.1 is publicly disclosed by the
Disclosing Party, either before or after it is disclosed to the Receiving Party hereunder; 
 10.2.2 is known to the Receiving Party
or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party; 

10.2.3 is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and
without any obligation to keep it confidential or any restriction on its use; 
 10.2.4 is now, or hereafter becomes, through no act
or failure to act on the part of the Receiving Party, or any of its Affiliates, generally known or available, either before or after it is disclosed to the Receiving Party; 

10.2.5 is independently discovered or developed by or on behalf of the Receiving Party or any of its Affiliates without the use of
Confidential Information belonging to the Disclosing Party; or 
 10.2.6 is the subject of written permission to disclose provided
by the Disclosing Party. 
 10.3 Authorized Disclosure. Subject to the limitations in Section 2.2.9(e), the Receiving Party may
disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

10.3.1 filing or prosecuting patents; 

10.3.2 regulatory filings and obtaining regulatory approvals for Products; 

10.3.3 prosecuting or defending litigation, including responding to a subpoena in a Third Party litigation; 

10.3.4 subject to Section 10.5, complying with Laws (including the rules and regulations of the Securities and Exchange
Commission or any national securities exchange) and with applicable court orders; 

  
 - 70 - 

 FINAL VERSION 

 

 10.3.5 potential or actual acquirers, merger partners or assignees, investment
bankers, lenders or other potential financial partners and their and each of their respective Affiliates’ directors, employees, consultants, contractors and agents, each of whom prior to disclosure must be bound by obligations of
confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations in this Article 10; provided, however, that, in each of the above situations, the Receiving Party shall remain
responsible for any failure by any Person who receives Confidential Information pursuant to this Section 10.3.5 to treat such Confidential Information as required under this Article 10; and 

10.3.6 on a “need to know basis” in order for the Receiving Party to exercise its rights or fulfill its obligations under
this Agreement, to Affiliates, potential or actual collaborators (including sublicensees or potential sublicensees), potential or actual research and development collaborators, potential or actual subcontractors, and their and each of the
Parties’ and their respective Affiliates’ directors, employees, consultants, contractors and agents, each of whom prior to disclosure must be bound by obligations of confidentiality and restrictions on use of such Confidential Information
that are no less restrictive than the obligations in this Article 10; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information
pursuant to this Section 10.3.6 to treat such Confidential Information as required under this Article 10. 
 If and whenever any Confidential
Information is disclosed in accordance with this Section 10.3, such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such
information (other than by breach of this Agreement). Notwithstanding the foregoing, in the event a Receiving Party is required to make a disclosure of the other Party’s Confidential Information pursuant to Sections 10.3.3 or 10.3.4, the
Receiving Party shall, except where not reasonably possible and subject to Section 10.5, notify the Disclosing Party of the Receiving Party’s intent to make such disclosure pursuant to this Section 10.3 sufficiently prior to making
such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information. 

10.4 Terms of this Agreement. The Parties acknowledge that this Agreement and all of the respective terms of this Agreement shall be
treated as Confidential Information of both Parties. 
 10.5 Securities Filings. Notwithstanding anything to the contrary in this
Article 10, any disclosure that is required by securities Laws, including the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, or the rules of a securities exchange or the Securities and Exchange Commission or
the securities regulations of any state or other jurisdiction, as reasonably advised by the disclosing Party’s counsel, may be made; provided, however, in the event either Party proposes to file with the Securities and Exchange
Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document which describes or refers to the terms and conditions of this Agreement under the Securities Act of 1933, as
amended, the Securities Exchange Act of 1934, as amended, or any other applicable securities Laws, such Party shall notify the other Party of such intention and shall provide such other Party with a copy of relevant portions of the

  
 - 71 - 

 FINAL VERSION 

 

 
proposed filing at least ten (10) Business Days prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any
exhibits thereto relating to the terms and conditions of this Agreement. The Party making such filing shall use Commercially Reasonable Efforts to obtain confidential treatment of the terms and conditions of this Agreement that such other Party
requests be kept confidential or otherwise afforded confidential treatment, and shall only disclose Confidential Information that it is reasonably advised by counsel is legally required to be disclosed. No such notice shall be required under this
Section 10.5 if the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by the either Party hereunder or otherwise approved by the other Party. 

10.6 Relationship to Confidentiality Agreement. This Agreement supersedes the Mutual Confidential Disclosure Agreement between Orexigen
and Takeda, effective as of April 20, 2010; provided that all “Confidential Information” disclosed or received by the Parties thereunder shall be deemed “Confidential Information” hereunder and shall be subject to the
terms and conditions of this Agreement. 
 10.7 Publications. 

10.7.1 Publication Plan. Within thirty (30) days after the Original Effective Date, each Party shall designate an individual to
serve as that Party’s “Publication Manager.” The Parties shall, through the Publication Managers, cooperate in good faith and develop and execute a coordinated publication plan in or for the Territory that will
include strategy, budget and policies for the publication activities related to the Products. The publication plan will also cover intended timing, venue, media, review, authors and other relevant considerations for each publication. The
publication plan will be included in the Commercialization Plan for approval by the JSC. A Party may change its Publication Manager at any time upon written notice to the other Party. 

10.7.2 Publication of Clinical Trial Results. Takeda will have the right to publish summaries of results of all Clinical Trials
conducted by either Party with respect to a Product after the Original Effective Date in Takeda’s Clinical Trial register; provided, however, that Orexigen will have the right to review all proposed publications prior to
submission of such publication. The Parties shall discuss and reasonably cooperate in order to facilitate the process to be employed in order to ensure the publication of any such summaries of Clinical Trials data and results as required under Laws
on the Clinical Trial registry of each respective Party, and shall provide the other Party at least sixty (60) days prior notice to review the Clinical Trials results to be published for the purposes of preparing any necessary Patent filings.

 10.7.3 Publication Guidelines. All publications relating to the Licensed Compounds and/or the Products shall be prepared,
presented and/or published in accordance with pharmaceutical industry accepted guidelines including: (1) International Committee of Medical Journal Editors (ICMJE) guidelines, (2) Uniform Requirements for Manuscripts Submitted to
Biomedical Journals: Writing and Editing for Biomedical Publication, (3)

  
 - 72 - 

 FINAL VERSION 

 

 
Pharmaceutical Research and Manufacturers of America (PhRMA) guidelines, and (4) Principles on Conduct of Clinical Trials. 

10.8 Publicity. As of the Original Effective Date, the Parties shall issue the press release announcing the existence of this Agreement
in the form and substance as set forth on Exhibit 10.8. Each Party agrees not to issue any press release or other public statement disclosing information relating to this Agreement or the transactions contemplated hereby that contains information
not previously publicly disclosed in accordance with this Section 10.8 without the prior written consent of the other Party, not to be unreasonably withheld, conditioned, or delayed; provided, however, that the Party intending to make
any such press release or other public statement relating to this Agreement shall not disclose any Confidential Information that the other Party reasonably deems inappropriate for disclosure. 

10.9 Third Party Information. Notwithstanding anything to the contrary in this Agreement, Takeda acknowledges that it may be required
to enter into appropriate confidentiality agreements with or with respect to specific Third Party contract manufacturers or other independent contractors engaged by Orexigen before Orexigen can share with Takeda information relating to its agreement
with such Third Party(ies) or such Third Party(ies)’ confidential information as required under this Agreement. In such case, Orexigen shall notify Takeda promptly of such requirement, and the Parties shall cooperate to take such actions as are
necessary to enable Orexigen to comply with such confidentiality requirements of Orexigen’s agreements with any such Third Party(ies). 

11. INDEMNITY AND INSURANCE 

11.1 Takeda Indemnity. Takeda shall indemnify, defend and hold harmless Orexigen and its Affiliates, and their respective officers,
directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives, (the “Orexigen Indemnitees”), from and against any and all claims, threatened claims, damages, losses, suits,
proceedings, liabilities, costs (including reasonable legal expenses, costs of litigation and reasonable attorney’s fees) or judgments, whether for money or equitable relief, of any kind (“Losses and Claims”), to the extent
arising out of or relating to, directly or indirectly: (a) the practice by Takeda or its Affiliate or Sublicensee of any license or sublicense granted to it under Sections 6.1 and 6.2; (b) the Commercialization or Development of the
Product by Takeda or its Affiliate or Sublicensee; (c) the Manufacture, use, handling, storage, sale or other disposition of any Product by Takeda or its Affiliate or Sublicensee; (d) the breach by Takeda of any warranty, representation,
covenant or agreement made by Takeda in this Agreement, or, if Orexigen exercises its option to Co-Promote pursuant to Section 3.5, the Co-Promote Agreement; or (e) the negligence, recklessness or willful misconduct (including to the
extent such negligence, recklessness or willful misconduct gives rise to product liability Losses and Claims under any legal theory) of Takeda or its Affiliate or Sublicensee, or any officer, director, employee, agent or representative thereof;
except, with respect to each of subsections (a) through (e) above, to the extent such Losses and Claims arise directly or indirectly from the negligence, recklessness or willful misconduct of any Orexigen Indemnitee or the breach by
Orexigen of any warranty, representation, covenant or agreement made by Orexigen in this Agreement or, if Orexigen exercises its option to Co-Promote pursuant to Section 3.5, the Co-Promote Agreement. 

  
 - 73 - 

 FINAL VERSION 

 

 11.2 Orexigen Indemnity. Orexigen shall indemnify, defend and hold harmless Takeda and
its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives (the “Takeda Indemnitees”), from and against any and all Losses and
Claims, to the extent arising out of or relating to, directly or indirectly: (a) the practice by Orexigen or its Affiliate or sublicensee of any license or sublicense granted to it under Section 6.3; (b) the Commercialization or
Development of the Products by Orexigen or its Affiliate or sublicensee, or the commercialization or development of Products for use outside the Territory by Orexigen or its Affiliate or sublicensee; (c) the Manufacture, use, handling, storage,
sale or other disposition of the Product by Orexigen or its Affiliate or licensee (other than Takeda or its Affiliate or Sublicensee); (d) the breach by Orexigen of any warranty, representation, covenant or agreement made by Orexigen in this
Agreement, or, if Orexigen exercises its option to Co-Promote pursuant to Section 3.5, the Co-Promote Agreement; or (e) the negligence, recklessness or willful misconduct (including to the extent such negligence, recklessness or willful
misconduct gives rise to product liability Losses and Claims under any legal theory) of Orexigen or its Affiliate or licensee (other than Takeda or its Affiliate or Sublicensee), or any officer, director, employee, agent or representative thereof;
except, with respect to each of subsections (a) through (e) above, to the extent such Losses and Claims arise directly or indirectly from the negligence, recklessness or willful misconduct of any Takeda Indemnitee or the breach by Takeda
of any warranty, representation, covenant or agreement made by Orexigen in this Agreement or, if Orexigen exercises its option to Co-Promote pursuant to Section 3.5, the Co-Promote Agreement. 

11.3 Indemnification Procedure. A claim to which indemnification applies under Section 11.1 or Section 11.2 shall be referred
to herein as an “Indemnification Claim”. If any Person or Persons (collectively, the “Indemnitee”) intends to claim indemnification under this Article 11, the Indemnitee shall notify the other Party (the
“Indemnitor”) in writing promptly upon becoming aware of any claim that may be an Indemnification Claim (it being understood and agreed, however, that the failure by an Indemnitee to give such notice shall not relieve the Indemnitor
of its indemnification obligation under this Agreement except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice). The Indemnitor shall have the right to assume and control the defense of the
Indemnification Claim at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and
expenses to be paid by the Indemnitee, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnitee and any other party represented by
such counsel in such proceedings. If the Indemnitor does not assume the defense of the Indemnification Claim as described in this Section 11.3, above, the Indemnitee may defend the Indemnification Claim but shall have no obligation to do so.
The Indemnitee shall not settle or compromise the Indemnification Claim without the prior written consent of the Indemnitor, and the Indemnitor shall not settle or compromise the Indemnification Claim in any manner which would have an adverse effect
on the Indemnitee’s interests (including any rights under this Agreement or the scope or enforceability of the Orexigen Intellectual Property, or Confidential Information or Patent or other rights licensed to Orexigen by Takeda hereunder),
without the prior written consent of the Indemnitee, which consent, in each case, shall not be unreasonably 

  
 - 74 - 

 FINAL VERSION 

 

 
withheld, conditioned, or delayed. The Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor’s expense and shall make available to the Indemnitor all pertinent
information under the control of the Indemnitee, which information shall be subject to Article 10. 
 11.4 Dante Indemnity. To the
extent that Takeda is a “SUBLICENSEE” under the Dante License pursuant to the licenses granted to Takeda in Section 6.1 of this Agreement, Takeda shall indemnify Dante against any “CLAIMS” as set forth in Section 14.01
of the Dante License. 
 11.5 Insurance. 

11.5.1 By Takeda. Takeda represents and covenants that as of the Original Effective Date it is, and during the Term and for three
(3) years thereafter it shall be, self-insured against liability and other risks associated with the activities to be conducted by it under this Agreement and that such self-insurance meets the requirements for insurance set forth in
Section 14.02 of the Dante License and Section 12.05 of the OHSU Agreement. 
 11.5.2 By Orexigen. During the Term and for
three (3) years thereafter, Orexigen shall either (a) maintain, at its sole expense, Clinical Trial and product liability insurance relating to the Product that is comparable in type and amount to the insurance customarily maintained by
Orexigen with respect to similar prescription pharmaceutical products that are marketed, distributed and sold in the Territory, or (b) self insure for such risks. 

12. TERM AND TERMINATION 

12.1 Term; Expiration. This Agreement shall become effective as of the Original Effective Date and shall continue in full force and
effect until expiration as described in this Section 12.1, unless earlier terminated pursuant to this Article 12 (the “Term”), and shall expire upon the expiration of the Royalty Term with respect to all Products in the
Territory. 
 12.2 Termination for Cause. 

12.2.1 Material Breach. Either Party (the “Non-Breaching Party”) may, without prejudice to any other remedies
available to it at law or in equity, terminate this Agreement in its entirety in the event the other Party (the “Breaching Party”) has materially breached this Agreement, and such breach has continued for ninety (90) days (the
“Cure Period”) after written notice thereof is provided to the Breaching Party by the Non-Breaching 

  
 - 75 - 

 FINAL VERSION 

 

 
Party, such notice describing the alleged material breach in sufficient detail to put the Breaching Party on notice. 

12.2.2 Disagreement as to Material Breach; Cure Period. If the Parties reasonably and in good faith disagree as to whether there has
been a material breach, the Party that disputes that there has been a material breach may contest the allegation in accordance with Section 13.3. Notwithstanding the preceding sentence, the Cure Period for any allegation made in good faith as
to a material breach under this Agreement will run from the date that written notice was first provided to the Breaching Party by the Non-Breaching Party. Any such termination of this Agreement under this Section 12.2 shall become effective at
the end of the Cure Period, unless the Breaching Party has cured any such breach or default prior to the expiration of such Cure Period, or, if such breach is not susceptible to cure within the Cure Period, then, the Non-Breaching Party’s right
of termination shall be suspended only if and for so long as the Breaching Party has provided to the Non-Breaching Party a written plan that is reasonably calculated to effect a cure and such plan is acceptable to the Non-Breaching Party (such
acceptance not to be unreasonably withheld, conditioned, or delayed), and the Breaching Party commits to and carries out such plan as provided to the Non-Breaching Party. The right of either Party to terminate this Agreement as provided in this
Section 12.2, shall not be affected in any way by such Party’s waiver or failure to take action with respect to any previous default. It is understood and acknowledged that, during the pendency of such a Dispute, all of the terms and
conditions of this Agreement shall remain in effect, and the Parties shall continue to perform all of their respective obligations under this Agreement. Any payments that are made by one Party to the other Party pursuant to this Agreement pending
resolution of the Dispute shall be promptly refunded if the panel determines pursuant to Section 13.3 that such payments are to be refunded by one Party to the other Party. 

12.3 Termination for Safety Reasons. Either Party shall have the right to terminate this Agreement with respect to any Product in the
Territory, without liability for any compensation or other payment obligation to the other Party due to such termination except as expressly specified in this Agreement, by providing the other Party with at least sixty (60) days prior written
notice of termination, if, at any time, (a) the JSC determines that such Product, caused or is likely to cause a fatal, life-threatening or other serious adverse safety event that is reasonably expected, based upon then available data, to
preclude obtaining Regulatory Approval for such Product, or, if Regulatory Approval of such Product has already been obtained, to preclude continued marketing of such Product, or (b) either Party determines in good faith that, based on
prevailing scientific or medical best practices or FDA guidances, that material safety issues adversely affecting patient health and welfare exist with respect to such Product. Notwithstanding anything to the contrary in the foregoing, neither Party
shall have the right to terminate this Agreement pursuant to this Section 12.3 based on a safety concern with respect to the Product or either of the Licensed Compounds for the same type of event and rate of incidents of the event identified in
(i) the labels of Wellbutrin SR® and ReVia® as of the Original Effective Date or (ii) the NDA for Contrave as of the date of
Regulatory Approval in the Territory. 
 12.4 Termination for Insolvency. 

  
 - 76 - 

 FINAL VERSION 

 

 To the extent permitted under Law, either Party may terminate this Agreement, if, at any
time, the other Party files in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy for insolvency or for reorganization or for the appointment of a receiver or trustee of the Party or of
substantially all of its assets, or if the other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within one hundred and eighty (180) days after the filing
thereof, or if the other Party shall propose or be a party to any dissolution or liquidation, or if the other Party shall make an assignment of substantially all of its assets for the benefit of creditors. All licenses granted under or pursuant to
any section of this Agreement are and shall otherwise be deemed to be for purposes of Section 365(n) of Title 11, United States Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined in
Section 101(56) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. Upon the bankruptcy of any Party, the non-bankrupt Party shall further be entitled
to a complete duplicate of, or complete access to, any such intellectual property, and such intellectual property, if not already in its possession, shall be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue,
and continues, to perform all of its obligations under this Agreement. 
 12.5 Termination for Patent Challenge. Orexigen shall have
the right to terminate this Agreement immediately upon written notice if Takeda directly or through a Third Party indirectly challenges the validity, scope or enforceability of or otherwise opposes any Patent included in the Orexigen Patents or any
foreign counterparts thereof. Takeda shall have the right to terminate this Agreement immediately upon written notice if Orexigen directly or through a Third Party indirectly challenges the validity, scope or enforceability of or otherwise opposes
any Patent included in the Takeda Patents or any foreign counterparts thereof. If a Sublicensee of Takeda challenges the validity, scope or enforceability of or otherwise opposes any such Patent, then Takeda shall, upon written notice from Orexigen,
terminate such Sublicense. Takeda shall include provisions in all Sublicenses providing that, if the Sublicensee challenges the validity or enforceability of or otherwise opposes any such Patent, Takeda may terminate its Sublicense agreement with
such Sublicensee. In the event that all or any portion of this Section 12.5 is invalid, illegal or unenforceable, then the Parties will use Commercially Reasonable Efforts to replace the invalid, illegal or unenforceable provision(s) with
valid, legal and enforceable provision(s). 
 12.6 Unilateral Termination by Takeda. Takeda shall have the right to terminate this
Agreement in its entirety for any reason or no reason upon one hundred eighty (180) days prior written notice to Orexigen. Takeda shall be responsible for any of its payment obligations accrued and unpaid as of the date of such notice or that
become due and owing during such notice period.  
 12.7 Consequences of Termination. All of the following effects of
termination are in addition to the other rights and remedies that may be available to either of the Parties hereunder and shall not be construed to limit any such rights or remedies. 

  
 - 77 - 

 FINAL VERSION 

 

 12.7.1 Consequences of Termination by Orexigen or Takeda. In the event of termination
of this Agreement either by Orexigen pursuant to Section 12.2.1 (for material breach), Section 12.4 (for insolvency), or Section 12.5 (for challenge), or by Takeda pursuant to Section 12.3 (for safety) or Section 12.6
(unilateral right): 
 (a) Notwithstanding anything contained in this Agreement to the contrary, all rights and licenses granted
herein to Takeda shall terminate, and Takeda shall cease any and all Development, Manufacturing, and Commercialization activities with respect to all Products; 

(b) all payment obligations hereunder shall terminate, other than those that are accrued and unpaid as of the effective date of such
termination or expiration; 
 (c) Orexigen will thereafter have all rights, on a fully paid-up and royalty-free basis, previously
licensed to Takeda hereunder, itself or with a Third Party or through a Third Party sublicensee, to Develop and Commercialize any and all Products at Orexigen’s sole discretion; 

(d) Takeda hereby grants to Orexigen, effective as of the effective date of such termination, an exclusive (even as to Takeda),
transferable, fully paid-up, royalty-free, sublicenseable license in the Field in the Territory, under the Takeda Intellectual Property, to make, use, sell, offer to sell, import all Products, and otherwise Develop and Commercialize Products; 

(e) the JSC shall coordinate the wind-down of Takeda’s efforts under this Agreement and Takeda, as soon as reasonably practical
after the effective date of such termination, will provide to Orexigen, as applicable and to the extent permitted under any applicable Third Party contract, (i) any information, materials, and data, including copies of all Clinical Trial data
and results, and all other information, and the like developed by or for the benefit of Takeda relating to Products, including control of, and all information relating to, the global safety database, and (ii) other documents to the extent
relating to Products that are necessary in the continued Development and Commercialization of Products (including material documents and agreements relating to the sourcing and Manufacture of a Product or, to the extent the First Commercial Sale of
a Product has occurred, for sale, promotion, distribution, sale or use of such Product) throughout the Territory. Orexigen shall have the right to assume all prosecution, maintenance, and enforcement activities under Sections 9.2 through 9.6 with
respect to Patents within the Collaboration Patents. Takeda will cooperate with Orexigen to provide a transfer of such material information, materials, data, and documents, and to assist Orexigen with the prosecution, maintenance, and enforcement
activities with respect to Patents within the Collaboration Patents. At Orexigen’s request, Takeda shall assign to Orexigen any and all Collaboration Patents and agreements to which Takeda or its Affiliate and a Third Party are parties and that
govern the Development, Commercialization and Manufacturing activities conducted in connection with Products prior to such termination, or if such assignment is not permitted under the relevant agreement, (A) grant to Orexigen other rights to
provide to Orexigen the benefit of such non-assignable agreement, at Orexigen’s expense, to the extent permitted under the terms of such non-assignable agreement or (B) to the extent not permitted under the terms of such non-assignable
agreement, the Parties shall discuss in good faith an 

  
 - 78 - 

 FINAL VERSION 

 

 
alternative solution to enable Orexigen to receive, at Orexigen’s expense, the benefit of the terms of such non-assignable agreement; 

(f) Subject to the payment of all amounts required under subsection 12.7.1(b), Takeda shall have the right to sell or otherwise
dispose of any inventory of any Product on hand at the time of such termination or in process of manufacture; provided, however, that, at Orexigen’s request, Takeda shall transfer to Orexigen any Product that has not been sold or used
within six (6) months following such termination; 
 (g) Takeda shall transfer to Orexigen any and all Regulatory Filings
directly and solely related to any Products, including any INDs and NDAs, and, upon Orexigen’ request, shall make available to Orexigen any other relevant information reasonably related to such Regulatory Filings; and 

(h) the license set forth in Section 6.3.1 shall survive. 

12.7.2 Consequences of Termination by Takeda. In the event of termination of this Agreement by Takeda pursuant to Section 12.2.1
(for material breach), Section 12.4 (for insolvency) or Section 12.5 (for challenge): 
 (a) Notwithstanding anything
contained in this Agreement to the contrary, all rights and licenses granted herein to Orexigen shall terminate, and, upon Takeda’s request, Orexigen shall cease any and all Development, Manufacturing, and Commercialization activities with
respect to all Products; 
 (b) Takeda will thereafter have all rights previously licensed to Orexigen hereunder, itself or with a
Third Party or through a Third Party sublicensee, to Develop and Commercialize any and all Products at Takeda’s sole discretion; 

(c) all licenses granted to Takeda shall continue in full force, in accordance with the terms and conditions of this Agreement,
provided, however, notwithstanding anything to the contrary contained herein, such licenses shall survive the Term and Orexigen’s reservation of rights contained in Section 6.1 shall cease; 

(d) the JSC shall coordinate the wind-down of Orexigen’s efforts under this Agreement and Orexigen, as soon as reasonably
practical after the effective date of such termination, will provide to Takeda, as applicable and to the extent permitted under any applicable Third Party contract, (i) any information, materials, and data, including copies of all Clinical
Trial data and results, and all other information, and the like developed by or for the benefit of Orexigen relating to Products in the Territory, and (ii) other documents to the extent relating to Products that are necessary in the continued
Development and Commercialization of Products (including material documents and agreements relating to the sourcing and Manufacture of a Product or, to the extent the First Commercial Sale of a Product has occurred, for sale, promotion,
distribution, sale or use of such Product) throughout the Territory. Orexigen will cooperate with Takeda to provide a transfer of such material information, materials, data, and documents. At Takeda’s request, Orexigen shall assign to Takeda
any and all Collaboration Patents and agreements to which Orexigen or its Affiliate and a Third Party are parties and that govern Development, Commercialization and Manufacturing activities conducted in or for the

  
 - 79 - 

 FINAL VERSION 

 

 
Territory in connection with Products for the Territory prior to such termination, or if such assignment is not permitted under the relevant agreement or if Orexigen conducts activities in or for
countries outside of the Territory under such agreement, (A) grant to Takeda other rights to provide to Takeda the benefit of such non-assignable agreement, at Takeda’s expense, to the extent permitted under the terms of such
non-assignable agreement or (B) to the extent not permitted under the terms of such non-assignable agreement, the Parties shall discuss in good faith an alternative solution to enable Takeda to receive, at Takeda’s expense, the benefit of
the terms of such non-assignable agreement; 
 (e) Article 7 shall survive, provided, however, any and all payment
obligations under the provisions of Article 7 shall be reduced by thirty-five percent (35%); and 
 (f) Takeda shall use
Commercially Reasonable Efforts to Develop and Commercialize a Product in the Territory or, if Takeda does not materially perform such obligation, Orexigen shall have the right to terminate the licenses granted to Takeda in Article 6 as if Takeda
were committing a material breach of this Agreement, as provided in Section 12.2. 
 12.8 Consequences of Expiration. Following
the expiration of the Term pursuant to Section 12.1, the following terms shall apply: 
 12.8.1 Subject to the terms and
conditions of this Agreement, following expiration of the Term with respect to this Agreement in its entirety pursuant to Section 12.1, Takeda shall have a perpetual, irrevocable, non-exclusive, fully-paid and royalty-free right and license,
with the right to grant sublicenses, under the Orexigen Intellectual Property to make, have made, use, sell, offer to sell and import such Products in the Field in the Territory. 

12.8.2 Subject to the terms and conditions of this Agreement, following expiration of the Term with respect to this Agreement in its
entirety pursuant to Section 12.1, Orexigen shall have a perpetual, irrevocable, non-exclusive, fully-paid and royalty-free right and license, with the right to grant sublicenses, under the Takeda Intellectual Property to make, have made, use,
sell, offer to sell and import such Products in the Field in the Territory. 
 12.8.3 Sections 2.2.5, 2.2.6, 2.2.9, 3.3.3, 3.4, 3.6,
and 3.7 shall survive, to the extent applicable to activities contemplated hereunder that are still being carried out following expiration of the Term, and Article 10 shall survive with respect to any information exchanged under such Sections for a
period of five (5) years after the date of disclosure of such information; provided that, for clarity, any and all information shall be exchanged directly between the Parties, and not through any Committees. 

12.8.4 For as long as Takeda continues to use the Product Trademarks, (a) Takeda shall pay Orexigen the Trademark Royalty
provided in Section 7.3.2, and (b) Takeda shall continue to have the license rights provided in Section 6.1.2. 
 12.9
Survival. 

  
 - 80 - 

 FINAL VERSION 

 

 The following provisions shall survive termination or expiration of this Agreement in its
entirety, as well as any other provision which by its terms or by the context thereof, is intended to survive such termination: Articles 1, 7 (solely with respect to payments, including under Section 9.7.3, that have accrued prior to the
effective date of termination or expiration that have remained unpaid), 10 (for the period set forth in Section 10.1 or such longer period of time as set forth in Section 12.8.3), 13, and 14 and Sections 3.6, 6.5, 8.7, 8.8, 9.1, 11.1,
11.2, 11.3, 11.4 (for the time period set forth therein), 12.7 (as applicable), 12.8 (as applicable), 12.9, and 12.10. All other rights, licenses and obligations shall terminate upon expiration of this Agreement. 

12.10 No Limitation on Remedies. Notwithstanding anything to the contrary in this Agreement, except as otherwise set forth in this
Agreement, termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor prejudice either Party’s right to
obtain performance of any obligation. Each Party shall be free, pursuant to Article 13, to seek (without restriction as to the number of times it may seek) damages, costs and remedies that may be available under applicable Law or in equity and shall
be entitled to offset the amount of any damages and costs obtained in a final determination under Section 13.3 of monetary damages or costs (as permitted by this Agreement) against the other Party against any amounts otherwise due to such other
Party under this Agreement. 
 13. DISPUTE RESOLUTION 

13.1 Exclusive Dispute Resolution Mechanism. The Parties agree that the procedures set forth in this Article 13 shall be the exclusive
mechanism for resolving any dispute, controversy, or claim between the Parties that may arise from time to time pursuant to this Agreement relating to any Party’s rights or obligations hereunder (collectively, “Disputes”) that
is not resolved through good faith negotiation between the Parties. 
 13.2 Resolution by Executive Officers. Except as otherwise
provided in this Section 13.2, in the event of any Dispute, the construction hereof, or the rights, duties or liabilities of either Party hereunder, the Parties shall first attempt in good faith to resolve such Dispute by negotiation and
consultation between themselves. In the event that such Dispute is not resolved on an informal basis within ten (10) Business Days, either Party may, by written notice to the other Party, refer the Dispute to the other Party for attempted
resolution by good faith negotiation within thirty (30) days after such notice is received. Any Disputes shall be referred to the Executive Officers for attempted resolution. Except as set forth in Sections 5.7.3, 13.5 or 13.6, each Party may,
in its sole discretion, seek resolution of any and all Disputes that are not resolved under this Section 13.2 in accordance with Section 13.3. 

13.3 Alternative Dispute Resolution. The Parties acknowledge that they desire for any alternative dispute resolution process to be
conducted in an efficient, speedy and economical manner and, to achieve that end, any 

  
 - 81 - 

 FINAL VERSION 

 

 
Dispute shall be resolved by the Alternative Dispute Resolution provisions set forth in Exhibit 13.3, the result of which shall be binding upon the Parties. The Parties shall have the right to be
represented by counsel in such a proceeding. 
 13.4 Survivability. Any duty to engage in alternative dispute resolution under this
Agreement shall remain in effect and be enforceable after termination of this Agreement for any reason. 
 13.5 Preliminary
Injunctions. Notwithstanding anything in this Agreement to the contrary, a Party may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury,
loss, or damage on a provisional basis, pending the decision of the arbitrator(s) on the ultimate merits of any Dispute. 
 13.6 Patent
Disputes. Notwithstanding anything in this Agreement to the contrary, any and all issues regarding the scope, construction, validity, and enforceability of any patent within the Territory shall be determined in a court or other tribunal, as the
case may be, of competent jurisdiction under the applicable patent laws of the Territory. 
 13.7 Confidentiality. Any and all
activities conducted under Sections 13.1 through 13.3, including any and all proceedings and decisions of arbitrator(s) under Section 13.3, shall be deemed Confidential Information of each of the Parties, and shall be subject to Article 10.

 14. MISCELLANEOUS 

14.1 HSR. Prior to taking any action pursuant to the terms of this Agreement for which it is necessary to obtain clearance under the
Hart-Scott-Rodino Antitrust Improvement Act (“HSR Act”), the Parties shall each make or cause to be made all filings and submissions required under the HSR Act with respect to such action within such period of time that is
reasonably necessary to obtain clearance under the HSR Act prior to taking such action, and thereafter shall make any other required submissions with respect to such action under the HSR Act and otherwise use its reasonable best efforts to cause the
expiration or termination of the applicable waiting period under the HSR Act as soon as practicable. No Party will extend any waiting period or comparable period under the HSR Act without the prior written consent of the other Party. 

14.2 Severability. If any one or more of the provisions of this Agreement is held to be invalid, illegal or unenforceable, the
provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable
one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 
 14.3 Notices. Any notice
required or permitted to be given by this Agreement shall be in writing and shall be (a) delivered by overnight courier with tracking capabilities, (b) mailed postage prepaid by first class, registered or certified mail addressed as set
forth below unless changed by notice so given, or (c) delivered by facsimile to the number set forth below 

  
 - 82 - 

 FINAL VERSION 

 

 
unless changed by notice so given, followed by delivery via either of the methods set forth in Section 14.3(a) and (b): 

If to Takeda: 
 Takeda
Pharmaceutical Company Limited 
 1-1, Doshomachi 4-Chome Chuo-ku 

Osaka 540-8645 
 Japan 

Attn: Head of Global Licensing & Business Development Department 

Fax: (+81) 6-6204-2328 

Attn: General Counsel, Legal Department 

Fax: (+81) 6-6204-2055 

With a copy to: 
 Takeda
Pharmaceuticals U.S.A., Inc. 
 One Takeda Parkway 

Deerfield, Illinois 60015 

Attn: General Counsel 
 Fax:
(224) 554-7831 
 Takeda Pharmaceuticals International, Inc. 

One Takeda Parkway 
 Deerfield,
Illinois 60015 
 Attn: Alliance Manager 

Fax: (224) 554-7903 
 If to
Orexigen: 
 Orexigen Therapeutics, Inc. 

3344 N. Torrey Pines Ct., Suite 200 

La Jolla, CA 92037 
 Attn:
Chief Financial Officer 
 Fax: (858) 875-8650 

Attn: General Counsel 
 Fax:
(858) 875-8650 

  
 - 83 - 

 FINAL VERSION 

 

 With a copy to (which shall not constitute notice under this Agreement): 

Orexigen Therapeutics, Inc. 

3344 N. Torrey Pines Ct., Suite 200 

La Jolla, CA 92037 
 Attn:
Alliance Manager 
 Fax: (858) 875-8650 

Cooley LLP 
 4401 Eastgate Mall

 San Diego, CA 92121 
 Attn:
L. Kay Chandler, Esq. 
 Fax: (858) 550-6014 

Any such notice shall be deemed given on the date received if delivered in accordance with Section 14.3(a), five (5) days after mailing if mailed in
accordance with Section 14.3(b), or the date of transmission if delivered in accordance with Section 14.3(c). A Party may add, delete, or change the person or address to which notices should be sent at any time upon written notice
delivered to the Party’s notices in accordance with this Section 14.3. 
 14.4 Force Majeure. Neither Party shall be liable
for delay or failure in the performance of any of its obligations hereunder if such delay or failure is due to causes beyond its reasonable control, including acts of God, fires, earthquakes, acts of war, terrorism, or civil unrest (“Force
Majeure”); provided, however, that the affected Party shall (a) promptly notify the other Party, (b) use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and to mitigate the effect of such
occurrence, and (c) continue performance with the utmost dispatch whenever such causes are removed. When such circumstances arise, the Parties shall negotiate in good faith any modifications of the terms of this Agreement that may be necessary
or appropriate in order to arrive at an equitable solution. 
 14.5 Assignment. 

14.5.1 Each Party may, without the consent of the other Party, assign or transfer all of its rights and obligations hereunder only to
an Affiliate, of or to a successor in interest by reason of merger or consolidation or sale of all or substantially all of the assets of such Party relating to the subject matter of this Agreement; provided, however, that
(a) except as provided in Section 14.5.5, such assignment includes all rights and obligations under this Agreement, (b) such successor in interest shall have agreed as of such assignment or transfer to be bound by the terms of this
Agreement in a writing provided to the non-assigning Party, and (c) where this Agreement is assigned or transferred to an Affiliate, the assigning Party remains responsible for the performance of this Agreement. 

14.5.2 Subject to Section 14.5.1, this Agreement shall inure to the benefit of and be binding on the Parties’ successors and
assigns. Any assignment or transfer in violation of the foregoing shall be null and void and wholly invalid, the assignee or transferee in any such assignment or transfer shall acquire no rights whatsoever, and the non-assigning non-transferring
Party shall not recognize, nor shall it be required to recognize, such assignment or transfer. In 

  
 - 84 - 

 FINAL VERSION 

 

 
the event that Takeda assigns or otherwise transfers this Agreement to an Affiliate of Takeda, Takeda hereby agrees to be jointly and severally liable with any such Affiliates for the actions of
such Affiliates and for any and all amounts that become due and payable hereunder to Orexigen. If Takeda assigns this Agreement to an Affiliate, and such assignment has an adverse tax consequence to Orexigen, then Takeda shall make additional
payments to Orexigen under this Agreement to provide Orexigen the payments that would have been due to Orexigen had such assignment not occurred. For purposes of the preceding sentence, adverse tax consequences shall be determined taking into
account ultimate actual utilization of any foreign tax credits arising as a result of such assignment and the time value of money if there is any delay in the utilization of such foreign tax credits, if any (based on applicable federal rates). 

14.5.3 Notwithstanding anything to the contrary in this Agreement, in the event of any such assignment, the intellectual property
rights of the acquiring party (if other than one of the Parties to this Agreement) shall not be included in the technology licensed to the other Party hereunder to the extent held by such acquirer prior to such transaction, or to the extent such
technology is developed outside the scope of activities conducted with respect to Products. The Orexigen Intellectual Property and the Takeda Intellectual Property shall exclude any intellectual property owned or Controlled by a permitted assignee
or successor and not developed in connection with Products. 
 14.5.4 Notwithstanding anything to the contrary in this Agreement,
Orexigen shall have the right to assign its rights to receive payments pursuant to Article 7, in whole or in part, to a Third Party in connection with the monetization of Orexigen’s revenue stream under Article 7. 

14.5.5 Notwithstanding anything to the contrary in this Agreement, without the consent of Orexigen, Takeda may directly or
through multiple tiers (a) sublicense or transfer some or all of its rights or obligations hereunder to one or more Affiliates, or (b) grant one or more of its Affiliates distribution rights under this Agreement; provided,
however, in each case, such sublicense, transfer or grant of rights shall be subject to the provisions of Section 14.5.1 and 14.5.2. 

14.6 Further Assurances. Each Party agrees to do and perform all such further acts and things and shall execute and deliver such other
agreements, certificates, instruments and documents necessary or that the other Party may deem advisable in order to carry out the intent and accomplish the purposes of this Agreement and to evidence, perfect or otherwise confirm its rights
hereunder. Takeda and its Affiliates shall take all measures reasonably requested by Orexigen to give effect to the provisions of this Agreement. Any Affiliate that acquires rights hereunder will be deemed to be bound by the provisions of this
Agreement. 
 14.7 Waivers, Modifications and Amendments. The failure of any Party to insist on the performance of any obligation
hereunder shall not be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any succeeding
occasion. No waiver, modification, release or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by both of the Parties. 

  
 - 85 - 

 FINAL VERSION 

 

 14.8 Governing Law. This Agreement shall be governed by, enforced, and shall be
construed in accordance with the Laws of the State of New York, U.S. without regard to any conflicts of law provision that would result in the application of the Laws of any State other than the State of New York, U.S. 

14.9 Relationship of the Parties. Each Party is an independent contractor under this Agreement. Nothing contained herein is intended or
is to be construed so as to constitute Orexigen and Takeda as partners, agents or joint venturers. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party
or to bind the other Party to any contract, agreement or undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder. 

14.10 Entire Agreement. This Agreement and the attached exhibits, together with the Mutual Release Agreement between the Parties of
even date herewith, the Manufacturing Services Agreement, Quality Agreement, and Pharmacovigilance Agreement, constitute the entire agreement between the Parties as to the subject matter of this Agreement, the Mutual Release Agreement, Manufacturing
Services Agreement, Quality Agreement, and Pharmacovigilance Agreement. This Agreement amends, restates, and supersedes the Original Collaboration Agreement in its entirety as of the Amended and Restated Effective Date, and otherwise supersedes and
merges all prior and contemporaneous negotiations, representations, agreements and understandings regarding the same including as provided in Section 10.6, excluding the Mutual Release Agreement, Manufacturing Services Agreement, Quality
Agreement, and Pharmacovigilance Agreement. References to the Collaboration Agreement in the Manufacturing Services Agreement, Quality Agreement and Pharmacovigilance Agreement will be deemed to reference this Agreement as of the Amended and
Restated Effective Date. 
 14.11 Exports. Each Party agrees not to export or re-export, directly or indirectly, any information,
technical data, the direct product of such data, samples or equipment received or generated under this Agreement in violation of any applicable export control Laws. 

14.12 Interpretation. Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by
and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties
hereto and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if
any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. 

14.13 Performance by Affiliates. Each Party recognizes that the other Party may perform some or all of its obligations under this
Agreement through Affiliates to the extent permitted under this Agreement; provided, however, that such other Party shall remain responsible for the performance by its Affiliates as if such obligations were performed by such other Party. 

  
 - 86 - 

 FINAL VERSION 

 

 14.14 Counterparts; Electronic Delivery. This Agreement may be executed in
counterparts with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. Signatures to this Agreement
transmitted by facsimile, by email in “portable document format” (“.pdf”), or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement shall have the same effect as
physical delivery of the paper document bearing original signature. 
 [Signature Page Follows] 

  
 - 87 - 

 FINAL VERSION 

 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective
duly authorized officers effective as of the Amended and Restated Effective Date. 
  

									
	OREXIGEN THERAPEUTICS, INC.	 		 	TAKEDA PHARMACEUTICAL COMPANY LIMITED
					
	By:	 	/s/ Michael A. Narachi	 		 	By:	 	/s/ Christophe Weber
					
	Name:	 	Michael A. Narachi	 		 	Name:	 	Christophe Weber
					
	Title:	 	President & CEO	 		 	Title:	 	President & CEO
					
	Date:	 	July 31, 2015	 		 	Date:	 	July 31, 2015
					
	By:	 	/s/ Joseph P. Hagan	 		 		 	
					
	Name:	 	Joseph P. Hagan	 		 		 	
					
	Title:	 	EVP, Chief Business and Financial Officer	 		 		 	
					
	Date:	 	July 31, 2015	 		 		 	

  
 [Signature Page
to Amended and Restated Collaboration Agreement] 

 Execution Version 

Exhibit 1.98 
 Orexigen
Logo 
  
 

 

 Exhibit 1.99 

Orexigen Patents 

					
	 Pat. or Pub. No.
	  	 Title
	 	 Date Filed

	U.S. 5,512,593
 Issued 4/30/96
	  	COMPOSITION AND METHOD OF TREATING DEPRESSION USING NATOXONE OR NALTREXONE IN COMBINATION WITH A SEROTONIN REUPTAKE INHIBITOR*	 	2-Mar-1993
	U.S. 5,817,665
 Issued 10/6/98
	  	COMPOSTION AND METHOD OF TREATING DEPRESSION USING WITH A SEROTONIN REPUTAKE INHIBITOR*	 	20-Nov-1995
	U.S. 7,375,111
 Issued 5/20/08
	  	COMPOSITIONS FOR AFFECTING WEIGHT LOSS**	 	21-Apr-2004
	U.S. 7,462,626
 Issued 12/9/08
	  	COMPOSITIONS FOR AFFECTING WEIGHT LOSS**	 	17-Feb-2006
	U.S. 2007-0275970
 (Serial No. 11/779,008)
	  	COMPOSITIONS FOR AFFECTING WEIGHT LOSS**	 	17-July-2007
	Ser. No. 12/751,970	  	COMPOSITIONS FOR AFFECTING WEIGHT LOSS**	 	31-Mar-2010
	Canada
 2522708
	  	COMPOSITIONS FOR AFFECTING WEIGHT LOSS**	 	21-Apr-2004
	Mexico
 PA/a/2005/011557
	  	COMPOSITIONS FOR AFFECTING WEIGHT LOSS**	 	21-Apr-2004
		  		 	
	U.S. 2007-0128298
 (Serial No. 11/602,571)
	  	COMPOSITIONS AND METHODS FOR INCREASING INSULIN SENSITIVTY	 	21-Nov-2006
	Canada
 2630624
	  	COMPOSITIONS AND METHODS FOR INCREASING INSULIN SENSITIVITY	 	22-Nov-2006
	Mexico
 MX/a/2008/006515
	  	COMPOSITIONS AND METHODS FOR INCREASING INSULIN SENSITIVITY	 	22-Nov-2006
	U.S. 2008-0110792
 (Serial No. 11/937,367)
	  	METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS	 	08-Nov-2007
	Canada
 2668885
	  	METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS	 	08-Nov-2007
	Mexico
 MX/a/2009/004871
	  	METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS	 	08-Nov-2007
		  		 	
	U.S. 2007-0281021
 (Ser. No. 11/757773)
	  	SUSTAINED RELEASE FORMULATION OF NALTREXONE	 	04-June-2007

  
 i 

					
	 Pat. or Pub. No.
	  	 Title
	  	 Date Filed

	U.S. 2008-0113026
 (Ser. No. 11/937,421)
	  	LAYERED PHARMACEUTICAL FORMULATIONS	  	08-Nov 2007
	Canada
 2668884
	  	LAYERED PHARMACEUTICAL FORMULATIONS	  	08-Nov-2007
	Mexico
 MX/a/2009/004874
	  	LAYERED PHARMACEUTICAL FORMULATIONS	  	08-Nov-2007
		  		  	
	PCT WO 2009 158114
 (PCT/US2009/045720)
	  	METHODS FOR TREATING VISCERAL FAT CONDITIONS	  	29-May-2009
	U.S. Ser. No. 61/293,844
 (Provisional)
	  	METHODS OF PROVIDING WEIGHT LOSS THERAPY IN PATIENTS WITH MAJOR DEPRESSION	  	11-Jan-2010
		  		  	
	U.S. 5,358,970
 Issued 10/25/94
	  	PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION HYDROCHLORIDE AND A STABILIZER***	  	12-Aug-1993
	U.S. 5,427,798
 Issued 6/27/95
	  	CONTROLLED SUSTAINED RELEASE TABLETS CONTAINING BUPROPION***	  	12-Aug-1993
	U.S. 5,731,000
 Issued 3/24/98
	  	STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION***	  	22-Mar-1996
	U.S. 5,763,493
 Issued 6/9/98
	  	STABILIZED PHARMACEUTICAL***	  	21-June-1996
	Canada
 2168364
	  	STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION***	  	29-July-1994
	Mexico
 214071
	  	STABILIZED PHARMACEUTICAL***	  	29-July-1994

 * Patents associated with the Dante License. 

** Patents/patent applications associated with the OHSU Agreement. 

*** Patents associated with the GSK License. 

  
 ii 

 Exhibit 3.3.3 

Commercialization Reports 
  

									
	 REPORT
	  	 FREQUENCY OF REPORTING

		  	  
 Weekly

 
	  	 Monthly
  
	  	 Semi-Annually
  
	  	 Annually
  

	IMS by decile (1st
 6 months)]

 
	  	X	  		  		  	
	IMS by PBR
 alignment (1st 6

months)]
  
	  	X	  		  		  	
	IMS trend reports
 (1st 12 months)]

 
	  		  	X	  		  	
	IMS by
 prescription

decile]
  
	  		  	X	  		  	
	IMS by PBR
 footprint]

 
	  		  	X	  		  	
	Promotional Data
 (assuming

Qnexa/Locasarin)]
  
	  		  	X	  		  	
	 PBR PDE report] 
	  		  	X	  		  	
	Pipeline
 Wholesale]

 
	  		  	X	  		  	
	Managed
 Markets]

 
	  		  	X	  		  	
	 ATU] 
	  		  		  	X	  	
	Message Recall]	  		  		  	X	  	

 *PBR stands for Potential Based Resourcing 

 Exhibit 3.5.3 

Co-Promote Agreement Terms 
 The
Co-Promote Agreement shall include the following terms and conditions: 
 1. Commercialization Rights; Co-Promote Activities. Orexigen shall be
entitled to participate in the Commercialization of Contrave in the Initial Indication in the U.S. as follows: (i) through membership in the JCC pursuant to Section 5.3 of this Agreement; (ii) by performing a portion of the PDEs in
the U.S., subject to the applicable rights, obligations and limitations contained in Article 3 of this Agreement (including, for the avoidance of doubt, Section 3.5.4 of this Agreement (Change of Control of Orexigen)); and (iii) conducting
such other activities necessary to support its PDE obligation. The Co-Promote Agreement shall be structured to reflect the following, subject in all events to the terms of Section 3.5 of this Agreement: 

 

	 	•	 	The number of PDEs to be performed annually by the Parties shall be determined by the JCC and set forth in the Commercialization Plan, within the limitations and rights set forth in Sections 3.5.1 and 3.5.2 of this
Agreement, taking into consideration prescribing levels, geographic territory, centers of excellence, target groups, detail position and other relevant considerations as the JCC may determine; 

 

	 	•	 	Each Party shall provide its PDE requirements in the Commercialization Plan with the goal of achieving the call plan, but in accordance with the following: (i) during each Calendar Quarter, at least eighty percent
(80%) of its PDE requirement under the call plan; and (ii) during each Calendar Year, at least ninety percent (90%) of its PDE requirement under the call plan. If either Party fails to achieve eighty percent (80%) of its PDE
requirement under the call plan in a Calendar Quarter, it must exceed ninety percent (90%) of its PDE requirement under such call plan in the following Calendar Quarter by the number of PDEs that such Party failed to achieve in the prior
Calendar Quarter (i.e., that caused it to achieve less than eighty percent (80%) of its PDE requirement under the call plan). If either Party fails to achieve ninety percent (90%) of its PDE requirement under the call plan in any Calendar
Year, it must exceed ninety percent (90%) of its PDE requirement under the call plan in the following two (2) Calendar Quarters by the number of PDEs that such Party failed to achieve in the prior Calendar Year (i.e., that caused it to
achieve less then ninety percent (90%) of its PDE requirement under the call plan). Any failure by either Party to correct a PDE shortfall (i.e., achieving less than eighty percent (80%) of its PDE requirement under the call plan in a
Calendar Quarter or ninety percent (90%) of its PDE requirement under the call plan in a Calendar Year) in the timeframe specified above shall be a material breach of the Co-Promote Agreement, and the non-breaching Party shall have the remedies
set forth in paragraph 7 of this Exhibit 3.5.3; provided, for the avoidance of doubt, if a Party achieves the PDE requirements set forth above, including through the correction of any shortfall, it may not be held in material breach for
failure to achieve one hundred percent (100%) of the PDE requirements under call plan within the Commercialization Plan. 

	 	•	 	The Parties shall implement and maintain sales force incentive plans regarding the promotion of the Product that ensure that the targeted incentive weighting for each Sales Representative’s performance is
commensurate with the PDE requirement for each Sales Representative as determined in the call plan. For example, a Sales Representative who is expected to deliver forty percent (40%) of his/her PDEs in support of the Product (with the remainder
being allocated to other products) shall have an incentive plan that ensures that forty percent (40%) of the targeted incentive within a specified time period under the call plan is dependent upon performance of the Product. For the avoidance
of doubt: (i) the incentive weighting for the Product may, but does not have to, equal or exceed fifty percent (50%) of the overall incentive weighting applied to both the Product and the other products, and (ii) the incentive
weighting for the Product is intended to apply on a Sales Representative-by-Sales Representative and target-by-target basis, and to achieve the overall JCC approved call plan and contractual PDE requirements. 

2. Commercialization Costs. 
  

	 	•	 	Except as otherwise specifically provided in this Exhibit 3.5.3, Orexigen shall be responsible for all costs and expenses relating to its Commercialization activities under the Co-Promote Agreement, including the costs
and expenses relating to the activities of its Sales Representatives. 

  

	 	•	 	Takeda shall only be responsible for Commercialization Costs incurred by Orexigen during the Initial Co-Promote Period. 

  

	 	•	 	Orexigen’s Commercialization Costs shall not include FTE costs of Orexigen’s personnel, and shall be limited to (a) its PDE Cost and (b) those Third Party costs approved by the JCC in the
Commercialization Plan; provided, for the avoidance of doubt, Takeda and Orexigen contemplate such Third Party costs arising only in connection with Orexigen’s and Takeda’s Third Party market research service providers and its
advertising agency working together to create and produce promotional materials intended for the obstetrician and gynecological targets on which the Orexigen sales force will call during the Initial Co-Promote Period. 

 

	 	•	 	During the Initial Co-Promote Period, Orexigen shall be entitled to receive the PDE Cost, or Sixty-Six Dollars ($66.00) per PDE. Takeda’s cost-per-PDE is One Hundred Ten Dollars ($110.00). 

 

	 	•	 	Following the end of each Calendar Quarter during the Initial Co-Promote Period, but not the Secondary Co-Promote Period, Takeda shall reimburse Orexigen for its PDE Cost and other Commercialization Costs approved by
the JCC in the Commercialization Plan. 

  

	 	•	 	During the Initial Co-Promote Period, all Commercialization Costs incurred by Takeda (other than PDE Costs) pursuant to the Co-Promote Agreement shall be applied toward Takeda’s Commercialization Cost obligations
pursuant to Section 3.2.3 of the Agreement. 

 3. PDE and Sample Reporting. 
  

	 	•	 	Each Party shall maintain complete and accurate records of each PDE performed by its Sales Representatives using a call document, in a form agreed upon by the Parties, which records the name and address of each target
prescriber, the date and position of the PDE, the number of samples delivered, and any other information reasonably requested by Takeda. 

  

	 	•	 	Each Party shall provide the other Party with a monthly written report of the number of total PDEs performed, including the position of the PDEs, in a form agreed upon by the Parties. The monthly report shall be
provided no later than the 20th calendar day of the following month, or within such timeframe as is consistent with each Party’s then-current systems and processes for creating such written
reports. 

  

	 	•	 	Takeda shall determine sampling procedures to be followed by Orexigen, if applicable, and will consider in good faith input from Orexigen. 

 

	 	•	 	During the term of the Co-Promote Agreement, and for a period of three (3) years thereafter, Takeda shall have the right to perform audits of Orexigen’s files, records, databases, and other information solely
related to the Product and as necessary to confirm the accuracy of any PDE or sample reports provided by Orexigen to Takeda under the Co-Promote Agreement for any period during the preceding three (3) years. Takeda shall perform such audits at
reasonable times, upon twenty (20) days prior written notice and in no case more than one (1) time per Calendar Year and no more than one (1) time for each Calendar Year. 

4. Performance Standards. 
  

	 	•	 	The Parties shall use Commercially Reasonable Efforts to Commercialize the Products and shall perform their Commercialization obligations in accordance with this Agreement, the Co-Promote Agreement and the applicable
Commercialization Plan, including the specific diligence obligations of Takeda pursuant to Section 3.2 of this Agreement. 

  

	 	•	 	 The Parties shall comply with all laws, rules and regulations applicable to the marketing, sale and promotion of pharmaceutical products, including
the statutes, regulations and written directives of the FDA, including the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time, and the regulations promulgated thereunder, the Prescription Drug Marketing Act, the Federal
Health Care Programs Anti-Kickback Law, 42 U.S.C. 1320a-7b(b), the statutes, regulations and written directives of Medicare, Medicaid and all other health care programs, as defined in 42 U.S.C. §1320a-7b(f), the Health Insurance Portability and
Accountability Act of 1996, the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals, the American Medical Association: (i) Guidelines on Gifts to Physicians from Industry, and
(ii) Prescriber Data Restriction Program, each as may be 

	 	 
amended from time to time. Consistent with the “Compliance Program Guidance for Pharmaceutical Manufacturers,” published by the Office of Inspector General, U.S. Department of Health
and Human Services, Orexigen agrees to maintain a compliance program with respect to its promotional and sales activities relating to the Products containing all of the elements described in such guidance document. Upon either Party’s request,
the other Party shall provide the requesting Party with copies of its policies for such compliance programs. 

 5. Promotional
Materials and Samples. Takeda shall provide to Orexigen reasonable quantities of promotional materials (i.e., developed and approved by Takeda), samples, or sample vouchers for Product to support Orexigen’s Co-Promote activities in
accordance with the following: 
  

	 	•	 	During the Initial Co-Promote Period, Takeda shall provide such promotional materials, samples or sample vouchers to Orexigen at Takeda’s sole expense; 

 

	 	•	 	During the Secondary Co-Promote Period, Takeda shall provide such promotional materials to Orexigen at Orexigen’s sole expense with samples or sample vouchers being provided to Orexigen at Takeda’s
cost-of-goods; and 

  

	 	•	 	During the Initial Co-Promote Period and Secondary Co-Promote Period, Orexigen shall not, and shall ensure that its Sales Representatives do not, make any changes to the promotional materials. 

6. Training and Related Sales Force Issues. 
  

	 	•	 	During the Initial Co-Promote Period and prior to launch of the Product, Takeda shall, at its expense: (i) provide training to Orexigen’s sales managers and trainers (i.e., train-the-trainer), and
(ii) ship training materials to Orexigen as reasonably required for Orexigen’s training activities. 

  

	 	•	 	During the Initial Co-Promote Period and after launch of the Product, Orexigen shall be responsible for: (i) conducting training for its sales managers and trainers at its expense, and (ii) paying for the
shipment of training and promotional materials to Orexigen. 

  

	 	•	 	Except as set forth above in this paragraph 6, during the Initial Co-Promote Period and the Secondary Co-Promote Period, Orexigen shall be responsible, at its expense, for training, supervising and maintaining its sales
force, including as is necessary for launch of the Product. 

 7. Term and Termination. 

 

	 	•	 	 Except as set forth below in this paragraph 7, the term of the Co-Promote Agreement shall commence on the effective date of the Co-Promote activities
and shall continue in 

	 	 
effect until expiration or termination of this Agreement, unless otherwise terminated as set forth below. 

 

	 	•	 	The Co-Promote Agreement shall contain reasonable and appropriate termination rights, including the following: (i) during the Initial Co-Promote Period, Orexigen may terminate upon six (6) months prior written
notice to Takeda; (ii) during the Secondary Co-Promote Period, Orexigen may terminate upon twelve (12) months prior written notice to Takeda; and (iii) upon termination for material breach, the non-breaching Party shall have the
rights and remedies set forth in Article 12 of this Agreement. 

 8. Medical Inquires. Takeda shall be responsible for and shall
establish procedures for handling any medical inquires from health care professionals or others and any requests for medical information about the Product. Orexigen shall follow such procedures to the extent applicable to its Commercialization
activities. 
 9. Adverse Events. The Parties shall establish a process for communicating and reporting any adverse events and complaints relating to
the Products in accordance with the Pharmacovigilance Agreement described in Section 3.6 of this Agreement. 
 10. Non-Solicitation. During the
term of the Co-Promote Agreement and for twelve (12) months thereafter, neither Party shall actively recruit or solicit, directly or through a Third Party, for employment any then-current Sales Representative or associated field support of the
other Party without the written consent of the other Party. Nothing in this Agreement shall limit a Party from engaging in general recruitment through advertisements or recruiting through “head-hunters” so long as the Sales Representatives
or associated field support of the other Party are not specifically targeted in such recruitment effort. 
 11. Additional Terms and Conditions. The
Co-Promote Agreement shall contain such other terms and conditions as are customarily contained in similar agreements in the pharmaceutical industry; provided that, with respect to provisions also set forth in this Agreement,
the Parties shall endeavor to incorporate such provisions in the Co-Promote Agreement (e.g., insurance, indemnification, representations, recalls). In the event of any conflict between the Co-Promote Agreement and this Agreement, the terms of this
Agreement shall govern. 

 Exhibit 3.8.1 

Product Trademarks 
 Registered
Marks 
 CONTRAVE® (Class 5) 

Pending Marks 
 CONTRAVETM (Classes 16, 44)

 

 (Classes 5, 16, 44) 
 (The approved color for the CONTRAVE Logo is PANTONE 2425) 

 Exhibit 8.2.12 

Agreements 
 Reference is made to the
following types of agreements that Orexigen has entered into prior to the Original Effective Date in connection with the Products: 
 -Consulting agreements
in connection with development, regulatory and commercialization matters; 
 -Services agreements (including, but not limited to, master services agreements
and the work orders/statements of work related thereto) in connection with development, regulatory and commercialization matters; 
 -Research agreements in
connection with development, regulatory and commercialization matters; 
 -Letter agreements in connection with development, regulatory and commercialization
matters; 
 -Investigator clinical research agreements in connection with development matters; 

-Clinical study agreements in connection with development matters; 

-Quality agreements in connection with supply and manufacturing matters; and 

-the following license agreements: 
 - reference
is made to those certain Upstream Agreements; 
 - License Agreement between Orexigen and Duke University dated as of March 31, 2004, as
amended; and 
 - License Agreement between Orexigen and Cypress Bioscience, Inc. dated January 3, 2005. 

Orexigen’s Third Party Manufacturers as of the Original Effective Date are as follows and include any of their respective affiliates or successors: 

-Manufacturing Services Agreement between Orexigen and Patheon Pharmaceuticals Inc. and Patheon Inc. dated March 12, 2010. 

-Bupropion Hydrochloride Supply Agreement between Orexigen and Interchem Corporation dated August 9, 2010 (Erregierre S.p.A is referenced here as an
affiliate of Interchem Corporation). 
 -Master Services Agreement between Orexigen and Analytical Bio-Chemistry Laboratories, Inc. dated June 1, 2009.

 - Naltrexone Hydrochloride Supply Agreement between Orexigen and Cilag GmbH International dated January 29, 2009, as amended by that certain
Amendment No. 1 by and between the parties dated December 3, 2009. 
 -Bupropion Hydrochloride Supply Agreement between Orexigen and Chemi, S.p.A.
dated November 24, 2009. 
 -Covidien/Mallinckrodt Pharmaceuticals – Orexigen has not entered into a formal agreement with Covidien/Mallinckrodt
Pharmaceuticals. All work has been and is currently performed pursuant to purchase orders. 

 Exhibit 10.8 

Press Release 

 Exhibit 13.3 

Dispute Resolution 
 All references to
“days” in this ADR provision are to calendar days. 
  

	1.	To begin an ADR proceeding, a Party shall provide written notice to the other Party of the issues to be resolved by ADR. Within fourteen (14) days after its receipt of such notice, the other Party may, by written
notice to the Party initiating the ADR, add additional issues to be resolved within the same ADR. 

  

	2.	Within twenty-one (21) days following receipt of the original ADR notice, the Parties shall select a mutually acceptable panel of three (3) neutrals to preside in the resolution of any disputes in this ADR
proceeding. If the Parties are unable to agree on a mutually acceptable panel of three (3) neutrals within such period, either Party may request the President of the International Institute for Conflict Prevention and Resolution
(“CPR”), 575 Lexington Avenue, 21st floor New York, New York 10022, to select a panel of three (3) neutrals pursuant to the following procedures: 

 

	 	(a)	The CPR shall submit to the Parties a list of not less than nine (9) candidates within fourteen (14) days after receipt of the request, along with a Curriculum Vitae for each candidate. No candidate
shall be an employee, director, or shareholder of either Party or any of their Affiliates. 

  

	 	(b)	Such list shall include a statement of disclosure by each candidate of any circumstances likely to affect his or her impartiality. 

  

	 	(c)	Each Party shall number the candidates in order of preference (with the number one (1) signifying the greatest preference) and shall deliver the list to the CPR within seven (7) days following receipt of the
list of candidates. If a Party believes a conflict of interest exists regarding any of the candidates, that Party shall provide a written explanation of the conflict to the CPR along with its list showing its order of preference for the candidates.
Any Party failing to return a list of preferences on time shall be deemed to have no order of preference. 

  

	 	(d)	 If the Parties collectively have identified fewer than four (4) candidates deemed to have conflicts, the CPR immediately shall designate as the
panel of three (3) neutrals the three candidates for whom the Parties collectively have indicated the greatest preference. If a tie should result between two candidates, the CPR may designate either candidate. If the Parties collectively have
identified four (4) or more candidates deemed to have conflicts, the CPR shall review the explanations regarding conflicts and, in its sole discretion, may either (i) immediately designate as the neutral the candidate for whom the Parties
collectively have indicated the 

	 	
greatest preference, or (ii) issue a new list of not less than nine (9) candidates, in which case the procedures set forth in subparagraphs 2(a) - 2(d) shall be repeated.

  

	3.	No earlier than ninety (90) days or later than one hundred twenty (120) days after selection, the panel shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding
shall take place at a location agreed upon by the Parties. If the Parties cannot agree, the panel shall designate a location other than the principal place of business of either Party or any of their Affiliates. Commencing on the date twenty-one
(21) days after receipt of the initial ADR notice described in paragraph 1 above, the Parties shall be entitled to engage in reasonable discovery under procedures of the Federal Rules of Civil Procedure; provided, however, that a party
may not take more than six (6) depositions. There shall not be any, and the panel shall not permit any, discovery within thirty (30) days of the hearing. The panel shall decide any Disputes between the Parties related to discovery,
including ruling on reasonable requests to expedite discovery, taking into account the applicable period of time for discovery. 

  

	4.	At least seven (7) days prior to the hearing, each Party shall submit the following to the other Party and the panel: 

  

	 	(a)	a copy of all exhibits on which such Party intends to rely in any oral or written presentation to the panel; 

  

	 	(b)	a list of any witnesses such Party intends to call at the hearing, and a short summary of the anticipated testimony of each witness; 

 

	 	(c)	a proposed ruling on each issue to be resolved, together with a request for a specific damage award or other remedy for each issue. The proposed rulings and remedies shall not contain any recitation of the facts or any
legal arguments and shall not exceed one (1) page per issue. 

  

	 	(d)	a brief in support of such Party’s proposed rulings and remedies, provided that the brief shall not exceed twenty (20) pages. This page limitation shall apply regardless of the number of issues raised
in the ADR proceeding. 

  

	5.	The hearing shall be conducted on two (2) consecutive days and shall be governed by the following rules: 

  

	 	(a)	Each Party shall be entitled to five (5) hours of hearing time to present its case. The panel shall determine whether each Party has had the five (5) hours to which it is entitled. 

 

	 	(b)	 Each Party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal testimony, documents or other evidence,
to cross-examine witnesses, and to make a closing argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-

	 	
examination time shall be charged against the Party conducting the cross-examination. 

  

	 	(c)	The Party initiating the ADR shall begin the hearing and, if it chooses to make an opening statement, shall address not only issues it raised but also any issues raised by the responding Party. The responding Party, if
it chooses to make an opening statement, also shall address all issues raised in the ADR. Thereafter, the presentation of regular and rebuttal testimony and documents, other evidence, and closing arguments shall proceed in the same sequence.

  

	 	(d)	Except when testifying, witnesses shall be excluded from the hearing until closing arguments. 

  

	 	(e)	Settlement negotiations, including any statements made therein, shall not be admissible under any circumstances. Affidavits prepared for purposes of the ADR hearing also shall not be admissible. As to all other matters,
the panel shall have sole discretion regarding the admissibility of any evidence. 

  

	6.	Within seven (7) days following completion of the hearing, each Party may submit to the other Party and the panel a post-hearing brief in support of its proposed rulings and remedies, provided that such
brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. 

 

	7.	The panel shall rule on each disputed issue in writing within fourteen (14) days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one of the Parties on
each disputed issue but may adopt one Party’s proposed rulings and remedies on some issues and the other Party’s proposed rulings and remedies on other issues. The panel shall not issue any written opinion or otherwise explain the basis of
the ruling. 

  

	8.	The panel shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and expenses of the prevailing Party (including all reasonable expert witness fees and expenses), the
fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: 

  

	 	(a)	If the panel rules in favor of one Party on all disputed issues in the ADR, the losing Party shall pay 100% of such reasonable fees and expenses. 

 

	 	(b)	 If the panel rules in favor of one Party on some issues and the other Party on other issues, the panel shall issue with the rulings a written
determination as to how such fees and expenses shall be allocated between the Parties. The panel shall allocate fees and expenses in a way that bears a reasonable relationship to the outcome of the ADR, with the Party prevailing on more issues, or
on issues of 

	 	
greater value or gravity, recovering a relatively larger share of its legal fees and expenses. 

  

	9.	The arbitration shall be governed by the Federal Arbitration Act, 9 U.S.C. §§ 1 et seq., and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof.

  

	10.	Except as provided in paragraph 9 or as required by law, the existence of the Dispute, any settlement negotiations, the ADR hearing, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the
rulings shall be deemed Confidential Information as set forth in Section 13.7 of this Agreement. The panel shall have the authority to impose sanctions for unauthorized disclosure of Confidential Information.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]